{"efs24491-sup-0001-appendix_a.pdf": "riskassessmentoftheactivesubstanceabamectinwww.efsa.europa.eu/efsajournal9efsajournal2016;14(5):4491impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionmaximumbloodconcentrationwithin4-8h.approximately86%oforaldoseisabsorbed(basedonurinaryexcretionafteroralorintravenousadministration).distributiondistributedthroughoutallmajororgansandtissuespotentialforaccumulationnopotentialforaccumulationuponrepeatedoraladministrationrateandextentofexcretionrapidlyeliminated,almostexclusivelyvianon-biliaryexcretionbackintotheintestineandeliminatedwiththefaeces.metabolisminanimalsmajorpathwaysincludedemethylation,hydroxylation,cleavageoftheoleandrosylringandoxidationreactions.toxicologicallyrelevantcompounds(animalsandplants)parentand8,9-zisomerofavermectinb1a(photodegradationproduct)toxicologicallyrelevantcompounds(environment)parentand8,9-zisomerofavermectinb1a(photodegradationproduct)acutetoxicity(annexiia,point5.2)ratld50oral8.7mg/kgbw(oilvehicle)h300(r28)ratld50dermal>330mg/kgbw(highestdosetested);>2000mg/kgbw(rabbit)ratlc50inhalation0.034mg/l<lc50<0.051mg/l(4h;noseonly)h330(r26)skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnon-sensitizing(m&k)'", "efs24492-sup-0001-appendix_a.pdf": "classificationandlabellingwithregardtophysicalandchemicaldata(regulation(eu)n283/2013,annexparta,point10)substancemaleichydrazideharmonisedclassificationaccordingtoregulation(ec)no1272/2008anditsadaptationstotechnicalprocess[table3.1ofannexviofregulation(ec)no1272/2008asamended]1:nonepeerreviewproposal2forharmonisedclassificationaccordingtoregulation(ec)no1272/2008:noneimpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityapproximately90%(basedoncomparisonofthepatternsofexcretionafteroralvs.ivadministrations).correctionofaoelfororalabsorptionisnotconsiderednecessary.toxicokineticsrat:tmax~0-4h,t1/2~4h(nopkstudies,estimatedfromavailablestudies,cmaxandauccouldnotberetrieved).distributionwidelydistributed.totalresiduesinratswerelessthan1%(highestlevelsinboneandwholebloodoffemalesandinfatandlungsofmales)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(approximately90%within24hours),mainlyviaurine(repeatedorallowdose:86and89%,singleorallowdose:87and95%,singleoralhighdose:88and88%within24hours,femalesandmalesrespectively).metabolisminanimalstheparentcompoundundergoeslimitedmetabolismmajormetaboliteinraturineisthemaleichydrazidesulphateconjugate(lessthan20%).minormetaboliteinrattissueis3-pyridazinone(accountsforapproximately4%ofthetotalkidneyandliverradioactivity).invitrometabolismnodatadatarequiredtoxicologicallyrelevantcompounds(animalsandplants)maleichydrazidetoxicologicallyrelevantcompoundsmaleichydrazide1regulation(ec)no1272/2008oftheeuropeanparliamentandofthecouncilof16december2008onclassification,labellingandpackagingofsubstancesandmixtures,amendingandrepealingdirectives67/548/eecand1999/45/ec,andamendingregulation(ec)no1907/2006.ojl353,31.12.2008,1-1355.2itshouldbenotedthatharmonisedclassificationandlabellingisformallyproposedanddecidedinaccordancewithregulation(ec)no1272/2008.'(environment)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>3.2mg/lair/4h(dust,nose-only,maximumachievableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k,buehler)phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectdog:bodyweight(reducedinbothsexes)andheartweight(reducedinmales).rat(byinhalation):motoractivityandambulatorycountschangesrelevantoralnoael1-year,dog:25mg/kgbwperdayrelevantdermalnoael21-day,rat:1000mg/kgbwperday(highestdosetested)relevantinhalationnoael28-day,rat:22mg/kgbwperday(noaec100mg/m3)genotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesbacterial(reverse)genemutation(containing0.31ppmhydrazine)negativemutagenicitytestintherec-assaywithbacillussubtilis(containing0.31ppmhydrazine)positivemammalianchromosomeaberration(micronucleus)(containing0.0281ppmhydrazine)negativechromosomeaberrationsinchinesehamsterovarycells(containing0.31ppmhydrazine)positive,butosmolaricinterferencepossiblesisterchromatidexchangeinchinesehamsterovarycells(containing0.31ppmhydrazine)positivemammaliangenemutation(tkforwardmutation)(containing0.0281ppmhydrazine)negativemutagenicityevaluationinthemouselymphomaforwardmutationassay'", "efs24493-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)rateandextentoforalabsorptionextensiveandrapid(80%basedonurinaryexcretionwithin8hours).distributionwidelydistributed;mainlyinspleen,kidneyandliverpotentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretionrapid,mainlyviaurine(80%within8h)metabolisminanimalsextensivelymetabolisedintosulfateandglucuronideconjugatestoxicologicallyrelevantcompounds(animalsandplants)8-hydroxyquinolinetoxicologicallyrelevantcompounds(environment)8-hydroxyquinolineacutetoxicity(annexiia,point5.2)790mg/kgbwmouseld50oral177mg/kgbwacutetox3ratld50dermal>10000mg/kgbwratlc50inhalationnodata-notrequiredskinirritationnotirritatingeyeirritationcornealopacitynotreversibleeyedam1skinsensitizationsensitising;medicaldataskinsens1shorttermtoxicitytarget/criticaleffectrat:haematologicalalterations,increasedkidneyandspleenrelativeweightdog:notreatment-relatedeffectsrelevantoralnoaelrat:97.7mg/kgbwperday(90-d)dog:100mg/kgbwperday(90-d,highest'", "efs24494-sup-0001-appendix_a.pdf": null, "efs24498-sup-0001-appendixa.pdf": "flurtamonewww.efsa.europa.eu/efsajournal8efsajournal2016;14(6):4498impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability92.5%(oral,5mg/kgbw),34.5%(oral,500mg/kgbw)toxicokineticsoraldose5mg/kg(bygavage),plasmakinetics:cmax=3.1/2.7mgeq/kgtmax=0.8/1.1h;t1/2=47/27h,auc0-168=24/17mg.hour/kgdistributionwidely,higherlevelsintheliverpotentialforbioaccumulationlowrateandextentofexcretionviafaeces(49-61%,7d)andurine(38-43%,7d),mostlyoccurringwithin24hmetabolisminanimalsextensivelymetabolizedusingflurtamonelabelledonthetrifluoromethyl-phenylring:byaromaticringhydroxylation,n-demethylation,o-alkylationofthering-hydroxylatedproducts,hydrolysisofthefuranringandconjugation.invitrometabolismmetabolismofflurtamonebyratandhumanlivermicrosomeswassimilar,metabolisminmicewasmorerapid.toxicologicallyrelevantcompounds(animalsandplants)flurtamonetoxicologicallyrelevantcompounds(environment)flurtamoneacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>2.2mg/lskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotasensitizer(m&k)phototoxicityopenshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectliver:increasedweight(rat,dog),clinicalchemistrychanges(rat,dog),andcentrilobularhypertrophy(rat,dog,mouse)blood:haematologicalchanges(mouse)'", "efs24500-sup-0001-appendix_a.pdf": ",4-dbwww.efsa.europa.eu/efsajournal10efsajournal2016;14(5):4500impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)studieswith2,4-dbrateandextentoforalabsorption/systemicbioavailabilityrapidandalmostcomplete(>80%,48hoursbasedonurinaryexcretion)toxicokineticsforparentatlowdose:cmax=18gequiv/g,tmax=1.5hour,plasmat1/2=2.2hour;auc0-102hgequiv/gdistributionwidelydistributed,highestresidueinfatpotentialforbioaccumulationlowrateandextentofexcretionmainlyexcretedviaurine(~67-80%)andlessviafaeces(~6%)oversevendaysmetabolisminanimals2,4-db,2,4-d,conjugatesof2,4-dichlorophenolinvitrometabolismnodatadatarequiredtoxicologicallyrelevantcompounds(animalsandplants)2,4-db,2,4-d,conjugatesof2,4-dichlorophenoltoxicologicallyrelevantcompounds(environment)2,4-db,2,4-d,conjugatesof2,4-dichlorophenolacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral1470mg/kgbwh302ratld50dermal>2000mg/kgbwratlc50inhalation>2.3mg/lair/4h(wholebody)skinirritationnon-irritanteyeirritationirritatingtoeyesh319skinsensitisationnotsensitiser(llna)phototoxicityinconclusiverelevantuvbwavelengthshavenotbeentestedshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:rel.kidneyweight,convolutedtubulecytoplasmicvacuolation,degenerationdescendingpctdog:bun(90d);bun,creatinine,kidneyinflammation,kupffercell.at80mg/kgbwperday:moribundity.parenchymalcellpigmentation,liversinusoidectasia(1-yr)stotre2,h373'", "efs24503-sup-0001-appendix_a.pdf": "mpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability15%basedonoralbioavailabilitystudy(rat,singledose,30mg/kgbw).toxicokineticslowdose(0.5mg/kgbwperday):tmax=0.5hrs.highdose(1000mg/kgbwperday):tmax=0.25hrs.nosignificantsex-relateddifferences.distributionatlowdose(0.5mg/kgbwperday),radioactivityinalmostallofthetissueswasbelowlodafter168hrs.highestconcentrationsweredeterminedinblood,kidneys,liver,muscleandfatattmax.nosignificantsex-relateddifferences.potentialforbioaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandextensive(app.90%within24h),equivalentlyviaurinefaecesandbileatlowdose(0.5mg/kgbwperday),andmainlyviafaecesathighdose(1000mg/kgbwperday).nosignificantsex-relateddifferences.metabolisminanimalshydrolysisofthedimethylsulfonamidegroup(ccim)followedbyoxidationofthebenzylmethylgroup(ccba).glutathioneandcysteineconjugationthroughthebenzylmethylgroup.mainmetaboliteinraturinewasccba.invitrometabolismcomparativeinvitrometabolismstudynotprovided(datagap)toxicologicallyrelevantcompounds(animalsandplants)cyazofamid,ccim.toxicologicallyrelevantcompounds(environment)cyazofamid.acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw(mouse,rat)ratld50dermal>2000mg/kgbw(rat)ratlc50inhalation>5.5mg/lair/4h(rat,whole-bodyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(m&k)phototoxicityprobablyphototoxic'", "efs24504-sup-0001-appendix_a.pdf": "iewofthepesticideriskassessmentoftheactivesubstanceoxathiapiprolinwww.efsa.europa.eu/efsajournal16impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemic30%basedonrecoveriesinurine,bile,andcarcass(reducedoralabsorptionafterhighdoseof200mg/kgbw)toxicokineticsaftersinglelowdoseadministration(10mg/kgbw):cmax0.17-0.81geq/gtmax1.75-6hrt1/240-51hrwidelydistributed,withlowdetectiblelevelsfoundinalltissues.tissueswiththehighestmeanpercentageswereskin,fat,liver,gitracttissue,andmusclenoevidenceforaccumulation.faecalexcretionwastheprimaryrouteofurineandfaeceswasquickand>95%completeby48hoursaftersingledosing.thepatternofexcretionwassimilaraftermultipledosing.oxathiapiprolinand43metaboliteswere(tentatively)identifiedamongfaeces,urineandbile.theproposedmetabolicpathwayincludesmultiplereactionsiteswithhydroxylation,cleavage,reduction,and/orconjugation.invitrometabolismdatagaptoxicologicallyrel(animalsandplants)oxathiapiprolin(environment)oxathiapiprolinacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50>5000mg/kgbwratld50>5000mg/kgbwratlc505.0mg/l(4hour,noseonly)non-irritantnon-irritantnonsensitising(m&k)phototoxicitynotphototoxic(invitro)shorttermtoxicity(regulation(eu)n283/2013,annexparta,point5.3)dog:liver(increasedrelativeweight>20%)'", "efs24515-sup-0001-appendix_a.pdf": "drinking/groundpicoxystrobinairpicoxystrobinbodyfluidsandtissuespicoxystrobinmonitoring/enforcementmethodsfood/feedofplantorigin(analyticaltechniqueandloqformethodsformonitoringpurposes)hplc-ms/ms;0.01mg/kgfood/feedofanimalorigin(analyticaltechniqueandloqformethodsformonitoringpurposes)hplc-ms/ms;0.01mg/kgsoil(analyticaltechniqueandloq)hplc-ms/ms;0.01mg/kgwater(analyticaltechniqueandloq)lc/ms/ms;0.1g/lair(analyticaltechniqueandloq)lc-ms/ms;0.009g/m3bodyfluidsandtissues(analyticaltechniqueandloq)hplc-ms/ms;0.01mg/kgclassificationandlabellingwithregardtophysicalandchemicaldata(regulation(eu)n283/2013,annexparta,point10)substancepicoxystrobinharmonisedclassificationaccordingtoregulation(ec)no1272/2008anditsadaptationstotechnicalprocess[table3.1ofannexviofregulation(ec)no1272/2008asamended]1:notyetavailablepeerreviewproposal2forharmonisedclassificationaccordingtoregulation(ec)no1272/2008:noneimpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability>75%within48h(bile-ductcannulatedrats,lowdose)toxicokineticsdosecmaxtmaxplasmat1/2auc1regulation(ec)no1272/2008oftheeuropeanparliamentandofthecouncilof16december2008onclassification,labellingandpackagingofsubstancesandmixtures,amendingandrepealingdirectives67/548/eecand1999/45/ec,andamendingregulation(ec)no1907/2006.ojl353,31.12.2008,1-1355.2itshouldbenotedthatharmonisedclassificationandlabellingisformallyproposedanddecidedinaccordancewithregulation(ec)no1272/2008.proposalsforclassificationmadeinthecontextoftheevaluationprocedureunderregulation(ec)no1107/2009arenotformalproposals.'mg/kgeq/ghhh*eq/g(labeledonphenyl-phorpyridine-py)means(males/females)10(ph)4.8/2.82.2/7.147/40110/8610(py)3.4/4.53.0/0.633/34102/87100(ph)12/1812/9.337/30605/710100(py)15/1112/1246/33579/453distributioninitialwidedistribution,highestresiduesinliver,kidneys,git,bloodandbone(malesonly).total:<1%,lowdose,5days.potentialforbioaccumulationnopotentialforaccumulationrateandextentofexcretion>95%within5days(lowdose);mainlybile/faecal(78%inmalesand61%infemales)metabolisminanimalscompletemetabolisationofabsorbeddose;34of42metabolitesfoundwereidentified;mainlyesterhydrolysisandglucuronideconjugation.invitrometabolismnatoxicologicallyrelevantcompounds(animalsandplants)parentcompound(picoxystrobin)andmetabolitestoxicologicallyrelevantcompounds(environment)parentalcompound(picoxystrobin)andmetabolitesacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation1ststudy:2.124.59mg/l(m),3.19(f)air/4h(noseonly)(particlesize:mmad5.896.81m)2ndstudy:0.11mg/l(m/f)(noseonly)(particlesize:mmad:3.354.08m)acutetox.4,h332skinirritationslightirritationeyeirritationirritant(irritationclearingby7days)eyeirrit.2,h319skinsensitisationnotsensitizing(gpmt)phototoxicitytestingnotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:reducedfoodconsumptionandbodyweight'", "efs24517-sup-0001-appendix_a.pdf": "classificationandproposedlabelling(symbol,indicationofdanger,riskphrases,safetyphrases)withregardtophysical/chemicaldata:noclassificationwithregardtotoxicologicaldata:noclassificationwithregardtofateandbehaviour:noclassificationwithregardtoecotoxicologicaldata:noclassificationmethodsofanalysis(regulation(eu)n283/2013,annexpartb,point4andregulation(eu)n284/2013,annexpartb,point5)analyticalmethodsforthemicroorganism(ma4.1&mp5.1;oecdiim4.3&iiim5.1)manufacturedmicroorganism(principleofmethod):thespeciesisidentifiedandquantifiedbymicroscopyandbydilutionplatingoncommonlaboratorymedia.impuritiesandcontaminatingmicroorganismsinmanufacturedmaterial(principleofmethod):microscopicallyandbymicrobiologicalmethods(dilutionplatingonanon-selectivemedium)microbialpestcontrolproduct(principleofmethod):microscopicallyandbymicrobiologicalmethods(dilutionplatingonanon-selectivemedium)analyticalmethodsforresidues(viableandnon-viable)inexposedcompartmentsandorganisms(ma4.2&mp5.2;oecdiim4.5&iiim5.2)oftheactivemicroorganism(principleofmethod):noresiduedefinition/mrlisset,sonomethodsarerequired.ofrelevantmetabolites(principleofmethod):noresiduedefinition/mrlisset,sonomethodsarerequired.impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)therearenocasereportsoninfectionorotherincidentsinhumansrelatedtoconiothyriumminitans.noadversehealtheffectshavebeenobservedinanyoftheemployeesinvolvedintheproduction,'handlingandapplicationofconiothyriumminitansstraincon/m/91-08.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)noreportsofsensitizationorallergenicresponseofworkers;norinthepublishedliterature.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)rat:ld50>2500mg/kgbwor2.5x108cfu/animal;nomortality,nosignsoftoxicitypathogenicityandinfectivitywerenotinvestigated.acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)rat,intra-tracheal:nodistributionofconidiaoutsidethelungsafterintratrachealadministration;completeclearancewithin8days(2.8x107cfu/animal).rat,inhalation(4h,nose-only):lc50>1.89mg/latleast,probablymuchhigher.nosignsoftoxicity,pathogenicityandinfectivityacuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)rat,intraperitoneal:ld50>2000mg/kgbw(2x108cfu/animal);nomortality,nosignsoftoxicity.pathogenicityandinfectivitywerenotinvestigated.genotoxicity:(ma5.2.3;oecdiim5.3.5)amestest:negative.invitrochromosomeaberrationtest:negative.cellculturestudy:(ma5.2.4;oecdiim5.3.6)nainformationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)nadermaltoxicity:(mp7.1.3;oecdiiim7.1.2)rat:ld50>2500mg/kgbw;nomortality,nosignsoftoxicitypathogenicityandinfectivitywerenotinvestigated.specifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)skinirritationandeyeirritationtest:notirritatinggenotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)na'", "efs24518-sup-0001-appendix_a.pdf": "riskassessmentoftheactivesubstancelinuronwww.efsa.europa.eu/efsajournal9efsajournal2016;14(7):4518impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(regulation(eu)no283/2013datapoint5.1)rateandextentofabsorption/systemicbioavailability:ratsanddogs:rapidaround70%basedonurinaryexcretionwithin48h;intheabsenceofastudyonbiliaryexcretion,thepresenceofmetabolitesinthefaeceswasnotconsideredsufficienttobeincluded.70%tobeusedfortheaoelcalculationtoxicokineticsrat:tmax=12h,cmax(blood)=1/2(12-48h)inblood=10h;t1/2(48-168h)inblood=48h;auc(0-168h)inblood=212gh/gdogs:tmax=2h,cmax(blood)=1/2(2-24h)inblood=10h;t1/2(48-168h)inblood=142h;auc(0-168h)inblood=430gh/gdistribution:widelydistributed.thehighestresidueconcentrationswereobservedinblood,liverandkidneys.potentialforaccumulation:lowpotentialforbioaccumulation.someevidenceofaccumulationinsubcutaneousfatbutonlyathighdosesrateandextentofexcretion:rapid-andextensive;majorityofradioactivityeliminatedmainlyviaurine(70-80%);around20-25viafaeceswithin48hoursmetabolisminanimalsextensive-onlyasmallamountofparentcompound(lessthan10%)detectedinfaeces(but27%oftotallyexcretedradioactivityuncharacterised).metabolisminvolvesdemethylation,demethoxylation,phenyloxidationandconjugation.newstudiesinvivoconfirmedthesedata.invitrometabolismnewstudiesinvitroindicatequantitativedifferencesbetweenrat,dogandhumans,withratbeingthemostactivefollowedbydogandhumansbeingtheleastactive,butdifferencescannotbequantifiedonthebasisoftheavailabledata.qualitativelynouniquehumanmetaboliteswereformed.toxicologicallysignificantcompounds(animalsandplants)parentcompound;3,4-dichloroanilinetoxicologicallysignificantcompounds(environment)parentcompoundacutetoxicity(regulation(eu)no283/2013datapoint5.2)ratld50oral1146and1508mg/kgbwformalesandfemalesrespectively.newstudy:between300and2000mg/kgbwcalculatedmedianld501000mg/kgbwh302ratld50dermal>2000mg/kgbwratlc50inhalation>0.849mg/lair/4h(noseonly,aerosol,maximumachievableconcentration)'", "efs24554-sup-0001-appendix_a.pdf": "section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability88%basedonexcretioninurineafteroralandintravenousadministrationtoxicokineticspeak14c-concentrationwasachievedintheplasmaat24hrafteroraladministration.biphasicelimination(rapidphasehalf-lifeof13hr;slowphasehalf-lifeof37-45hr)aftersinglelowdose,andmonophasicelimination(24-25hrhalf-life)aftersinglehighdose.distributionwelldistributed,butresidueswerelow(1-3%).highestlevelsinliver,kidneys,andblood.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretion47-60%inurineand40-45%infaeceswithin8daysafterasinglelowdoseadministrationmetabolisminanimalsextensivelymetabolisedbycyp-mediatedpathway,morethan32metaboliteswhereshowntobeproduced(with13characterised).invitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)propyzamidetoxicologicallyrelevantcompounds(environment)propyzamideacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>2.1mg/lair/4h(aerosol,noseonly)skinirritationmildirritationeyeirritationnon-irritantskinsensitisationnotsensitising(magnusson/kligmantest)phototoxicitynotphototoxic(balb/c3t3mousefibrobasts)short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectliver(rat,mouse,dog),kidneys(rat,mouse,dog),spleen(rat,mouse),adrenals(rat,mouse),pituitary(rat),thyroid(rat),pancreas(rat)relevantoralnoael90-day,rat:4.5mg/kgbwperday28-day,mouse:15mg/kgbwperday1-year,dog:loaelis12mg/kgbwperday,nonoaelwasdetermined'", "efs24569-sup-0001-appendix_a.pdf": "section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidly,72-81%basedonurinaryexcretionover7daystoxicokineticstmax:0.8-2.5h,t1/2:4.0-6.3hdistributionwidelydistributedpotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidlyandalmostcompletein7days,mainlyviaurinemetabolisminanimalsextensivelymetabolised;hydrolysisoftheestermoietyandhydroxylationinvitrometabolismin-vitrocomparisoninratvs.humanhepatocytesindicatesquantitativelythesamemetabolicfate;noevidenceofchiralinversiontoxicologicallyrelevantcompounds(animalsandplants)carfentrazone-ethyltoxicologicallyrelevantcompounds(environment)carfentrazone-ethylandmetabolitesacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>4000mg/kgbwratlc50inhalation>5.09mg/lair/4h(whole-body)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k,llna)phototoxicitynotrequired(noabsorptioninemrrange290700nm)short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:haematotoxicity(haemsynthesis),liver,kidneydog:haematotoxicity(haemsynthesis),liverstot-re2h373relevantoralnoael90-day,rat:58mg/kgbwperday90-day&1-year,dog:150mg/kgbwperdayrelevantdermalnoael21-day,rat:>1000mg/kgbwperdayrelevantinhalationnoaelnodata-notrequired'", "efs24574-sup-0001-appendix_a.pdf": "b'peerreviewofthepesticideriskassessmentoftheactivesubstancesilthiofamwww.efsa.europa.eu/efsajournal8efsajournal2016;14(8):4574section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityabsorptionalmostcomplete(87.00%eliminatedonrepeateddose;91.6%onsinglelowdose;99.6%onhighdose)toxicokineticscmax=0.91.4hbiexponentialclearance:-phasehalf-liveswere2.00-3.43hoursinplasma,3.72-6.44hoursinurineand7.73-9.30hoursforwholebodyelimination.-phasehalf-liveswere19.8-43.0hoursinplasma,22.4-40.7hoursinurineand38.7-79.9hoursforwholebodyeliminationdistributionwidelydistributedwithfatcontaininghighestlevelsat7days(0.11-0.61%).verylowlevelsfoundinliver,kidney,lungs,redbloodcellsandskin.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(app.87.3-97.3%within48h),mainlyviaurine(48.5-61.5%inurineand27-40%infaeces,biliaryexcretionnotmeasured).metabolisminanimalsextensivelymetabolised(>95%)themajorroutesofmetabolismwerehydroxylationofthering-attachedmethylgroupsandsubsequentoxidationtothecarboxylicacid,dihydroxylationoftheallyldoublebond,oxidativeremovaloftheallylgrouptoformtheprimaryamideandhydrolysisoftheamidetoformthecarboxylicacid.thetwomainmetabolitesare;dihydroxyacid[9](24-37%ofdose)andtrihydroxyacid[11](11-19%).onlytwoothermetabolites,theamideacidmon65534[m6]andallylacidmon65533[m2][7]approachedorexceeded5percentofthedoseinanygroupinvitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)silthiofamtoxicologicallyrelevantcompounds(environment)groundwatermetabolitesmon65534andmon65533acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>2.8mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationtransientconjunctivalirritationnoc&lskinsensitisationnon-sensitising(m&k)'", "efs24575-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidandextensive(around90%),greateratlowdoses,inrats.nodataonsystemicbioavailability.toxicokineticscmax(g-eq/g):7.55-148tmax(hours):0.5-6(individualvalues)eliminationhalf-life(hours):17-36distributionwidelydistributedpotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionexcretionisalmostcomplete(>90%)within7days;mainlyinurine(greaterinfemales,90-94%)andsecondarilyinfaeces(greaterinmales,21-24%).metabolisminanimalslimited,30%-60%oftheparentcompoundisexcretedintheurine.itundergoesfourmajormetabolicreactionsinrats:intramolecularrearrangement,cleavageatthesulfonylureabridge,oxidationatthe5-positionofthepyrimidineringandonthemethoxygroupandconjugationwithglucuronicacidandglutathione.invitrometabolismonestudyinlivermicrosomesinthreespecies(human,dog,andrat).9metaboliteswerefound,4ofthemcommontoallspecies:flazasulfuron(sl-160,themostprevalent),htpp,dtpuandtpsa(minormetabolites).dmpu,hmtuandhtpuwereidentifiedasuniquehumanmetabolites.toxicologicallyrelevantcompounds(animalsandplants)flazasulfuron-methyltoxicologicallyrelevantcompounds(environment)flazasulfuron-methylacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw(ratsandmice)ratld50dermal>2000mg/kgbwratlc50inhalation>5.99mg/lair/4h(whole-body)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnonsensitiser(maximisationtests)phototoxicitynophototoxicpotentialshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectmice:liver(increasedweight,'", "efs24584-sup-0001-appendix_a.pdf": "section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitylimitedsystemicabsorption(15%basedonurineexcretionatlowdose(10mg/kgbw);2%athigh(1000mg/kgbw)andrepeateddoses(7x250mg/kgbwperday)basedonurinaryexcretion)toxicokineticsbloodtmax3-4(males)and2-4hours(females)atlowdoseand4hoursathighdose10mg/kgbw,singledose:meancmax1.39(males)and0.78(females)gequivalentai/gmeanbloodt1/212.0(males)and10.6(females)hours1000mg/kgbw,singledose:meancmax11.21(males)and4.51(females)gequivalentai/gmeanbloodt1/211.5(males)and8.2(females)hoursdistributionverylowlevelsintissues(tracedetectedinorgansandtissues);highestlevelsdetectedinliverandplasmapotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidlyexcreted(ca.95%within24h),mainlyinthefaecesurine:12.8%and1.3%afterlowandhighdoserespectivelybile:7-9%(lowdose)nosignificantsex-relateddifferencesmetabolisminanimalsweak(>70%unchangedparentinexcretaandtissues);themajormetabolicpathwaywasthebreakdownofthesulfonylurea-bridge.minormetabolicreactionsobservedweretheo-demethylationandcleavagereactionsinvitrometabolismnometabolismwasfoundinratlivermicrosomes.anunresolvedpeakregion(m-2)wasdetectedinhumanlivermicrosomesaccountingfor8.1%ofthetotalrelativepercentagedatagapfortheidentificationandassessmentofthetoxicologicalrelevanceofthepeakmetabolitem-2toxicologicallyrelevantcompounds(animalsandplants)mesosulfuron-methyltoxicologicallyrelevantcompounds(environment)mesosulfuron-methyl'acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw/ratld50dermal>5000mg/kgbw/ratlc50inhalation>1.33mg/lair/4h(maximumattainableconcentration;noseonly)/skinirritationnon-irritant/eyeirritationnon-irritant/skinsensitisationnoconclusiononsensitisingpotential(m&kmethod,2assayswithlowconcentrationsintopicalinduction/challengeandequivocalqsaralertforskinsensitisation/phototoxicitynotphototoxic/short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectnone,exceptforlocalfindingsinthestomachmucosaofmaledogstreatedfor1year/relevantoralnoael90-day,rat:908mg/kgbwperday(highestdosetested)90-day,mouse:1238mg/kgbwperday(highestdosetested)90-day,dog:648mg/kgbwperday(highestdosetested)12-month,dog:-systemicnoael:574mg/kgbwperday(highestdosetested)-localnoael:155mg/kgbwperday/relevantdermalnoaelnodata-notrequired/relevantinhalationnoaelnodata-notrequired/'", "efs24605-sup-0001-appendix_a.pdf": "www.efsa.europa.eu/efsajournal9efsajournal2016;14(11):4605impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityoralabsorptionvalueis60%,basedonrenalexcretion,exhalationandresiduesremaininginthebodytoxicokinetics1mg/kgbwp.o.,maleandfemalerat:trrcmax=0.324/0.424mgequ/kginm/fratstmax=2/4hourspostdoseinm/frats100mg/kgbwp.o.,male:trrcmax=25.4mgequ/kginmaleratstmax=4hourspostdoseinmaleratsdistributionwidelydistributedwithhighestresiduesinthethyroidglandspotentialforbioaccumulationnoevidenceofbioaccumulationrateandextentofexcretionexcretionalmostcompleteby48hourspostdose;approx.50%withtheurine,approx.45%withthefaeces;approx.3%withthebileandapprox.2%asco2metabolisminanimalsextensivemetabolismviaptu;ptuisfurthermetabolizedtopu,to2-methylthio-4-methylimidazolineandvias-oxidationto4-methyl-imidazolineinvitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)propinebandptutoxicologicallyrelevantcompounds(environment)propineb,ptuacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalationm>2420mg/m3airf~983mg/m3airacutecat4skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationmagnusson/kligmantest:sensitisingbuehlerpatchtest:notsensitisingskinsens1'", "efs24609-sup-0001-appendix_a.pdf": "ubstanceiprodionewww.efsa.europa.eu/efsajournal9efsajournal2016;14(11):4609section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability60%basedonurinaryexcretiontoxicokineticstmax=2(males)-4(females)hours(lowdose)/6hours(highdose)distributionwidelydistributed(gitract,liver,skin)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(98%within96h),mainlyviaurine(62%,36%viafaeces)metabolisminanimalsextensivelymetabolised(approximately95%ofabsorbeddose,20metabolites);hydroxylationofthearomaticring,degradationoftheisopropylcarbamoylchainandrearrangementfollowedbycleavageofthehydantoinmoietyinvitrometabolismratandhumanlivermicrosomesstudy:nouniquehumanmetabolitedetectedtoxicologicallyrelevantcompounds(animalsandplants)parentcompound,3,5-dichloroaniline,m610f007.toxicityofmetabolitesfoundinlivestocknotdetermined.toxicologicallyrelevantcompounds(environment)rp30228,rp35606andrp30181acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.16mg/lair/4h(wholebody)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(buehler9applicationsandmaximisationtest)phototoxicitynotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:decreasedbodyweightandfoodconsumption,adrenals,ovary,uterusmouse:liver,adrenalsdog:liver,adrenals,haematology,prostate,kidneyrelevantoralnoael1-year,dog:17.5mg/kgbwperday(400ppm)90-day,rat:30.8mg/kgbwperday(500'", "efs24610-sup-0001-appendix_a.pdf": "substanceacetamipridwww.efsa.europa.eu/efsajournal9efsajournal2016;14(11):4610section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidandalmostcomplete(>96%at24haftersingleoraladministration).toxicokineticssingleadministrationcmax:1ppm(lowdose),40.5ppm(highdose)tmax:0.52h(lowdose),3-7h(highdose)t1/2:5.8-7.1h(lowdose),815h(highdose)repeatedadministrationcmax:0.8g/mltmax:2.8ht1/2:4.45.6hdistributionhighestconcentrationaftersingleadministrationinadrenalglands,thyroid,liverandkidney;afterrepeatedadministrationinthegitract,liverandkidneypotentialforbioaccumulationlowpotentialforaccumulationrateandextentofexcretionrapidandhigherthan90%at96h,mainlyviaurine,aftersingleandrepeatedoraladministrations,regardlessofthedoselevel.metabolisminanimalsapproximately>90%metabolised.mainmetabolitesforthering-labelledcompound(rats):nicotinicacidderivativeic-0anddemethylatedcompoundim-2-1(approx..50%)mainmetabolitesforthecn-labelledcompound(rats):im-2-1,is-1-1andis-2-1(approx.70%)metaboliteim-1-5(4.5%)isdetectedinratmetabolismonlybyhplcanalysisoffreshurinesamples.invitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)acetamipridandim-1-5toxicologicallyrelevantcompounds(environment)acetamipridandim-1-5'substanceacetamipridwww.efsa.europa.eu/efsajournal10efsajournal2016;14(11):4610acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralinwater:217mg/kgbw(male)and146mg/kgbw(female)incornoil:195mg/kgbw(male)and140-200mg/kgbw(female)acutetox.3h301ratld50dermal>2000mg/kgbwratlc50inhalation>1.15mg/lair/4h(highestattainableconcentration,snout-onlyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(m&k)phototoxicitynotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectratandmouse:liver(increasedliverweight,hepatocellularhypertrophy)rat,mouse,dog:bodyweightdecreaserelevantoralnoael90-dayrat:12.4mg/kgbwperday90-daymouse:106.1mg/kgbwperday90-daydog:13mg/kgbwperday1-yeardog:20mg/kgbwperdayoverallshort-termdog:13mg/kgbwperdayrelevantdermalnoael21-day,rabbit:1000mg/kgbwperdayrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesacetamipriddidnotinducegenemutationintheamestestandinthemammaliancellstudy(cho/hprt),andwasinactivetoinducednadamageintheunscheduleddnasynthesis(uds)testwithratlivercells.acetamipridwaspositiveinachromosomalaberrationassayinchocells,withandwithoutmetabolicactivation.invivostudiesacetamipriddidnotinducednadamageintheunscheduleddnasynthesis(uds)testwithratlivercellsinvivo,anddidnotinduceanysignificantincreaseofchromosomeaberrationsinbonemarrowofratsandwasnotmutagenicinthemousebonemarrowmicronucleustest.photomutagenicitynotrequiredpotentialforgenotoxicityacetamipridisunlikelytobegenotoxicinvivo'", "efs24612-sup-0001-appendix_a.pdf": "propoxycarbazonewww.efsa.europa.eu/efsajournal9efsajournal2016;14(10):4612section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidbutincompleteabsorption(26.5%maleand31.2%femalebasedonurinaryexcretion,about3%viabile)within48hours.toxicokineticspeakplasmalevels0.3to1hourafterdosing.distributionwidelydistributed,highestresiduesintheliver.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandnearlycomplete(>88%oftheadministereddosewithin48hours)primarilyviafaeces(>66%)metabolisminanimalslimited,unchangedparentcompoundinurine(>90%)andfaeces(>80%);metabolismviacleavageoftheamidebond,sulfonamidemethylester(m05),sulfon-amideacid(m06)andsaccharin(m07)invitrometabolismradioactiverecovery>99.5%.reasonablestableinratandhumanmicosoomeincubations.twometabolitesformed,pr-1,4.5%(rat)and6.2%(human).pr-2,2.3%inthehumansamples.pr-2probablyformedbyo-demethylationofpropoxycarbazoneleadingtoapropoxycarbazonecarboxylicacidmetabolite.toxicologicallyrelevantcompounds(animalsandplants)parentcompound,plantmetabolite2-hydroxypropoxymkh6561(m01)wasnotobservedintheratmetabolismstudy,thereforeadditionaltoxicologicaltestswereperformed.toxicologicallyrelevantcompounds(environment)soilmetabolitesmkh6561carboxylicacid(m04),4-hydroxysaccharin(m08),n-methylpropoxytriazolinoneamide(m09),n-methylpropoxytriazolinone(m10)andmkh6561-methoxy-saccharin(m11)werenotobservedintheratmetabolismstudy,thereforeadditionaltoxicologicaltestswereperformed.acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.03mg/lair(4h;nose-only)skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnotsensitising(magnusson/kligmantest)phototoxicitynotrequired'", "efs24650-sup-0001-appendix_a.pdf": null, "efs24651-sup-0001-appendix_a.pdf": null, "efs24657-sup-0001-appendix_a.pdf": "www.efsa.europa.eu/efsajournal11efsajournal2016;14(12):4657section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability>80%(basedonurinaryexcretion80-99%within24hours)toxicokineticscmax,tmax,plasmat1/2;forparentandmetabolitesarenotavailabledistributionwidelydistributedpotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive,mainlyviaurine(80-99%within24h)metabolisminanimalsextensivelymetabolised(>95%);mainmetaboliteshippuricacid(upto100%)andbenzoyl-glucuronicacid(0-20%),conjugationreactionsinvitrometabolismrateofglycineconjugationinhumanlivercells254nmol/min,inhumanrenalcortexcells321nmol/min,inskinminimaltoxicologicallyrelevantcompounds(animalsandplants)parentcompound,benzoicacidtoxicologicallyrelevantcompounds(environment)parentcompound,benzoicacidacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralrat,mouse,rabbitanddog>2000mg/kgbwcat:ca.2000mg/kgbw-ratld50dermalnodata(rabbitld50dermal>2000mg/kgbw)-ratlc50inhalation>1.2mg/lair/6h(wholebody)-skinirritationirritanth315eyeirritationseriouseyedamage.h318skinsensitisationnotsensitising(llna)-phototoxicityprobablynotphototoxic-'", "efs24668-sup-0001-appendix-a.pdf": "8impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)healthsurveillanceofworkersinresearchorproductionofp.chlororaphisstrainma342hasnotrevealedsignsorsymptomsrelatedtooccupationalexposure.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)nosensitisationorallergenicresponseshaveoccurredorhavebeenreportedforthestaffinvolvedinresearchorproductionwithstrainp.chlororaphisstrainma342duringmorethan14years.p.chlororaphisstrainma342wasfoundtobenotsensitisingtoguineapigsaccordingtothebuehlermethod.warningphraseformicroorganismsisapplicable:pseudomonaschlororaphisstrainma342mayhaveacuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)ld50rat>21010cfu/kgbw(p.chlororaphisstrainma342).nomortality,notoxicityld50rat>1.8108cfu/animal(p.chlororaphisstrainma342).nomortality,notoxicity.infectivity/pathogenicityinconclusive(datagap)acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)noael,rat>1108cfu/animal(p.chlororaphisma342).nosignsoftoxicityorinfectivityobserveduponintratrachealadministration.noael,rat>5105cfu/animal(cedomon,bacterialsuspensionofp.chlororaphisstrainma342inacarrier).notestitem-relatedsignsoftoxicityobserved.noinfectivity.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)astudyontheacuteintravenous/intraperitonealinfectivityofp.chlororaphisma342isconsideredtobenotrequired.genotoxicity:(ma5.2.3;oecdiim5.3.5)p.chlororaphisma342producesthemetabolite2,3-deepoxy-2,3-didehydro-rhizoxin(ddr)whichhasbeenshowntoproduceaneuploidyinvitroandinvivo.genotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)themetabolite2,3-deepoxy-2,3-didehydro-rhizoxin(ddr)producedbyp.chlororaphisma342hasbeenshowntoproduceaneuploidyinvitroandinvivo.cellculturestudy:(ma5.2.4;oecdiim5.3.6)notrelevantinformationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)tobereconsidered,pendingfurtherclarificationoftheclearanceandofthegrowthtemperature.dermaltoxicity:(mp7.1.3;oecdiiim7.1.2)astudytoassesstheacutedermaltoxicityoftheformulationcerallisconsideredtobenotrequiredsincebacteriadonotpenetrateintactskin.furthermore,p.chlororaphisma342hasbeenshownnottobeaskinirritantoraskinsensitizerandnootheringredientintheformulationcerallisclassifiedregardingacutedermaltoxicity.specifictoxicity,pathogenicityandinfectivity:experimentalsafetytestswithp.chlororaphisma'", "efs24693-sup-0001-appendix_a.pdf": "ection2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrat:36%(basedonurinary(11%)biliary(24%,excludingbileexcretionduringfirst6hours)excretionwithin72handonremainingresiduesinblood/tissues/carcass(1%))followingsingleadministration(10mg/kgbw).thevalueisalsosupportedbydataonrepeateddoseadministrationanditisusedtoadjustforsystemicexposure.toxicokineticstmax(h)lowdosem/f:5/6highdose:18/24cmax(gequiv/g):lowdosem/f:6.37/5.58highdosem/f:119.06/71.35auc(gequivxh/g)lowdosem/f:121/79highdosem/f:5909/4733half-life(h)lowdosem/f:11.5/13.3highdosem/f:12/15.6distributionwidelydistributed(highestresiduesinliver,kidney,wholeblood,heart,spleen,redbloodcellsandlungs)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrat:lowdose:readilyexcretedwithbiliaryexcretionasthemajorrouteofeliminationhighdose:thepredominantrouteofeliminationisfaecalexcretionmetabolisminanimalslowdose:extensivelymetabolised(1-3%excretedasparent)highdose:lessmetabolised(48-61%excretedasparent);numerousmetabolitesformedfollowinghydrazineoxidationdemethylation,ringhydroxylation,eliminationofhydrazinecarboxylicacidpartandconjugationwithglucuronicacidorsulphateinvitrometabolismnodatadatarequiredtoxicologicallyrelevantcompounds(animalsandplants)bifenazatetoxicologicallyrelevantcompounds(environment)bifenazateacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>4.4mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(inguineapigmaximisationtest)skinsens.1phototoxicityinconclusive'", "efs24695-sup-0001-appendix_a.pdf": "ssmentoftheactivesubstanceimazosulfuronwww.efsa.europa.eu/efsajournal8efsajournal2017;15(2):4695section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidandextensiveabsorption(>89%),basedonurinary(64-66%)andbiliary(22%)excretionwithin6-72h(singledoseadministrationtorat,5mg/kgbw).toxicokineticscmax:22-30g/ml(plasma,rat)tmax:hr(plasma,rat)plasmat1/2:2.7-3.1hrs(rat)distributionwidelydistributed(highestlevelsingastrointestinaltract,liver,bloodandkidneys)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionmainlyviaurine:64-66%andviafaeces:32-37%metabolisminanimalsmainmetabolite(56-64%)hms[=1-(2-chloro-imidazo[1,2-a]pyridin-3-yl-sulfonyl)-3-(4-hydroxy-6-methoxy-pyrimidin-2-yl)urea)].metabolitesihdu,ihdu-glu,hds,ipsn,acis,adpmandudpmat<5%each.0.9-1.8%parentmaterial(faecesonly)proposedpathway:1)demethylation;2)hydroxylationofthepyrimidinering;3)methylationorglucuronidationofthehydroxylgroup;4)openingthepyrimidineringandformationofguanidine;5)hydrolysisofthesulfonylureabridgeinvitrometabolismnostudyavailable.datagapandissuenotfinalised.toxicologicallyrelevantcompounds(animalsandplants)nonetoxicologicallyrelevantcompounds(environment)ipsnacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw(m/f)ratld50dermal>2000mg/kgbw(m/f)ratlc50inhalation>2.12mg/l(nose-only).skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnonsensitiser(buehlerandmaximisationtests)phototoxicitynotphototoxic(3t3nru-pttest(a)).(a)the3t3nru-pttestmightnotbeappropriatetestforuvbabsorberasimazosulfuron.'", "efs24700-sup-0001-appendix_a.pdf": "sificationandlabellingwithregardtophysicalandchemicaldata(regulation(eu)n283/2013,annexparta,point10)substancethiramharmonisedclassificationaccordingtoregulation(ec)no1272/2008anditsadaptationstotechnicalprocess[table3.1ofannexviofregulation(ec)no1272/2008asamended]1:/peerreviewproposal2forharmonisedclassificationaccordingtoregulation(ec)no1272/2008:/impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability83-87%within96htoxicokineticsnodatadistributiontissuelevelsrangedfrom1.2to3.8%oftheadministereddose.thehighestlevelswereseeninblood,liver,muscle,boneandkidney.allothertissuescontained<0.1%oftheadministereddose.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretion85-90%within96h:40%exhaled;33%inurineand3.2%infecesmetabolisminanimalsextensivelymetabolised(>80%);reductionofdisulfideboundleadingtodimethyldithiocarbamicacidfurtheroxidizedmainlytodimethyl-thiosulfenicacidafterhighdose,ortothioxothiazolidinecarboxylicacidafterlowdoseandexhaledinairascso,cs2andco2probably.invitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)thiramtoxicologicallyrelevantcompounds(environment)thiramanddmcsacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralm:3700mg/kgbwf:1800mg/kgbwh302ratld50dermal>2000mg/kgbw-ratlc50inhalationmale>5.04mg/l(4haerosol)female=3.46mg/l(4haerosol)h332skinirritationnon-irritant(animaldata)irritantonhumanh3151regulation(ec)no1272/2008oftheeuropeanparliamentandofthecouncilof16december2008onclassification,labellingandpackagingofsubstancesandmixtures,amendingandrepealingdirectives67/548/eecand1999/45/ec,andamendingregulation(ec)no1907/2006.ojl353,31.12.2008,1-1355.2itshouldbenotedthatharmonisedclassificationandlabellingisformallyproposedanddecidedinaccordancewithregulation(ec)no1272/2008.'", "efs24722-sup-0001-appendix_a.pdf": "eviewofthepesticideriskassessmentoftheactivesubstanceoxasulfuronwww.efsa.europa.eu/efsajournal8efsajournal2017;15(3):4722harmonisedclassificationaccordingtoregulation(ec)no1272/2008anditsadaptationstotechnicalprocess[table3.1ofannexviofregulation(ec)no1272/2008asamended]1:nocurrentharmonisedclassificationwithregardtophysicalandchemicaldata.peerreviewproposal2forharmonisedclassificationaccordingtoregulation(ec)no1272/2008:noneimpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidlyandhighlyabsorbed:>80%within48hours,basedonurineexcretiontoxicokineticscmax:20ppmatadoseof5mg/kgbwand200ppmat100mg/kgbwtmax:1h(rat)t1/2:6-8h(female),11-14h(male)inrat(blood)distributionwidelydistributed;highestlevelsinplasma,liver,kidneysandredbloodcellspotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapid(app.84.4to97.2%within48h),mainlyviaurineandfaecesmetabolisminanimalsupto86%excretedasparentcompound(cga277476).metabolismincludedcleavageofthesulfonylureabridge,hydroxylationofthepyrimidinyl-methylgroup,hydrolysisoftheoxetanylester,andopeningoftheoxetaneringinvitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)oxasulfuron(cga277476)toxicologicallyrelevantcompounds(environment)oxetan-3-olacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5082mg/m(4h,nose-onlyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnot-sensitising(buehlertest,andmaximization1regulation(ec)no1272/2008oftheeuropeanparliamentandofthecouncilof16december2008onclassification,labellingandpackagingofsubstancesandmixtures,amendingandrepealingdirectives67/548/eecand1999/45/ec,andamendingregulation(ec)no1907/2006.ojl353,31.12.2008,1-1355.2itshouldbenotedthatharmonisedclassificationandlabellingisformallyproposedanddecidedinaccordancewithregulation(ec)no1272/2008.proposalsforclassificationmadeinthecontextoftheevaluationprocedureunderregulation(ec)no1107/2009arenotformalproposals.'", "efs24790-sup-0001-appendix_a.pdf": "14efsajournal2017;15(6):4790section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityatleast80%basedonurinaryexcretion.nosignificantdifferencebetweenbromoxynil,bromoxyniloctanoate,bromoxynilheptanoateandbromoxynilbutyrate.toxicokineticsplasmatmax:7hoursplasmat1/2:1.5to2.5daysdistributionwidelydistributed(plasma,blood,liver,kidneysandthyroid).morewidespreaddistributioninfemales.potentialforbioaccumulationnoevidenceforaccumulation.higherlevelsofradioactivityinthetissuesandcarcassesoffemales.rateandextentofexcretionalmostcompletelyeliminatedwithin7days,mainlyviaurine(80%)asbromoxynilphenol(freeandconjugates).metabolisminanimalshydrolysisandconjugation.thethreeestersrapidlyhydrolysedtobromoxynil,theonlymetaboliteidentifiedintissues,nobromoxynilesterbeingpresent.infemales,des-bromoxynil(m03)anditsconjugatesalsopresentinurine.invitrometabolismnonotabledifferenceofbromoxynilmetabolisminacomparativeinvitrostudywithratandhumanlivermicrosomes.toxicologicallyrelevantcompounds(animalsandplants)bromoxynilanditsestersoctanoate,heptanoateandbutyrate.toxicologicallyrelevantcompounds(environment)bromoxynil(bxp)anditsestersoctanoate(bxo),heptanoate(bxh)andbutyrate(bxb).acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralbxp:130mg/kgbwbxo:141mg/kgbwbxh:292mg/kgbwbxo/bxh:201mg/kgbwbxb:116mg/kgbwh301ratld50dermalbxp,bxo,bxh,bxo/bxhandbxb:>2000mg/kgbw-ratlc50inhalationbxp:0.15mg/lbxo:0.72mg/lbxh:1.48mg/lbxo/bxh:1.04mg/lbxb:1.217mg/lh330h331h332h332", "efs24831-sup-0001-appendix_a.pdf": "2017;15(5):4831impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)nomedicalconditionsoradversehealtheffectshaveresultedfromoccupationalcontactwithbeauveriabassianaimi389521.intheliteratureonlyafewcasesofopportunisticinfectionsinhumanshavebeenreported.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)nostudyhasbeenperformed.basedonliteraturedata,beauveriabassianastrainsshowallergicpotentialandsensitizingpropertiestobothskinandinhalatorycontact.agreedwarningphrase:acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)open,pendingconfirmationofgrowthtemperature(datagap).acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)noevidentsignsoftoxicity,pathogenicityorinfectivitywerereported.thetestitemclearstobelowthelimitofdetectionwithin7days.however,onemaleandsixfemalestreatedwiththetestitemshoweddarkredorred-browndiscolorationofthelung.themacroscopicfindingsdonotexcludeapulmonaryeffectprobablycausedbyasensitisationreactionasalsoseenforotherstrainsofbeauveriabassiana.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)nodata,notrequired.genotoxicity:(ma5.2.3;oecdiim5.3.5)amestest:noevidenceofgenotoxicitycellculturestudy:(ma5.2.4;oecdiim5.3.6)nodata,notrequired.informationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)open,pendingconfirmationofgrowthtemperature(datagap).dermaltoxicity:(mp7.1.3;oecdiiim7.1.2)nodata,notrequired.datahavebeenprovidedfortheplantprotectionproduct.specifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)tieriiassessmentisnotrequired.genotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)tieriiassessmentisnotrequired.referencevaluesaoel:open,pendingconfirmationofgrowthtemperature.aaoel:open,pendingconfirmationofgrowthtemperature.adi:notnecessaryarfd:notnecessaryexposure(operator,workers,bystander,consumer):(ma6.1&mp7.3,8.0;oecdiim5.6&iiim7.2,7.3)basedonamonitoringstudy,dustlevelsoftheformulation(containingkaolinasmaincomponent)duringapplicationareexceedingworkplaceexposurelimits.abystanderexposureassessmentisnotdeemed'", "efs24832-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityinrats90to100%inmalesand80to95%infemales(basedonurinaryexcretionwithin168h)(basedonavailabledata,singleadministration)100%oralabsorptionassumedforaoeltoxicokineticsfollowingsingleoraldoseof5mg/kgbw:cmax27.8/31.5gequivalents/gtmax1.8/2.7hrplasmat1/26.4/4.2hrinmales/femalesrespectivelydistributionthyroid,kidney,bloodandplasmaweremainorgansofexposure.potentialforbioaccumulationeliminationfromfatandskinslowerthanforothertissuesbutnoclearevidenceofaccumulation.rateandextentofexcretionrapid,>95%(lowdose)within48hours,mainlyviaurine(>90%)metabolisminanimalslimited,66-83%excretedasparent.mainmetabolicstephydroxylation.invitrometabolismmouseandratconsideredmorerelevanttohumans.limitedmetabolism(only3to5%)ininvitrocomparativemetabolismstudyinhuman,rat,mouse,dog,rabbitmicrosomes.toxicologicallyrelevantcompounds(animalsandplants)parentcompound(mecoprop-p;toxicityofindividualmetabolitesnotknown)toxicologicallyrelevantcompounds(environment)noneacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral(mecoprop-p)431mg/kgbwh302ratld50dermal(mecoprop-p)>2000mg/kgbwratlc50inhalation(mecoprop-p)>2.13mg/lair/4h(wholebodyexposure)skinirritation(mecoprop-p)non-irritanteyeirritation(mecoprop-p)severelyirritatingh318skinsensitisation(mecoprop-p)notsensitisingphototoxicity(mecoprop-p)notphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:kidney(increasedweight,increasedbloodureanitrogen)dog:haematologicalchangesrelevantoralnoael90-day,dog(mecoprop):4mg/kgbwperday7weekrat(mecoprop):4.4mg/kgbw'", "efs24836-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityverylimitedabsorption(<0.5%)toxicokineticsnospecificadmestudyavailable.notrequired.distributionlimitedtothegastrointestinaltractandtheliverpotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretiondegradationproductsrapidlyandextensivelyexcreted(approx.90%)viabreathandflatusmetabolisminanimalsextensivelymetabolisedintoshortchainfattyacidsviacolonicmicrobiotafermentationinvitrometabolismnodata-notrequiredtoxicologicallyrelevantcompounds(animalsandplants)none:laminarinisapolysaccharideofglucoseandmannitoltoxicologicallyrelevantcompounds(environment)none:laminarinisapolysaccharideofglucoseandmannitolacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>1.02mg/lair/4h(head-noseonly;maximumattainableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&ktest)phototoxicitynodata-notrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:noeffectsdog:noeffectsrelevantoralnoael90-day,dog:1000mg/kgbwperday90-dayrat:1000mg/kgbwperdayrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesamestest:equivocalgenemutationinmouselymphoma:negativechromosomeaberrationinchocells(publicliterature):negativeinvivostudiesmicronucleus:negativephotomutagenicitynotrequired'", "efs24852-sup-0001-appendix_a.pdf": "u/efsajournal10efsajournal2017;15(6):4852impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidlyandextensivelyabsorbedinrat(approximately80%oftheadministereddoseat5mg/kg,viafaeces(55%)andurine(25%)).inbileductcannulatedrats48-72%ofthedoseinbile.toxicokineticstmax=6hcmax=6.63g/mlauc=256.4gh/mlt1/2(6h-24h)=9.95hours;t1/2(48h-168h)=89.5hoursdistributionwidelydistributed(mainlyinfat,liver,skin,kidney,adrenals,thyroidat24h,mainlyinliveruntil168h)potentialforbioaccumulationnoevidenceforbioaccumulationrateandextentofexcretionrapid,representing>90%ofthedosewithin48h(18-28%inurineand65-73%infaeces,inmajorpartviabile(21-78%instudy4)).completeat168h.distributionandexcretionaresimilarbetween5mg/kgand500mg/kg.excretionthroughurineslightlydelayedathighdoseinrelationtothelowdose.patternsofdistributionandexcretionaresimilarforuniqueandrepeateddoses.metabolisminanimalsinvestigatedinbile,urine,faecesextractsandplasma.extensiveinratsbyhydroxylationofthephenylringandonthelateralchainsofthepyrimidinering.furtherconjugationreactionsleadtonumeroussulphate,glucuronideandcysteine-glycineconjugates.metaboliteidentificationwasconsideredsufficient.nosex-differences.unchangedparentisamajorcompoundinfaeces(20-35%)afterhighdoseadministrationinvitrometabolismnotperformedinvitrometabolismstudyismissingtoxicologicallyrelevantcompounds(animalsandplants)mepanipyrimtoxicologicallyrelevantcompounds(environment)mepanipyrimacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)rat,mouseld50oral>5000mg/kgbwratld50dermal>2000mg/kgbw'", "efs24868-sup-0001-appendix_a.pdf": "9efsajournal2017;15(6):4868impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)(animalsandplants)terbuthylazine(environment)terbuthylazineanddesethyl-metabolite(mt1),mt13,mt14,lm1,datagapregardinglm2,lm3,lm4,lm5,lm6othertoxicologicalstudies(annexiia,point5.8)nonesubmittedmt14acuteoralld50(rats):>2000mg/kgbw.90-daydietaryrats:noaelandloaelof10.3and45.7mg/kgbw/day,basedonincreasedmortalityandwaterconsumption,changesinhaematology,clinicalchemistryandurinalysisparametersandincreasedkidneyweight,renal(histo)pathologysecondarytochronicrenalfailure.mutagenicityinbacterialcells:negative.clastogenicityincho(chinesehamsterovary)cells:negative.mouselymphomaassay:negativemt13acuteoralld50(rats):>2000mg/kgbw.90-daydietaryrats:noaelandloaelof3.4and10.3mg/kgbw/daybasedonchangesinhaematologyandclinicalchemistryparameters.mutagenicityinbacterialcells:negativemouselymphomaassayinl5178ycells:negativeclastogenicityinculturedhumanlymphocytes:negativemt20acuteoralld50(rats):>5500mg/kgbw90-daydietaryrats:m:noaelandloaelof16.7and34.1mg/kgbw/day,basedondecreasedbodyweight,changesinclinicalchemistryandurinalysisparametersandorganweighteffectsf:noaelandloaelof0.7and7.6mg/kgbw/day,basedonalteredoestruscyclelengthandprolongedoestrusand/ordioestrusmutagenicityinbacterialcells:negativemousemicronucleusassay:10efsajournal2017;15(6):4868mt1acuteoralld50(rats):236mg/kgbwacuteoralld50(rats):300-500mg/kgbwmutagenicityinbacterialcells:negativesecondmutagenicityinbacterialcells:negativeinvitrocytogeneticassayinhumanlymphocytes:negativegenemutationassay:weaklypositivemousemicronucleusassay:negativeinvivounscheduleddnasynthesis:negative90-dayratstudyreducedbodyweightgaintotalwbc(whitebloodcells)reducednonoaellm1mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm2mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm3mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm4mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm5mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm6mutagenicityinbacterialcells:negativegenemutationassay:weaklypositiveinvitrochromosomeaberration:negativemousemicronucleusassay:negativesummary(annexiia,point5.10)value(mg/kgbw(perday))studyuncertaintyfactor0.004dog,1-year&rat,2-year1000.0032dog,1-yearoverall126*(100+79%*)0.008rabbitdevelopmentalstudy100*correctionfororalabsorptio", "efs24874-sup-0001-appendix_a.pdf": "journal2017;15(6):4874impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrat(50mg/kgbw):>80%(m/f-basedonurinaryandbiliaryexcretion)within48h;tmax=1h.mouse(50mg/kgbw):35%(m)and41%(f)within72h,(basedonurinaryexcretiononly,bilenotmeasured);admeseemstobesimilarinmicecomparedtorats);tmax=0.5htoxicokineticsparametersmouse.doses,50and500mg/kgbwperd,singleandrepeated(21d)cmax(g-eq/g):11(females,low,single)-55(males,high,repeated)tmax(hours):0.5(low)-1(high)(forbothmales-femalesandsingle-repeated)eliminationhalf-life(hours):1.1(males,low,single)-3.5(males,high,repeated).rat.doses,50and250mg/kgbwperd,singleoraldosecmax(g-eq/g):low:40.6and40.2;high:73.8and62.3(formalesandfemales,respectivelyinbothcases)tmax(hours):1(low)(forbothmales-females);2and1.8(highdose,formalesandfemales,respectively)auc:low:104and92.6;high:397and446(formalesandfemales,respectivelyinbothcases).distributionratandmouse(50mg/kgbw):widelydistributed;highestresiduesinstomach,kidney,liver,serumandadrenalglandsat4h.potentialforbioaccumulationratsandmice:noevidenceofaccumulationrateandextentofexcretionrat(50mg/kgbw):89%(m/f)within48h,mainlyviaurine,62%(f),74%(m)andbile,16%(f),11%(m).mouse(50mg/kgbw):92%(m/f)within72hmainlyviafaeces,54%(f),59%(m)andurine,38%(f),33%(m)terminalhalf-life:1-2hmetabolisminanimalsrat,mouse:firststep,extensivemetabolizationbyp-hydroxylationofthephenylmoiety.rat:later,rapidsulphateconjugationandbyn-glucuronideconjugation;mouse:followedbyrapido-glucuronicacidconjugation.invitrometabolisminhepatocytes,km(m)=39(human),95(rat),(112)mouse;vmax(nmoles/min)=1.4(human),7(rat),2.7(mouse).noqualitativedifferencesinmetaboliteformationbylivermicrosomes(rat,mouse,human).majormetabolite,4-ohforchlorfenuron(rat,mouse).toxicologicallyrelevantcompounds(animalsandplants)forchlorfenurontoxicologicallyrelevantcompounds(environment)forchlorfenuron'journal2017;15(6):4874acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral4917mg/kgbw(m/f)rabbitld50dermal>2000mg/kgbw(m/f)ratlc50inhalation>3mg/lmaxattainableconcentration(dust,whole-body).skinirritationnon-irritant.eyeirritationnon-irritant.skinsensitisationnonsensitizer(buehlertests+qsaranalysis).phototoxicitynoacutephototoxicpotentialinvitroshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectkidney:increaseinweight,dose-relateddilatedrenalpelvis,primarilychronicprogressivenephropathy(rat),lymphocyticcellinfiltrationintheinterstitiumandpelvisofthekidneys(mouse)liver(increaseinweight,mononuclearcellularinfiltrate)(rat)relevantoralnoaelrat:16.2mg/kgbwperday,90-daystudydog:100mg/kgbwperday,12monthstudymouse:609mg/kgbwperday,90-daystudyrelevantdermalnoaelnodata.notrequired.relevantinhalationnoaelnodata.notrequired.genotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesamestestnegativemammaliangenemutationtestnegativemammalianchromosomeaberrationtestnegativeudstestnegativeinvivostudiesudstestnegativemicronucleustestnegativephotomutagenicitynodata.norequired.potentialforgenotoxicityunlikelytobegenotoxiclong-termtoxicityandcarcinogenicity(regulation(eu)n283/2013,annexparta,point5.5)long-termeffects(targetorgan/criticaleffect)mouse:kidney(tubularhyperplasia)rat:bodyweightreduction,liverandkidneytoxicityrelevantlong-termnoaelmouse:4.9mg/kgbwperdayrat:7mg/kgbwperday)carcinogenicity(targetorgan,tumourtype)mouse:renaltumoursat500mg/kgbwperday)andhigherrat:nocarcinogeniceffectcarc.cat2'", "efs24903-sup-0001-appendix_a.pdf": "mpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)invitroin-vitroacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)'", "efs24905-sup-0001-appendix_a.pdf": "mpactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)thereisnodirectobservationsuggestingthatexposuretoclonostachysroseastrainj1446couldberelatedtoharmfuleffectsinhumans.thereisnoinformationsuggestingtheoccurrenceofpoisoningincidentswhichcouldberelatedtoanexposuretoclonostachysroseastrainj1446.noharmfuleffectstopeopleinvolvedinresearchwiththestraincolostachysroseaj1446since1991,ortoemployeesintheproductionplantsince1995,havebeenobservedorreported.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)equivocalresultsinabuehlertest.clonostachysroseaj1446mayhavetheacuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)noevidenceoftoxicityorinfectivity/pathogenicitytoratsfollowingasingleoraladministrationof2x109cfu/kgbodyweightofviableclonostachysroseacellmass.acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)noevidenceoftoxicity,infectivity/pathogenicitytoratsfollowingasingleintratrachealadministrationof6.60-7.98x107cfu/kgbodyweightofviableclonostachysroseacellmass.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)noevidenceofinfectivitytoratsfollowingasingleintra-peritonealadministrationof4.2.x108cfu/kgbodyweightofviableclonostachysroseacellmass.genotoxicity:(ma5.2.3;oecdiim5.3.5)negativeamestestwithcrudeextractandgliotoxin.theactivemicroorganismisnotlikelytohavegenotoxicpotential.cellculturestudy:(ma5.2.4;oecdiim5.3.6)clonostachysroseastrainj1446isnotlikelytocausecelltransformation.informationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)clonostachysroseastrainj1446isnotlikelytoshowshorttermtoxicity.dermaltoxicity:(mp7.1.3;oecdiiim7.1.2)prestopwp:ratld50>2000mg/kgbw;nomortality,nosignsoftoxicity,pathogenicityandinfectivity.specifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)nodata,notrequiredgenotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)nodata,notrequiredreferencevaluesaoel:clonostachysroseastrainj1446isconcludedasnottoxic,pathogenicorinfective.aoelisnotrequired.adi:clonostachysroseastrainj1446isconcludedasnottoxic,pathogenicorinfective.adiisnotrequired.arfd:clonostachysroseastrainj1446isconcludedasnottoxic,pathogenicorinfective.arfdisnotrequired.exposure(operator,workers,bystander,consumer):(ma6.1&mp7.3,8.0;oecdiim5.6&iiim7.2,7.3)notrequiredforclonostachysroseastrainj1446.datagapforpotentialexposureofworkersandresidentstosecondarymetabolites/toxins.'", "efs24912-sup-0001-appendix_a.pdf": "ww.efsa.europa.eu/efsajournal12efsajournal2017;15(7):4912section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityoralabsorptionis67%(basedonurinaryexcretion)toxicokineticshalf-live:26-33h(lowdosegroups,basedoncumulativeexcretion)distributionwidelydistributed.highestlevelswerefoundinblood,kidneyandliverpotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(98.8%after96h),mainlyviaurinemetabolisminanimalsextensivelymetabolised(>90%);mainmetabolites:saccharin(in-00581),metsulfuron-methyl(in-t6376)invitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)tribenuron-methyltoxicologicallyrelevantcompounds(environment)tribenuron-methylacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>6.0mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(buehler;magnussonandkligman)skinsens1,h317phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:liver(hypertrophy),spleen(increasedrelativeweight),mortality,depressionofbodyweightmouse:depressionofbodyweight,liver(increasedabsoluteandrelativeweights),spleen(increasedrelativeweight)dog:thyroid/parathyroid(increasedabsoluteandrelativeweights),depressionofbodyweight,haematotoxicity,kidney(clinicalchemistryparameters)relevantoralnoael90-day,rat:7mg/kgbwperday90-day,mouse:70mg/kgbwperday90-daydog:15mg/kgbwperday1-yeardog:8mg/kgbwperdayrelevantdermalnoael28-day,rabbit:noaelnotestablished,loael'", "efs24976-sup-0001-appendix_a.pdf": "eerreviewofthepesticideriskassessmentoftheactivesubstanceflurtamonewww.efsa.europa.eu/efsajournal8efsajournal2017;15(8):4976impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability92.5%(oral,5mg/kgbw),34.5%(oral,500mg/kgbw)toxicokineticsoraldose5mg/kg(bygavage),plasmakinetics:cmax=3.1/2.7mgeq/kgtmax=0.8/1.1h;t1/2=47/27h,auc0-168=24/17mg.hour/kgdistributionwidely,higherlevelsintheliverpotentialforbioaccumulationlowrateandextentofexcretionviafaeces(49-61%,7d)andurine(38-43%,7d),mostlyoccurringwithin24hmetabolisminanimalsextensivelymetabolizedusingflurtamonelabelledonthetrifluoromethyl-phenylring:byaromaticringhydroxylation,n-demethylation,o-alkylationofthering-hydroxylatedproducts,hydrolysisofthefuranringandconjugation.invitrometabolismmetabolismofflurtamonebyratandhumanlivermicrosomeswassimilarbothqualitativelyandquantitatively,metabolisminmicewasmorerapid.toxicologicallyrelevantcompounds(animalsandplants)flurtamone,tfmba,tfatoxicologicallyrelevantcompounds(environment)flurtamone,tfaacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>2.2mg/lair/4h(wholebodyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotasensitizer(m&k,modifiedbuehler)phototoxicitynodata,datarequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectliver:increasedweight(rat,dog),clinicalchemistrychanges(rat,dog),andcentrilobularhypertrophy(rat,dog,mouse)blood:haematologicalchanges(mouse)'", "efs24978-sup-0001-appendix_a.pdf": "section2mammaliantoxicologyimpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityabout60-70%within72hintherat(biliaryexcretiontakenintoaccount)followingasinglegavagedoseof10mg/kgbwthevaluefororalabsorptionchosenforcalculationoftheaoelwas60%.pre-treatmentofanimalswithmethoxyfenozideinthedietfor2weeksdidnotappreciablyaltertheabsorption,distributionoreliminationfindingstoxicokineticsthemaximumconcentrationsofradioactivityinbloodandplasmawereobserved15to30minutespost-dose.peakbloodlevelswerenotproportionaltothedoseleveladministered.eliminationof14c-labelfromplasmafollowedabiphasicpattern.distributionwidelydistributed.highestabsorbedlevelsafter15minto2hintheliver.highestlevelsafter5daysalsochieflyinliver.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionthemajorityoftheadministereddosewasexcretedinfaeces(c.90%)andtoalesserextentintheurine(c.5-10%).therewassignificantbiliaryexcretion.metabolisminanimalsthemetabolismofmethoxyfenozidewasrapidandextensive(atotalof31metabolites,ofwhich25wereidentified).mostly,themainpartofthemethoxyfenozidemoleculeremainedintact,iethedibenzoyl-tert-butylhydrazinestructure)waspresentinmostmetabolites.invitrometabolismnodata,datagapidentifiedtoxicologicallyrelevantcompounds(animalsandplants)parentandmetabolitesm14anditsconjugates(m115andm40).m24andconjugatesandm16.toxicologicallyrelevantcompounds(environment)parentandm08acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralld50>5000mg/kgbwratld50dermalld50>5000mg/kgbwratlc50inhalationlc50>4.3mg/l(4h,noseonly,maximumachievableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiserinsubmittedstudy(m&k)'", "efs24980-sup-0001-appendix_a.pdf": "8efsajournal2017;15(9):4980impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability60%basedontherecoveryofradioactivityfromthebile,blood,urine,tissuesandcarcasses,oftheadministeredoraldose(rat,singledose,10mg/kgbwperday)toxicokineticsthemaximumconcentrationsofradioactivityinplasmawereobservedat8hourspostdose(cmaxinplasma=8hrs;cmax=22hrs).distributionwidedistribution.thehighestconcentrationsofresidueswereobservedinliver,intestinaltractandcarcass.potentialforbioaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandalmostcompletelyeliminated(over85%oftheadministeredradioactivitywasexcretedduringthefirst24-48hoursafterdosing)viathebile.metabolisminanimalsextensive,32metabolitesidentified(mainlybyhydrolysis,oxidation,reductivedehalogenationandconjugation).invitrometabolismnouniquehumanmetaboliteexpected.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw(rat)>5000mg/kgbw(mouse)ratld50dermal>2000mg/kgbwratlc50inhalation>5.3mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationirritanth319skinsensitisationsensitising(m&kandbuehler)h317cat1phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectdog:liver(increasedweight).", "efs24981-sup-0001-appendix_a.pdf": "efsajournal2017;15(9):4981impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrat(singledose,8mg/kgbw):absorption>80%()basedonthesumoftotalradioactivityexcretedinbile,urine,cagewashandcarcasswithin96htoxicokineticsrat(singledose,8mg/kgbw):cmax:0.795gand0.773gequivalents/ginplasma()tmax:ca.12hoursplasmat1/2:41-47hoursdistributionwidelydistributed,highestresiduesinliverandkidneypotentialforbioaccumulationnoaccumulationintissues;possiblebindingtoredbloodcells(slowdeclineinwhole-bloodafter168hrs)rateandextentofexcretion>90%within96h(approx.60%viafaeces,approx.35%viaurine);bilecannulatedrats:approx.74%viabilewithin48hmetabolisminanimalsextensivelymetabolisedbyconjugation,de-ethylationandoxidationtosulphoxidesandsulfonesinvitrometabolismnostudyavailable(datagap)toxicologicallyrelevantcompounds(animalsandplants)pethoxamidtoxicologicallyrelevantcompounds(environment)met-42,met-101,met-100andmet-22(relevantgroundwatermetabolites,basedontheproposedclassificationascarccat2forpethoxamid)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral983mg/kgbwacutetox4ratld50dermal>2000mg/kgbwratlc50inhalation>4.16mg/lair/4h(wholebody,maximumattainableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(guineapigmaximisationtestofmagnussonandkligman)skinsens1aphototoxicitynotphototoxic", "efs24988-sup-0001-appendix-a.pdf": ".efsa.europa.eu/efsajournal14efsajournal2017;15(9):4988impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidly,52%basedonrecoveryinbile,urineandcarcasswithin48haftersingledoseadministration.correctionisconsideredappropriatefortheaoel.toxicokineticswidelyandrapidlydistributed;peakplasmaconcentrations2-4hrsafteradministrationof5mg/kgof[14c-t-butylphenyl]etoxazoleor[14c-oxazole]etoxazole.terminalhalf-livesof52.9hoursand61.3hoursformaleandfemalerats,respectivelyafteradministrationof[14c-t-butylphenyl]etoxazole.terminalhalf-livesof71.4hoursand88.8hoursformaleandfemalerats,respectivelyafteradministrationof[14c-oxazole]etoxazole.distributionhighestresiduesintheliver,gitractandfatafter7dayspotentialforbioaccumulationlowevidenceforaccumulationrateandextentofexcretionrapidlyexcretedwithin48h,mainlyviafaeces[14c-t-butylphenyl]etoxazole:7.55-8.49%viaurine,86.8-88.3%viafaeceswithin7days(singlelowdose5mg/kgbw);[14c-oxazole]etoxazole:14.2-16.6%viaurine,77%viafaeces,within7days(singlelowdose5mg/kgbw)[14c-t-butylphenyl]etoxazole(bile-cannulatedrats):40.25-53.95%viabile,12.13-13.53%viaurine,33.99-46.55%viafaeces,within48hrs(singlelowdose5mg/kgbw)[14c-oxazole]etoxazole(bile-cannulatedrats):29.80-36.80%viabile,18.37-24.11%viaurine,39.14-50.46%viafaeces,within48hrs(singlelowdose5mg/kgbw)metabolisminanimalsextensivelymetabolised,principallybyhydroxylationofthe4,5-dihydrooxazoleringfollowedbycleavageofthemoleculeandhydroxylationofthetertiary-butylsidechain.invitrometabolismm9(r-2)majormetaboliteinhumansandmalerats.minormetabolitesinhumansalsodetectedinrats.m10majormetaboliteinmaleandfemalerats.themajormetabolicpathwayofhumanswassimilartothatofrats.nouniquemetabolitesdetectedinhumans.toxicologicallyrelevantcompounds(animalsandplants)parentcompound.toxicologicallyrelevantcompounds(environment)parentcompound.'.efsa.europa.eu/efsajournal15efsajournal2017;15(9):4988acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.09mg/l(wholebody,max.attainableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitisingphototoxicitynotphototoxicundertheexaminedconditions**the3t3nru-pttestmightnotbeappropriatetestforuvbabsorbersasetoxazole.short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectdog,rat,mouse:liver(indicationsoflivertoxicity)relevantoralnoaeldog:90-d&1-yr,dog:5mg/kgbwperdayrat:6.1mg/kgbwperday(male).mouse:55.1mg/kgbwperday(male).relevantdermalnoael28-d,rat:100mg/kgbwperdayrelevantinhalationnoaelnodata(nostudyrequired)genotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesreversegenemutationassay(salmonellatyphimuriumandescherichiacoli):negativemammaliancellgenemutation(mouselymphomal5178ycells):positive(+s9)invitrochromosomeaberrationassay(chinesehamsterlungcells):negativeinvivostudiesmousemicronucleuschromosomeaberrationassay:negativeunscheduleddnasynthsis(rat):negativecometassayinratliverandglandularstomach:negativephotomutagenicitynostudyregardingphotomutagenicitysubmittednotrequiredpotentialforgenotoxicitynon-genotoxicinvivolong-termtoxicityandcarcinogenicity(regulation(eu)n283/2013,annexparta,point5.5)long-termeffects(targetorgan/criticaleffect)rat,mouse:liver(indicationsoflivertoxicity'", "efs24989-sup-0001-appendix_a.pdf": "10):4989impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability60%(basedonurinary(%)andbiliary(%)excretionafter48hat0.5mg/kgbw)toxicokinetics0.5mg/kgbw[glyoxyl-phenyl-u-14c]trifloxystrobinmalefemalecmax(mgeq/kg)0.070.07tmax(hour)1212plasma(hour)t1/24823auc(0-48h)(mghour/kg)2.71.6100mg/kgbw[glyoxyl-phenyl-u-14c]trifloxystrobinmalefemalecmax(mgeq/kg)9.346.52tmax(hour)2412plasmat1/2(hour)5044auc(0-48h)(mghour/kg)334.6214.3distributionwidelydistributed(highestresidueswerefoundinblood,kidneysandliver.)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(94-96%within48h),mainlyviafaeces(62-75%)andurine(17-34%)metabolisminanimalsextensivelymetabolised(>95%)majorpathway:esterhydrolysis,o-demethylationofthemethoxyaminogroup,hydroxylationofmethylsidechanin,cleavagebetweentheglyoxylphenylandtrifluromethylphenylrings.invitrometabolismnouniquemetabolitestoxicologicallyrelevantcompounds(animalsandplants)parentcompound.openforthemetabolites(cga357262,cga357261andcga331409)andcga321113(m5).toxicologicallyrelevantcompounds(environment)cga321113,noa413161,noa413163.acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.6mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(weightofevidencebasedonm&kassay,buehlerassayandllna)phototoxicitynotphototoxictobalb/c3t3cellsshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:reducedbodyweightgainandfoodconsumptionandliver(increasedweight,'", "efs25078-sup-0001-appendix_a.pdf": "efsajournal2017;15(12):5078impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))noadversehealtheffectshavebeenobservedinanyoftheemployeesinvolvedintheproduction,handlingandapplicationofampelomycesquisqualisstrainaq10.sensitisation:(ma5.2.1&mp7.2.3)noreportofsensitizationorallergenicresponseofworkers.amagnusson&kligmantestgivesequivocalresults.nevertheless,accordingtocommissionregulation(eu)no283/2013,theavailablemethodsfortestingdermalsensitizationarenotsuitablefortestingmicro-organisms.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)acuteoraltoxicityandinfectivity/pathogenicitytorats:therewasnomortalityorevidenceoftoxicitypathogenicityorinfectivityfollowingoraladministrationofampelomycesquisqualisstrainaq10atdoseof7.8x106cfu/animal(male)and7.5x106cfu/animal(female).immediatelyafterthedosing(day0),theclearancewascompletefromalltissuesanalysed.acuteoraltoxicity(withtechnicalmaterial):theld50toratsofaq10productafterasingleoraldoseis>5050mg/kgbw.acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)acutepulmonarytoxicityandinfectivity/pathogenicitytorats:2intratrachealstudiesavailableadministrationofampelomycesquisqualisstrainaq10atdoseof7.4x105cfu/animal(male)and7.5x105cfu/animal(female)(firststudy)or3.5x107cfu/animal(secondstudy).somemortalityobservedafterdosinginthefirststudyandassociatedtoinflammationinthesecondone.nosignofpathogenicityorinfectivityobserved.theclearancewascompletefromalltissuesanalysedatday3inthetwostudies.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3)acuteintraperitonealtoxicityandinfectivity/pathogenicitytorats:therewasnomortalityorevidenceoftoxicitypathogenicityorinfectivityfollowingintraperitonealadministrationofampelomycesquisqualisstrainaq10atdoseof7.9x106cfu/animal.theclearancewascompletefromalltissuesanalysedatday3.genotoxicity:(ma5.2.3)thedmsoextractofampelomycesquisqualisstrainaq10wasnotmutagenicinanamessalmonellatyphimuriumassayorgenotoxicinaninvitromammalianchromosomeaberrationtesteitherinthepresenceorabsenceofmetabolicactivation.cellculturestudy:(ma5.2.4)thereisnoindicationforintracellularreplicationofampelomycesquisqualis.themechanismsofintracellularreplicationareunknown.therefore,cellculturestudiesare'efsajournal2017;15(12):5078notconsiderednecessary.informationonshort-termtoxicityandpathogenicity:(ma5.2.5)therewerenochangesoftoxicologicalsignificancefororaltoxicityofampelomycesquisqualiswhenadministeredtospraguedawleyratsfor13consecutiveweeksatdosagesof2x108heatinactivatedspores/animalor2x108cfu/animal.dermaltoxicity:(mp7.1.3)acutedermaltoxicity(withtechnicalmaterial):theld50toratsofaq10productafterasingleoraldoseis>2020mg/kgbw.specifictoxicity,pathogenicityandinfectivity:(ma5.3)nodatanotrequired.genotoxicityinvivostudiesingermcells:(ma5.5)thedmsoextractofampelomycesquisqualisstrainaq10wasnotclastogenicinmammalianerythrocytemicronucleustest.referencevaluesacceptableoperatorexposurelevel(aoel)thereisnoneedtosetanaoelasthemicroorganismwasnotshowntobepathogenicorinfectivebasedontheavailabledataandstudiesacuteacceptableoperatorexposurelevel(aaoel)thereisnoneedtosetanaaoelasthemicroorganismwasnotshowntobepathogenicorinfectivebasedontheavailabledataandstudiesacceptabledailyintake(adi)thereisnoneedtosetanadiasthemicroorganismwasnotshowntobepathogenicorinfectivebasedontheavailabledataandstudiesacutereferencedose(arfd)thereisnoneedtosetanarfdasthemicroorganismwasnotshowntobepathogenicorinfectivebasedontheavailabledataandstudiesexposure(operator,workers,bystander,resident,consumer):(ma6.1&mp7.3,8.0)exposureestimatestothemicroorganismarenotnecessary.appropriateppeforoperatorandworkerconsideringpotentialsensitizingpropertiesofmicro-organisms.consideringthedatagapforidentificationandquantificationofsecondarymetabolitesproducedbyampelomycesquisqualisstrainaq10intheproductandafterapplication,non-dietaryexposureassessmenttopotentialsecondarymetabolites/toxinsremainsopen.residues(regulation(eu)n283/2013,annexpartb,point6andregulation(eu)n284/2013,annexpartb,point8)viableresidues:noriskfortheconsumerisexpectedfromtheorganismitselfi.e.itisnotpathogenictohumannon-viableresidues:ampelomycesquisqualisstrainaq10mayhaveapotentialtoproducesecondarymetabolitesand/ortoxinsofhumanhealthconcern.aconsumerriskassessmentcannotbeperformedduetomissinginformationonpossiblesecondarymetabolites/'", "efs25084-sup-0001-appendix_a.pdf": "4.2&mp5.2)oftheactivemicroorganism(principleofmethod):noresiduedefinitionisapplicableform.fructicolanrrly-27328ofrelevantmetabolites(principleofmethod):openimpactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))noevidenceofadversehealtheffectshavebeenobservedinanyoftheemployeesinvolvedintheproduction,handlingandapplicationofmetschnikowiafructicolanrrly-27328sensitization:(ma5.2.1&mp7.2.3)noreportofsensitizationorallergenicresponseofworkers.basedongeneralassumptionsformicro-organisms,usemetschnikowiafructicolanrrly-27328wasfoundtobenotsensitizingtoguineapigs.nevertheless,accordingtocommissionregulation(eu)no283/2013,theavailablemethodsfortestingdermalsensitizationarenotsuitablefortestingmicro-organisms.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)acuteoraltoxicityandinfectivity/pathogenicitytoratstherewasnomortalityorevidenceoftoxicitypathogenicityorinfectivityfollowingoraladministrationofmetschnikowiafructicolanrrly-27328atdoseof1.4-2.5108cfu/ratandthereforetheacuteoralld50is1.4-2.5108cfu/rat.clearanceoflivemicro-organismfromalltissuesanalyzedwascompleteatfirstsamplingindicatingarapidlossofviabilityfollowingoraladministration.acuteoraltoxicitynomortalitywasobserved.theld50tofemaleratsofmetschnikowiafructicolanrrly-27328afterasingleoraldoseis>2500mg/kgbw(correspondingto3.51010cfu/kgbw).acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)acutepulmonarytoxicityandinfectivity/pathogenicitytorats3unscheduleddeathsdirectlyfollowingadministrationonthedayofdosing(1malefromautoclavestestitemgroupand2malesfromthelivetestitemgroup)wereattributedtotreatmentprocedure.nosignofovertoxicityorpathogenicitywasobservedfollowingasingledoseof1.42.7108cfu/animalofmetschnikowiafructicolanrrly-27328byintra-trachealinstillation.totalclearancewasreachedatday8.acuteinhalationtoxicitystudyinratsnomortalitywasobserved.theld50tofemaleratsofmetschnikowiafructicolanrrly-27328after4hoursbynoseonlyexposureis>6.52mg/l(equivalentto2.05106cfu/l)acutesubcutaneousinfectivity,toxicityandpathogenicity:acutesubcutaneoustoxicityandpathogenicitytotherattherewasnomortalityorevidenceoftoxicity'5.2.2.3)pathogenicityorinfectivityfollowingsubcutaneousadministrationofmetschnikowiafructicolanrrly-27328atdoseof1.6-2.6108cfu/rat.clearanceoflivemicroorganismfrominjectionsiteswascompleteatday8.clearanceoflivemicroorganismfromallothertissuesanalyzedwascompleteatfirstsampling.genotoxicity:(ma5.2.3)nodata,notconsiderednecessarycellculturestudy:(ma5.2.4)nodata,notconsiderednecessary.informationonshort-termtoxicityandpathogenicity:(ma5.2.5)nodata,notconsiderednecessary.dermaltoxicity:(mp7.1.3)acutedermaltoxicitystudyinratsnomortalitywasobserved.theld50tofemaleratsofmetschnikowiafructicolanrrly-27328afterdermalexposureis>2000mg/kgbw(equivalentto2.81010cfu/kgbw)specifictoxicity,pathogenicityandinfectivity:(ma5.3)nodata,notconsiderednecessary.genotoxicityinvivostudiesingermcells:(ma5.5)nodata,notconsiderednecessary.aoel,adi,arfd,aaoelthereisnoneedtosetreferencevaluesasthemicroorganismwasnotshowntobepathogenicorinfectivebasedontheavailabledataandstudies.settingofreferencevaluestosecondarymetabolites/toxinscannotbefinalized.exposure(operator,workers,bystander,resident):(ma6.1&mp7.3,8.0)operator,worker,bystander,residentexposureestimatestothemicroorganismisnotneeded.appropriateppeconsideringpotentialsensitizingpropertiesofmicro-organisms.non-dietaryriskassessmenttosecondarymetabolites/toxinscannotbefinalised.residues(regulation(eu)n283/2013,annexpartb,point6andregulation(eu)n284/2013,annexpartb,point8)viableresidues:noriskfortheconsumerisexpectedfromtheorganismitselfi.e.itisnotpathogenic.non-viableresidues:metschnikowiafructicolanrrly-27328producespulcherriminandquantitativeinformationonconcentrationsofpulcherriminontherawagriculturalcommoditiesisnotreported(datagap).basedonthephiof1day,ithastobeassumedthatviablecellcountsofm.fructicolaofaround105cfu/fruitareexpectedatthetimeofharvestandtheirpotentialtoformtoxinsand/orsecondarymetabolitessuchaspulcherriminisnotinvestigated.theviablecellcountsofsecondary'", "efs25085-sup-0001-appendix_a.pdf": "assessmentofthepesticideactivesubstancequinoxyfenwww.efsa.europa.eu/efsajournal4efsajournal2018;16(1):5085impactonhumanandanimalhealthnotassessedinthistargetedevaluation'", "efs25126-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrat:20%basedontheradioactivityexcretedinurineandbile,excludingbileexcretionduringthefirst4hoursthatmaybeconsideredasnotsystemicallyavailablesincethekidneysandnottheliverarethetargetorgansofchlorothalonil.thisvalueissupportedbythecomparisonofurineexcretionafteroralvs.ivadministrationsdog:8%(within48h,bileandurine)mouse:minimal10%(within168h,urine)toxicokineticsrat,lowdose[14c]-chlorothalonil(1.5or5mg/kgbwp.o):cmaxofradioactivityinblood:0.18-0.23and0.11-0.31gequiv/g,maleandfemalerats,respectivelyobservedat(tmax)2-8hoursinmalesand1.5-4hoursinfemales,withat1/2of45-58hoursand53-60hoursandanauc0-tof3.2-5.0and2.9-7.6gequiv.h/mlinmalesandfemales,respectively.rat,highdose[14c]-chlorothalonil(43or200mg/kgbwp.o.):cmaxofradioactivityinblood:2.8-3.2and6.0-9.3gequiv/g,maleandfemalerats,respectively,observedat(tmax)12hoursandwithanauc0-tof66.5and168.3gequiv.h/mlinmalesandfemales,respectively.dog,males,highdose[14c]-chlorothalonil(50mg/kgbwp.o.)cmaxofradioactivityinplasma:0.25mgequiv/kgtissueobservedat(tmax)6hoursandwithanauc0-tof4.7mgeq/kgtissue.distributionwidelydistributed,highesttissueresiduesinkidneys.inaddition,thyroid,adrenals,blood,boneandspleenshowedresidue.affinityforredbloodcellbinding.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionmainlyviafaeces(65-90%inmice,>80%inrats,89-99%indogs,generallynotcompleted168hpostadministration.eliminationfromplasmaisquickerthanfrombloodduetoretentionobservedinbloodcells.metabolisminanimalsextensivemetabolismviahydroxylationtosds-3701andglutathioneconjugationandsubsequently-lyasepathwaysinvitrometabolismnodatadatarequiredtoxicologicallyrelevantcompounds(animalsandplants)chlorothalonil,r182281(sds-3701),r613636(sds-47525)andr417888toxicologicallyrelevantcompounds(environment)chlorothalonil,r417888,r418503,r419492,r471811,syn507900,r611965,r611968,syn548008(m3),syn548581(m11),m2,m7,m10'acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw(ratandmouse)ratld50dermal>5000mg/kgbw(ratandrabbit)ratlc50inhalation0.1mg/lair/4h(noseonly)h330,stotse3h335skinirritationnon-irritanteyeirritationirritanth318skinsensitisationsensitising(maximisationtest)h317cat1aphototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:kidney(histopathologicalchanges,increasedweight),forestomachlesions(consideredrodent-specific)mouse:forestomachlesions(consideredrodent-specific),kidney(tubularepithelialhyperplasia,increasedweight)dog:bodyweight,liverandkidneyweight,histopathologicalchangesinkidneyandadrenalsrelevantoralnoael90-day,dog:5.1mg/kgbwperday90-dayrat:1.5mg/kgbwperday(systemicandlocalnoael)90-daymouse:47.7mg/kgbwperday(systemic)and2.5mg/kgbwperday(local;consideredrodent-specific)relevantdermalnoael21-day,rat:<60mg/kgbwperdayrelevantinhalationnoael2-week(5days/week,6hours/day),rat:noaec(systemic)0.0011mg/lairbasedonreducedbodyweightgainnoaec(local)<0.0011mg/lairbasedonlocalirritationoftherespiratorytractgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesbacteriareversemutationassay(3studies):negativebacteriadna-repairassay(differentialkilling;1study):positivechromosomeaberrationassay(2studies);positive-s9,1negative+s9(chocells)and1equivocal+s9(humanlymphocytes).forward-mutationassay(2studies):negative'", "efs25130-sup-0001-appendix_a.pdf": "on2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityratandmouse:>90%oftheadministereddoses,basedontheradioactivityoftheurinemetabolitesfoundtoxicokineticstheradioactivitylevel(aftersingleadministrationof5mg/kg)reachedapeakin2hoursinalmostalltissues.at2hours,theconcentrationinkidneyswasthehighest(3to4timesthatinplasma),followedbytheliverandblood.mostoftheradioactivitywaseliminatedwithinfirst48hours.distributiontolclofos-methylisdistributedtoasmallextent.mainlytothebloodandliver.potentialforbioaccumulationdoesnotaccumulaterateandextentofexcretiontolclofos-methylwasreadilyexcretedinratsandmice,mainlyintheurine.lessthan1%ofthedosewasretainedinthetissuesafter7days.metabolisminanimalsthemainmetabolites(>85%oftotalradioactivity)weretm-ch2oh,tmo-ch2oh,ph-ch3,ph-ch2ohandtm-coohformedbyoxidativedesulfurationofthep=sgrouptop=o,oxidationof4-methylgroup,andcleavageofp-o-arylandp-o-methyllinkages).invitrometabolismthemetabolisminratandhumanmicrosomesaresimilartoxicologicallyrelevantcompounds(animalsandplants)tolclofos-methyl.dm-tm-ch2oh;tm-ch2oh;ph-ch3,.ph-ch2ohtoxicologicallyrelevantcompounds(environment)tolclofos-methyl;tmo-coohanddm-tmo(drinkingwater)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>2.07mg/l(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(maximisationtest)h317phototoxicitynophototoxicpotential(3t3nru-pttest)(a)(a)theoecd3t3nru-pttestmightnotbeappropriatetestforuvbabsorbersastolclofos-methyl(datagap).short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:liver(increasedweightandhypertrophy),kidney(increasedweight).mouse:liver(increasedweight),kidney(increasedweight)adrenal(increasedweight),decreasedcholinesteraseactivitiesdog:liver(increasedweight,increasedalkalinephosphatase,hypertrophy,pigment,intracytoplasmichomogenousmaterialrabbit:kidney(increasedorganweight)relevantoralnoael6-monthrat:18mg/kgbwperday9-monthmouse:3.8mg/kgbwperday'", "efs25133-sup-0001-appendix_a.pdf": "www.efsa.europa.eu/efsajournal10efsajournal2018;16(1):5133impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidlyabsorbed.oralbioavailability;88-89%within48h(basedonurine,bile,carcassandtissues,singleadministrationof14mg/kgbwinrats).indicationsoflowerrelativeabsorptionatahigherdoselevel(170mg/kgbw)toxicokineticsfollowingadministrationof14mg/kgbwinrats:plasma,males:cmax=4.75.4eq/g,tmax=2hours,t1/2=8.87hours(plasma),aucinf=52.0gh/g.plasma,females:cmax=5.9eq/g,tmax=2hours,t1/2=8.9hours,aucinf=56gh/g.distributionwidelydistributed.highestresiduelevelsfoundinliver,thyroidandkidney(rat)andgi-tract,liverandkidney(mice)potentialforbioaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandextensive:approx.96%within48hfollowingadministrationof14mg/kgbwinrats,mainlyviaurine(47%)andbile(40%).7%excretedviafaeces.indicationsofashifttowardsfaecalexcretionathigherdose(170mg/kgbw).metabolisminanimalsextensivelymetabolised(>72-88%);mainmetabolite5-hydroxy-carbendazim-s(5-oh-mbc-s)invitrometabolismcomparativeinvitrometabolismstudyinratandhumanlivermicrosomes.metabolites4-hydroxy-thiophanate-methyl(4-oh-tm),carbendazim(mbc)and5-hydroxy-carbendazim(5-oh-mbc)weredetectedinmicrosomepreparationsfrombothspecies.metabolitesuniqueforhumanswerenotobserved.toxicologicallyrelevantcompounds(animalsandplants)thiophanate-methylandcarbendazim(mbc)toxicologicallyrelevantcompounds(environment)thiophanate-methylandcarbendazim(mbc)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation1.7mg/lair/4h(wholebody)acutetox.4h332skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(gpmt)skinsens.1h317phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:liver(increasedweight,hypertrophy),thyroidstot'", "efs25140-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthnote:thenewtechnicalspecificationdefinesindoxacarb(dpx-kn128)asthealmostpureactivesisomer.however,thetechnicalspecificationforthefirstinclusionwasamixtureofisomerssetbasedonstudiesperformedwithtwomixtures:theracemic(dpx-jw062)andindoxacarb75s:25r(dpx-mp062).forthepurposeoftherenewal,therarincludestoxicitystudiesperformedwiththedifferentisomerratiosofindoxacarb:indoxacarb(dpx-kn128),indoxacarb75s:25r(dpx-mp062)orwiththeracemicmixture(dpx-jw062).theexpertsagreedthatnoneoftheenantiomers(i.e.dpx-kn128)shouldbeconsideredmoretoxicthantheothers.therefore,thestudiesconductedwiththelessactiveenantiomerthantheindoxacarb(dpx-kn128)arealsoconsideredrelevantforthepurposeoftherenewal.absorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityslowabsorption,60%(overall,basedonurinaryexcretionandtissuelevels(excludinggitractandcontent)within168h,supportedbyurinaryandbiliaryexcretionwithin48-hourstudiesconductedondpx-jw062(racemic)anddpx-mp062(75s:25r)inratsafterasingledoseof5mg/kgbw)toxicokineticsdpx-jw062(racemic)anddpx-mp062(75s:25r)inratsafterasingledoseof5mg/kgbw:plasma:cmax=2.3-2.4g/ginmales,2.9-3.0g/ginfemales;tmax=6.8-8.0hinmales,5.3-7.3hinfemales;t1/2=35-39hinmales,49-52hinfemalesredbloodcells:cmax=1.1g/ginmales,1.4-1.5g/ginfemales;tmax=6.8-8.7hinmales,3.3-6.0hinfemales;t1/2=91-97hinmales,68-74hinfemalesdistributionhighestlevelsinfatandblood(redbloodcells);sex-specific(highertissuelevelsinfemales)potentialforbioaccumulationpotentialforaccumulationinfatandredbloodcellsrateandextentofexcretionslowexcretion(37-55%viaurine;27-47%viafaeceswithin7days-dpx-jw062(racemic)anddpx-mp062(75s:25r)metabolisminanimalsextensivelymetabolised,sex-andstereospecific.biotransformationstartedwithenzymaticremovalofthemethoxycarbonylgroupleadingtoin-jt333(mostlyinfemales)orhydroxylationatthebenzylicpositionintheindanonemoietyleadingto5-oh-jw062(mostlyinmales).invitrometabolismnocomparativeinvitrometabolismstudyavailable.datagaptoxicologicallyrelevantcompounds(animalsandplants)indoxacarb,in-jt333toxicologicallyrelevantcompounds(environment)indoxacarbacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oraldpx-kn128:179mg/kgbwdpx-mp062(75:25):268mg/kgbwh301'ratld50dermaldpx-kn128>5000mg/kgbwdpx-mp062(75:25):>5000mg/kgbwratlc50inhalationdpx-jw062(racemic):4.2mg/lair/4h(nose-only)h332skinirritationdpx-kn128:non-irritantdpx-mp062(75:25):non-irritanteyeirritationdpx-kn128:non-irritantdpx-mp062(75:25):non-irritantskinsensitisationdpx-kn128:sensitising(m&k),nonsensitising(buehler3-induction)dpx-mp062(75:25):sensitising(m&k)h317(1b)phototoxicitydpx-kn128:notphototoxicbasedonastudyshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat,mouse,dog:haematologicalparameterfindingswithhistopathologicalfindingsinspleenstot-re1h372relevantoralnoael90-day,rat:dpx-kn128:0.68mg/kgbwperdaydpx-mp062(75:25):loael=0.76mg/kgbwperdaydpx-jw062(racemic):0.99mg/kgbwperday90-day,mouse:dpx-jw062(racemic):5.5mg/kgbwperday90-day,dog:dpx-jw062(racemic):loael=1mg/kgbwperday1-year,dog:dpx-jw062(racemic):loael=1.1mg/kgbwperdayrelevantdermalnoael28-day,rat:loael=50mg/kgbwperdayrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesdpx-kn128anddpx-mp062(75:25):amestest,invitromammaliancellgenemutation(cho/hgprt),invitrochromosomeaberration:negativedpx-mp062(75:25):invitrounscheduleddnasynthesis:negativeinvivostudiesdpx-kn128anddpx-mp062(75:25):mouseinvivomicronucleus:negative'", "efs25146-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityoralabsorption:rats:20%(urine/rinse/air)rats(bilecannulated):16%(10mg/kgbwxde-777)and2%(300mg/kgbwxde-777)mice:12%(males);25%(females)(urine/rinse/air)rabbits:42%rabbits(urine/rinse/air)toxicokinetics(valuesinplasmafollowingoraladministrationinmaleratsandfemalerabbits)cmax:3.2g/g(varieswithdoseandspecies)tmax1-6hoursafteroraldosing(varieswithdoseandspecies)absorptiont1/2:0.3-0.5helimantiont:2.7-2.9h(rat);3hours(rabbit);eliminationt:8-19h(dependingondose)(rats);612.8h(rabbits)distributionnotextensivelydistributed.levelswerehighestinthegitract(52-99%),followedbyurinarybladder(<1%)andliver(<1%),whichwasconsistentwiththeportalofentryandprimaryexcretiontissues.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionthemajorityoftheadministereddosesinrats,miceandrabbitswaseliminatedduringthefirst24hourspost-dosing,primarythroughfaeces(51-91%)andsecondarythroughurine(12-42%).excretionindogswasalmostexclusivelythroughfaeces(urine<1%).biliaryexcretion2-13%dependingthedose.metabolisminanimalssystemicallyavailablexde-777ishighlymetabolised,withverylittleparentfoundinthebloodorurine.parentxde-777isthemajorradiolabelledcomponentpresentinthefaeces.thefouridentifiedmetabolitesariseviahydrolysisofvariousestermoieties,aswellaso-dealkylationofthehydroxymethoxysidechainofthepyridinering.invitrometabolismxde-777producednouniquehumanmetaboliteswhenevaluatedintheinvitrocomparativemetabolismstudyutilisingrat,mouseandhumanlivermicrosomes.toxicologicallyrelevantcompounds(animalsandplants)fenpicoxamid(xde-777)toxicologicallyrelevantcompounds(environment)fenpicoxamid(xde-777)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>5000mg/kgbw'", "efs25150-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityoverall,theabsorptionwasabout80%in24hoursinthelowdoseand33-45%inhighdosein96h(basedmainlyonurinaryexcretion)toxicokineticspcring:plasmat1/2:39-59hourslowdose(5mg/kgbwperday):cmax:2.08-2.31mgequivalents[14c]-desmedipham/kgtissueinfemalestmax:2hourshighdose(1000mg/kgbw/day:cmax:126.12-134.04[14c]-desmedipham/kgtissueinfemalestmax:12hoursepcring:lowdose:cmax(1mg/kgbwperday):0.290gequiv/g-0.503gequiv/g)cmax(5mg/kgbw/day):2.08mgequivalents[14c]-desmedipham/kgtissue-2.31mgequivalents[14c]-desmedipham/kgtissuetmax:2hourshighdose:cmax(100mg/kgbw):37.8gequiv/gand43.1gequiv/ginmaleandfemalerats,respectivelytmax(100&1000mg/kgbw/day):8-12hoursdistributionwidelydistributed(blood,plasma,liver,lungs,kidneys,heart,spleen,muscle,ovaries,testes,renalfat,thyroidsandadrenals)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive:lowdose:app.90%within24h,mainlyviaurine(80%)andviafaeces(12-13%)highdose:>93%within96h,viaurine(33-45%)andviafaeces(51-56%)metabolisminanimalsextensivelymetabolised(>95%);oxidative/hydrolyticcleavageofparentmolecule,hydroxylationofaromaticringstructures,acetylationofaminegroups,conjugationinvitrometabolismnosignificantinterspeciesdifferencesandnohumanspecificmetabolitestoxicologicallyrelevantcompounds(animalsandplants)desmedipham,4-aminophenolandanilinetoxicologicallyrelevantcompounds(environment)desmediphamacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw'ratld50dermal>2000mg/kgbwratlc50inhalation>7.4mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationinsufficientdata-dataneeded,sincethetesteddosesweretoolowtodrawaconclusionphototoxicitynotphototoxicinvitro(3t3nru-pttest)(a)butfurtherdataareneededtoconclude(a)theoecd3t3nru-pttestmightnotbeanappropriatetestforuvbabsorberssuchasdesmediphamshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:anaemiaandthyroiddog:anaemiaandthyroideffectsonredbloodcells(methaemoglobinaemiaandhaemolyticanaemia)andrelatedeffects(hemosiderindepositioninspleen,liverandkidneys).thyroidaleffectsinratanddog(hypertrophyandhyperplasia)relevantoralnoael28-daymice:22mg/kgbwperday90-dayrat:2.6mg/kgbwperday(shorttermtoxicity);5.2mg/kgbwperday(acutetoxicity)90-day&1-year,dog:9.7mg/kgbwperdayrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesnegativeinthreebacterialandonemammaliangenemutationtests;positiveinonemammaliangenemutationtest(l5178tk+/-mouselymphoma)inthepresenceandabsenceofs9.negativeinaninvitrochromosomeaberrationtestinhumanlymphocytes.positiveinaninvitromntest.invivostudiesnegativeintwomicronucleustestsinmiceandoneinrats.negativeinaninvivomammalianalkalinecometassay.photomutagenicitynodatanorequired(inwavelengthsabove290nmthemolecularextensioncoefficientisbelow1000lmol-1cm-1.)potentialforgenotoxicityadmedatasuggestsbonemarrowhasbeenexposedintheratmnstudy.overall,desmediphamisnotofconcernforchromosomeaberrationinvivo.aninvivomammalianalkalinecometassay,wasconductedasafollow-uptopositivegenemutationassayinvitroandwasnegative.desmediphamisthereforeunlikelytobegenotoxicinvivo.'", "efs25151-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrat:80-85%(basedonurinaryexcretionwithin24-30h)at2mg/kgbwperdaysingleandrepeateddose50-70%(basedonurinaryexcretionwithin24-30h)at20mg/kgbw40-50%(basedonurinaryexcretionwithin24-30h)at20mg/kgbwperdayrepeateddose10%(basedonurinaryexcretionwithin96h)at1000mg/kgbwcorrectionfororalabsorptionisnotconsiderednecessarytoderivetheaoel/aaoeltoxicokineticscmax,tmax,andplasmat1/2weregenerallynotdetermineddataneeded.tmaxwasfoundtobewithinthefirsttwohoursafterdosing(0.3-0.4mg/kgbwphenmedipham)inmonkey(n=3)anddog(n=1)and<4hinmousedosedwith2000mg/kgbwphenmedipham(n=3).t1/2was3hto3daysinmonkeysdependingonthelabeland8hinthedog;t1/2was<3hinmouse.distributionwidelydistributed;distributionismoreefficientafterrepeatedtreatment(inplasma,wholeblood,lungs,ovaries,pituitary,thyroidgland,skin,heart,adrenalglands,kidneys,spleenandliver)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensiveat2mg/kgbw(app.90-95%within24h),mainlyviaurine(80-85%within24h,5-6%%viafaeces)moderatelyrapidandextensiveat20mg/kgbw(approx.80-95%within24-30h),viaurine(50-70%within24-30h)andfaeces(12-40%)moderatelyrapidandextensiveat1000mg/kgbw(app.60-90%within24h),mainlyviafaeces(55-80%within24h,5-10%viaurine)metabolisminanimalsextensivelymetabolised(100%inurine)with9-10metabolitesidentifiedintherat;mainurinarymetabolitesaremethyl-n-(3-hydroxyphenyl)carbamate(mhpc)(majormetabolite).phenmediphamisinitiallybrokendowninratbyoxidative/hydrolyticcleavage(followedbyhydroxylation,acetylationandoxidationreactions).themajorcomponentinfaecesistheparentcompound.invitrometabolismnouniquehumanmetabolitesincomparisontorat(livermicrosomes)toxicologicallyrelevantcompounds(animalsandplants)phenmediphamtoxicologicallyrelevantcompounds(environment)phenmedipham'acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2500mg/kgbw(supplementarystudy)ratlc50inhalation>7.0mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationaweight-of-evidenceapproachindicatesthatphenmediphammighthaveskinsensitisingpropertiesandthedatasubmittedarenotsufficienttoconcludethatitisnotaskinsensitizer(dataneeded).phototoxicitynotphototoxicinvitro(3t3nru-pttest)(a)butfurtherdataareneededtoconclude(a)theoecd3t3nru-pttestmightnotbeanappropriatetestforuvbabsorberssuchasphenmediphamshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat/mouse/dog:methaemoglobinemiaandhaemolyticanaemiaandrelatedeffects(hemosiderindepositioninspleen,liverandkidneys,extramedullaryhaematopoiesis)stotre2h373relevantoralnoael60-day,dogloael:11.3mg/kgbwperday90-dayrat:3.5mg/kgbwperday8-weekmouse:125mg/kgbwperdayrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiessevengenemutationtestsinbacteriaandmammaliancells:allnegativethreechromosomeaberrationassays(humanlymphocytesandchocells):twopositivewithandwithouts9mix,onepositivewithouts9oneudstest:negativeclastogenicinvitroinvivostudiesthreemousebonemarrowmntests:twononacceptableduetolackofknownimpurityofthebatchesusedandonenegativebutwithoutevidenceofsufficientbonemarrowexposureinmousemousespermatogonialcells:negativeforinductionofchromosomalaberrations(instudywithlimitationsandnoevidenceofsufficienttargettissueexposure).aconclusioninrelationtotheinvivoclastogenicpotentialofphenmediphamcannotbedrawndataneeded.'", "efs25152-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability50%copperoralabsorptionfromamixeddietinhuman3(basedonfaecalexcretionconsideringendogenouslossesofcopper)similarabsorptioninratstoxicokineticstmax=12hours(liver)distributionwidelydistributed,theliverbeingtheregulationorgan.copperisboundtoceruloplasmin.potentialforbioaccumulationnopotentialforaccumulation,exceptincasesofgeneticdiseaseorchronicadministrationofhighdose(60mg/personperday),wherecopperaccumulatesintheliverrateandextentofexcretionrapidlyexcreted(>90%)within48hours.terminalhalf/lifeinratof10.1hours.excretionviathebile.noentero-hepaticcirculationoccurs.excretionmainlyboundtometallothioneinsoftheintestinalbrushborderandlostinfaeces.minoramountsinurineandfromskinandhair.metabolisminanimalsdoesnotoccur;copperisamonoatomicionandcannotbemetabolizedinvitrometabolismnotrequiredasnometabolismoccurstoxicologicallyrelevantcompounds(animalsandplants)coppertoxicologicallyrelevantcompounds(environment)copperacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralcopperhydroxide:489mg/kgbwcopperoxychloride:299mg/kgbwbordeauxmixture:>2000mg/kgbwtribasiccoppersulphate:300-500mg/kgbwcopper(i)oxide:300-500mg/kgbwh302h301h302h302ratld50dermalcopperhydroxide:>2000mg/kgbwcopperoxychloride:>2000mg/kgbwbordeauxmixture:>2000mg/kgbwtribasiccoppersulphate:>2000mg/kgbwcopper(i)oxide:>2000mg/kgbwratlc50inhalationcopperhydroxide:0.45mg/lair(wb)h3303basedondraftscientificopinionondietaryreferencevaluesforcopper;efsapanelondieteticproducts,nutritionandallergies(nda),july2015'", "efs25159-sup-0001-appendix-a.pdf": "impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)healthsurveillanceofworkersinresearchorproductionofp.nishizawaepn1hasnotrevealedsignsorsymptomsrelatedtooccupationalexposure.noadverseeffectsareknownforp.nishizawaepn1inthepublishedliterature.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)nosensitisationorallergenicresponseshaveoccurredorhavebeenreportedforthestaffinvolvedinresearchorproductionwithstrainp.nishizawaepn1.thereisnoevidenceforp.nishizawaepn1orotherbacterialstrainstoinducehypersensitivityinhumans.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)nomortalitiesorclinicalobservationswerenotedinratsfollowingoralexposureto1.6109sporesp.nishizawaepn1/animal.ld50rat>5000mgpasteurianishizawaepn1perkgbw.nomortalityld50rat>2000mgpasteurianishizawaefs(156)(a19824d)perkgbw.nomortalityacuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)nomortality,noadverseeffects,nopathogenicityfollowingintratrachealadministrationof1.6108sporesp.nishizawaepn1perrat.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)followingintravenousexposureto1109sporesofpasteurianishizawaepn1peranimal,notreatmentrelatedmortalitiesandnotoxiceffectswereobservedinrats.genotoxicity:(ma5.2.3;oecdiim5.3.5)sporeswillonlybemetabolicallyactiveincloseassociationwiththeirhost.hostrangeisrestrictedtocystnematodesfromthegeneraheteroderaandgloboderaonly.moreover,noreportontheproductionoftoxinsormetabolitesbyp.nishizawaeorotherspeciesfromthesamegenusspecifictonematodes,hasbeenfoundthroughsearchesofthepublishedliterature.cellculturestudy:(ma5.2.4;oecdiim5.3.6)p.nishizawaepn1isnotanintracellularreplicatingmicroorganism.p.nishizawaepn1onlygrowsonitsnematodehost.informationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)short-termtoxicitystudiesinmammalswithp.nishizawaepn1arenotconsiderednecessary.noadverseeffectswerefoundreportedinstudieswithratsuponoral,intravenousorintratrachealchallengeofacutesingledosesofp.nishizawaepn1.dermaltoxicity:(mp7.1.3;oecdiiim7.1.2)ld50rats>4000mgpasteurianishizawaefs(156)(a19824d)/kgbw.nomortalityoccurred.notestitemrelatedadverseeffectswereobserved.specifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)experimentalsafetytestswithp.nishizawaepn1havebeenconductedinratsusingoral,respiratoryandintravenousapplicationsofacutesingledosestoevaluatetoxicity,infectivityandpathogenicpotential.noadverseeffectswerereportedevenatthehighdosesofmicro-organismsapplied.theabsenceofclinicalsignsormajortissueabnormalitiesindicatedthatthetestsubstanceisnon-pathogenic.furthermore,asp.nishizawaepn1isanobligateparasiteofplant-parasiticnematodes,infectingandbeingpathogeniconlytocystnematodesfromthegeneraheteroderaandglobodera,infectioninhumansorothermammalsisunlikely.therefore,nofurtherspecificstudyontoxicity,pathogenicityandinfectivenesshavebeenconductedwiththestrainp.nishizawaepn1.genotoxicityinvivostudiesingermcells:nodata.notneeded.'", "efs25177-sup-0002-appendices_b-i.pdf": null, "efs25211-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealththetoxicologicaldossierofdimethenamid-pisbasedonstudiesperformedonbothdimethenamidasracemicmixture(50:50r/sisomers)andonthes-isomeralonethathasbeenshowntoretaintheherbicidalactivity.comparisonofacute,shorttermtoxicity,genotoxicityanddevelopmentaltoxicityperformedonbothsubstanceshasdeterminedthattheypresentasimilartoxicologicalprofileatequivalentdoselevelsandthatallavailablestudiesfortheracemicmixturecouldbeconsideredinthehazardidentificationandcharacterisationofdimethenamid-p;*/**refertostudiesperformedondimethenamid-panddimethenamidracematerespectively.absorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability94%(basedonurinary(7.6-12.4%)andbiliary(82.2-75.1%)excretionwithin72h;singledose10mg/kgbw)**consideredappropriateforthederivationoftheaoelor85%(basedonurinary(30%)andbiliary(50%)excretionplusamountincarcassandcagewashwithin72h;singledose250mg/kgbw)*toxicokineticsnotoxicokineticparameters(cmax,tmax,plasmat1/2)forparentandmetabolitesareavailablefordmta-p*valuesfromastudyperformedwithdmta:toxicokineticparametersforparentandmetabolites(10mg/kgbwp.o.)**wholeblood:auc=80.66-139.78geqxh/g(males-females)cmax5-10geq/mlmale/femalestmax72h,t1/2255h(male)and359h(female)plasma:auc1-(10mg/kgbw)=2.85-3.41(male-female)cmax0.07-0.13geq/mlmale/femalestmax1-4ht1/263h(male)and56h(female)distributionwidely(highestresiduesinraterythrocytesduetospeciesspecificbindingtohaemoglobin)**potentialforbioaccumulationnoevidenceforaccumulationpotential*(bindingtorathaemoglobinbutnottohumanhaemoglobin**)rateandextentofexcretionrapid,40.9-54.9%inurine,46.4-32.2%infaecesand2-2.4%incagewash(highdose250mg/kgbw;maleandfemale,respectively);about90%excretedwithin168h*79.6%inbile(10mg/kgbw;male)and50.3%(250mg/kgbw;female)within72h*metabolisminanimalsextensivelymetabolised(>40metabolites;<2%excretedasparentinfaeces),primarilyviaglutathioneconjugation;mainmetabolitem656ph025(iso);mainbiotransformationstepsareglutathioneconjugation,enzymaticcleavageofthetripeptideintermediateandsubsequentmetabolicreactionsontheresultingcysteine'conjugate(n-acetylationofthecysteinemoiety,hydrolysisofs-conjugatestothemercaptan(followedbys-methylation),oxidationofthesulphuratomtoformsulphoxidesandsulphones;o-demethylation;hydroxyla-tion,conjugationwithglucuronicacid,replacementofthechlorineatombyhydrogen(reduction)orbyahy-droxylgroup(hydrolysis),dimerisationofamercaptan)*invitrometabolismmetabolismoftheracemateanddimethenamid-pinratliverslicesisqualitativelyandquantitativelycomparable.14c-dimethenamid-pisextensivelymetabolisedbyhepatocytesfromdogs,ratsandhumans.allmetabolitesdetectedafterincubationwithhumanhepatocyteswerealsopresentinanimalhepatocytesamples,exceptforthemetabolitem656ph007.m656ph007wasfoundinthein-vivoratstudy.toxicologicallyrelevantcompounds(animalsandplants)dimethenamid-ptoxicologicallyrelevantcompounds(environment)dimethenamid-pandmetabolitem656ph051*basedondataofdimethenamid-p**basedondatawithdimethenamidracemateacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral429mg/kgbw*h302acutetoxcat.4ratld50dermal>2000mg/kgbw*ratlc50inhalation>5.16mg/lair(4-h,head/nose-only)*skinirritationnon-irritant*eyeirritationnon-irritant*skinsensitisationsensitising(buehler-test*;magnussonandkligman**)h317skinsens.1phototoxicitynon-phototoxic*invitro(3t3nru-pttest)(a)dataneeded(a)the3t3nru-pttestmightnotbeappropriatetestforuvbabsorbersasdimethenamid-p*basedondataofdimethenamid-p**basedondatawithdimethenamidracemateshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectliver(weightincreases,biochemicalandhistopathologicalchanges)anddecreasedbodyweightgaininrats,dogsandmice.relevantoralnoael90-day,rat:34mg/kgbwperday**90-day,rat:37mg/kgbwperday*'", "efs25229-sup-0001-appendix_a.pdf": "section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability%),cagewash,carcassandtissueswithin168h;irrespectiveofdoseandsex)toxicokineticslowdose-cmax0.5-1.3,tmax0.25h,bloodt1/2<0.6h;auc0.25-48h1ghequiv/g;tissuesslowphaset1/2highdose-cmax73-85,tmax0.25h,bloodt1/2<0.8h;auc0.25-48h170ghequiv/g;tissuesslowphaset1/2distributionwidelydistributedwiththehighestconcentrationsinkidneys,liverandplasmapotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretion(95-97%,viafaeces0.9-2.4%)within168h,irrespectiveofdoseandsexmetabolisminanimalsextensivelymetabolised;majormetabolitetrinexapac(cga179500)(92%inurine,~50%infaeces)andanunidentifiedmetabolite(probablyaconjugateofeitherparentorcga179500)(8%oftheurine,94%ofthebiliaryradiolabel)afterlowdoseadministrationhydrolysisinvitrometabolismthemetabolismof[14c]-txpbyhumanlivermicrosomeswasqualitativelycomparablebutwasslowertothatseeninrat.allthehumanmetabolitesformedweredetectedinrat.datagapidentifiedforacomparativeinvitrometabolismstudybetweendogandhumantoxicologicallyrelevantcompounds(animalsandplants)trinexapac-ethyl/metabolitecga179500toxicologicallyrelevantcompounds(environment)trinexapac-ethyl/metabolitecga179500acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral4210mg/kgbwratld50dermal>4000mg/kgbwratlc50inhalation>5.3mg/lair/4h(noseonly,liquidaerosol)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(llna)h317,skinsens.1bphototoxicitynotphototoxic'", "efs25230-sup-0001-appendix_a.pdf": "20yy;volume(issue):nnnnimpactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)noadverseeffectsinemployeeswhohadbeeninoccupationalcontactwithstrainppri5339.forbeauveriabassianaingeneral,fewcasesoflocal(eye)andsystemicinfectionswerereportedwiththelatteroccurringonlyinimmunocompromisedorseverelyillpatients.evidenceofallergenicitybyrespiratoryorskincontact.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)microorganismsmayhavethepotentialtoprovokesensitisingreactions.aguineapigmaximizationtestgaveapositiveresultsforsensitizationforthemicro-organism.evidenceofallergenicitybyinhalationinlaboratoryanimalsandhumansandindicationsofallergicskinreactionsinhumans.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)ld50>2000mg/kgbwinrats;noevidenceoftoxicity,pathogenicityorinfectivity;rapidclearance(byday3postdosing)withotherstrain(lf14)at1108cfu/animalacuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)intratracheal:lc50>7.7107cfu/animalinratsafterintratrachealapplication;noevidenceofinfectivitybutlocaleffectsonthelungs(inflammation/immunereaction,organweightincrease),clearancecompletebyday7postdosing.inhalation:lc50<2.59mg/l(1.79x1010cfu/4h),mortalitybyday3afterdosing,histopathologicalfindingsinthelungs(acuteinflammation,necrosis,congestionandhemorrhage).acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)ld50>7.8x107cfuinrats;noevidenceoftoxicity,orpathogenicityafterintraperitonealadministration.genotoxicity:(ma5.2.3;oecdiim5.3.5)amestest:negativecellculturestudy:(ma5.2.4;oecdiim5.3.6)notrequiredinformationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)waitingconfirmationofthegrowthtemperaturedermaltoxicity:(mp7.1.3;oecdiiim7.1.2)rat:ld50>5050mg/kg;nosystemiceffects,slightlyirritatingtotheskininonefemale(nospecifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)inrabbits:irritatingtoeyes;slightlyirritatingtoskingenotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)nodatanotrequired.additionalstudieswithmetabolitesbeauvericingenotoxicpropertiesininvitrotests:-ames:negative-chromosomalaberrations(humanlymphocytes,withouts9):positive-micronucleus(humanlymphocytes,withouts9):positive-micronucleus(porcinekidneycells,withouts9):positive-sisterchromatidexchanges(humanlymphocytes,'", "efs25234-sup-0001-appendix_a.pdf": "b'peerreviewofthepesticideriskassessmentoftheactivesubstanceazadirachtin(margosaextract)identifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleswww.efsa.europa.eu/efsajournal11efsajournal2018;16(4):5234impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionazadirachtintechnicalisamixtureofseveraldifferentlimonoidsandothercompoundsextractedfromtheseedkernelsoftheneemtree.itisthereforenotfeasibletoperformadmestudieswithazadirachtintechnical.itisfurthermorealsonotpossibletoperformsuchastudyforitsseveralcomponents(azadirachtinaandothers)duetotheunavailabilityofchemicallysynthesisedandradioactivelylabelledcomponents,sinceitcanbeobtainedbyextractionandcleanupoftheseedkernelsoftheneemtreeonly.thereforeitisnotpossibletoobtainradioactivelabelledmaterial.distributionpotentialforaccumulationrateandextentofexcretionmetabolisminanimalstoxicologicallyrelevantcompounds(animalsandplants)azadirachtinextract(aswholeextract)toxicologicallyrelevantcompounds(environment)azadirachtinextract(aswholeextract)acutetoxicity(annexiia,point5.2)ratld50oral>5000mgtrifolioextract/kgbw>5000mgsipcamextract/kgbw>5000mgmitsuiextract/kgbwratld50dermal>2000mgtrifolioextract/kgbw>2000mgsipcamextract/kgbw>2000mgmitsuiextract/kgbwratlc50inhalationallstudies:highestattainableconcentration>0.72mgtrifolioextract/lair(4h,wholebody)>2.45mgsipcamextract/lair(4h,wholebody)skinirritationnotirritating(trifolio,sipcam,mitsuiextracts)eyeirritationnotirritating(trifolio,sipcam,mitsuiextracts)skinsensitisationsensitising(m&k,trifolio,sipcamextracts)sensitising(buehler,mitsuiextract)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat:liver,thyroid(organweight,clinicalchemistry)nostudyindogsubmitted,notrequiredrelevantoralnoaelrat,90-day:32mgtrifolioextract/kgbwperdayrat,90-day:33mgsipcamextract/kgbwperday'", "efs25251-sup-0001-appendix_a.pdf": "fsa.europa.eu/efsajournal9efsajournal2018;16(4):5251impactonhumanandanimalhealth1absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyandextensivelyabsorbed;tmax~30urinaryexcretionwithin24h.distributionrapidlyandwidelydistributed;higherlevelsinskin/fur,kidneysandgastro-intestinaltract.someevidenceofbindingtobloodcells.potentialforaccumulationnoevidenceforaccumulationinthebody.rateandextentofexcretionrapidexcretion,predominantly(80%)intheurine.limitedbiliaryexcretion.metabolisminanimalslimitedmetabolism:excretedlargelyunchanged.majormetabolite:acetyl-asulam(upto16%inurine,upto2.2%infaeces)minormetabolites:sulfanilamide(upto1%inurine)andacetyl-sulfanilamide(upto2.8%inurine).toxicologicallyrelevantcompounds(animalsandplants)asulamandsulfanilamide(includingacetyl-sulfanilamide)toxicologicallyrelevantcompounds(environment)asulamandsulfanilamide(includingacetyl-sulfanilamide)acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw(asulam-sodium)-ratld50dermal>2000mg/kgbw(asulam-sodium)-rabbitld50dermal>4000mg/kgbw(asulam-sodium)-ratlc50inhalation>5.46mg/l(asulam-sodium)(4hour,wholebody,aerosol)-skinirritationslightirritant(asulam-sodium)-eyeirritationmoderateirritant(asulam-sodium)-skinsensitisationsensitiser(m&k)(asulam-sodium)h3171listofendpointsoftoxicitystudiessubmittedaccordingtoregulation(ec)544/2011.'", "efs25252-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability40%oralabsorptionbasedonbilefindingstoxicokineticsspinosyna:tmaxsinglelowdose(10mg/kgbw)1h,highdose(100mg/kgbw)6h(m)and2h(f);repeateddose(10mg/kgbw)1h.t1/2:2542hspinosynd:t1/2:2933h.distributionwidelydistributed(adrenals,liver,lung,thyroid,kidney,perirenalfat,thymus)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapid:>90%in168h,mainlyviafaecesmetabolisminanimalsextensivemetabolism(n-ando-demethylatedspinosynsand/orglutathionconjugates)invitrometabolismnostudywasperformed-datagap-toxicologicallyrelevantcompounds(animalsandplants)spinosadtoxicologicallyrelevantcompounds(environment)spinosadacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.18mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(buehlerandmaximisation)phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:bodyweight,vacuolation(thyroid),clinicalchemistry,accumulationrecells(spleen,liver,lymphnodes).dog:bodyweight,anaemia(regenerative(f)/non-regenerative(m)),clinicalchemistry,vacuolation(spleen,liver,testes,lymphnodes,intestines,adrenal)mouse:bodyweight,anaemia,neutrophilicleucocytosis(f),clinicalchemistry,vacuolation(kidney,liver,pancreas),inflammationandnecrosis(lung,spleen,lymphnodes,thymus,tongue,bonemarrow).'", "efs25258-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability62%(basedonurinaryexcretionafterrepeatedlowdose(25mg/kgbw)administration0.62willbeusedascorrectionfactorfororalabsorptioninderivationofaoeltoxicokineticsdataoncmax,tmaxandplasmat1/2arenotavailabledatagapdistributionwidelydistributed(highestlevelsinblood,skin,liver,lungsandkidneys)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(92-95%within72hrs),approximatelytwothirdofthedoseinurineandonethirdinthefecesmetabolisminanimalsinurine42-55%ofradioactivityrepresentedunmetabolisedparentrimsulfuronandinfeces5-16%.inurinemetabolitesin-e9260(7.2-9.6%),in-70941(3.9-5.7%)in-jf999(3-7.9%)wereobserved.infecesin-e9260(4.9-6.9%),in-jf999(0.4-1.6%)andp4(5.9-9.4%)weredetected.proposedpathway:1)contractionofsulfonylureabridgetoformthemajormetabolitein-70-941andthenin-70942,2)in-70942demethylationtometabolitep5,3)oxidationonpyrimidineorpyridineringtop4,4)cleavageofsulfonylureabridge.invitrometabolismafter4hrsmostlyparentcompound(94-97%)wasobservedwithalowlevelofin-70941(3-6%).themetabolicactivityofhepatocyteswasprovedby[14c]7-ethoxycoumarin.toxicologicallyrelevantcompounds(animalsandplants)rimsulfurontoxicologicallyrelevantcompounds(environment)rimsulfuronandin-e9260acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.4mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationdatagapphototoxicityunlikelytobephototoxic(3t3nru-pttest)'", "efs25261-sup-0001-appendix_a.pdf": "ab/bs03www.efsa.europa.eu/efsajournal6efsajournal2018;16(5):5261impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)limiteddatabase:noadversehealtheffectsobservedamongpersonnelinvolvedinlaboratoryinvestigations.b.subtilisiscapableofproducingsubtilisinwhichmaycauseallergicreactionsafterrepeatedexposure.b.subtilishasbeenreportedtobeassociatedwithfoodpoisoningandinfectionsinimmuno-deficientpatients.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)nospecificsensitisationstudywasperformedontechnicalconcentrate.indeed,basedoninformationfromtheliterature,bacillussubtilisstrainsduetosubtilisinshowallergicpotentialandsensitizingpropertiestobothskinandinhalatorycontactsalthoughnoclinicalobservationsonworkerswerereported.followingthegeneralacceptedrecommendationformicrobialplantprotectionproductsofthepraperm3meetinginjune2009atefsainparma,thephrase\"micro-organismsmayhavethepotentialtoonthelabel.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)ratld50oral:>7.8x109cfu/animal;nomortality,nosignsoftoxicityacuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)ratinhalation(nose-only):nosignsoftoxicityacuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)ratintravenous:non-toxictoratswheninjectedintravenouslyatadoseof1.4x107cfu/rat.slowclearanceintheliverandspleen.itwasalsopresentinthecaecumcontents(datagap).nomortality,nosignsoftoxicity.genotoxicity:(ma5.2.3;oecdiim5.3.5)noevidenceofmutagenicityforsurfactinc,openforothersecondarymetabolites/toxins.noneoftheextractsfromculturesofbacillussubtilisstrainiab/bs03inducedmutationsbyshiftreading(strainta98)orbasepairsubstitution(ta100)cellculturestudy:(ma5.2.4;oecdiim5.3.6)nainformationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)na.tieriiassessmentpendingonfinalizationoftieriassessment.surfactinc:28daysnoael:500mg/kgbwperday,basedonchangesinclinicalchemistryparameters,increasedliverweightandzonalhepatocytenecrosis.nomaternalordevelopmentaltoxicitywasobservedinmice,treatedupto500mg/kgbwperdaydermaltoxicity:(mp7.1.3;oecdiiim7.1.2)ratld50rabbitld50dermal>8.8x109cfu/animal;conclusion:nosignsoftoxicity,pathogenicityandinfectivity.'", "efs25288-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)dichlorprop-pdichlorprop-p2-eherateandextentoforalabsorption/systemicbioavailability>87%(basedonurinaryexcretion)rapidandextensiveabsorptiontoxicokineticscmax,1926at5mg/kgoraltmax,2.5-4.5hrfollowingoraldosesof5and100mg/kgrespectively.plasmat1/2;4.414.8hrat5mg/kgoraldoseplasmat1/2;1.92.4hrfollowingani.v.doseof1or25mg/kg(thisrepresentsthemostaccuratet1/2estimate)cmax,16.4at5mg/kgoraltmax,1.2hrfollowingoraldoseof5mg/kg.plasmat1/2;3.9hrat5mg/kgoraldosedistributionwidelydistributed(highestresiduesinblood,liver,kidney,thyroid,adrenal,heartanduterus)widelyanduniformlydistributedasdichlorprop-p.potentialforbioaccumulationnosignificantaccumulationnosignificantaccumulationrateandextentofexcretionmin.88%excretedwithin120hoursor168hours(lowandhighdoserespectively)viaurine.3-12%viafaeces.eliminatedrapidlyandextensivelyentirelyasdichlorprop-pacid,mainlyviaurine:min.75%ofadministereddoseover168hours,70%in12hours.approximately5%excretedviafaecesasdichlorprop-pacid.metabolisminanimalslimitedmetabolism.3%unidentifiedmetabolites.rapidlyandcompletelyhydrolysedtodichlorprop-pacidinvitrometabolismnodifferencebetweenmetabolisminhuman,rat,mouse,dogandrabbitlivermicrosomes.refertodichlorprop-ptoxicologicallyrelevantcompounds(animalsandplants)parentcompoundand3%unidentifiedmetabolites(animals)sumofdichlorprop-pandisomer(plants)dichlorprop-ptoxicologicallyrelevantcompounds(environment)dichlorprop-pdichlorprop-p2-eheacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)dichlorprop-pclass.*dichlorprop-p2-eheclass.*ratld50oral567mg/kgbwh302824mg/kgbwh302ratld50dermal>4000mg/kg/bwnone>2000mg/kg/bwnone'", "efs25290-sup-0001-appendix_a.pdf": "8efsajournal2018;16(5):5290impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidandextensiveabsorption(>90%)followingoraladministrationtotheratbasedoncomparisonofexcretionpatternafteroralandintravenousadministrationsevidenceofreducedabsorptionathighdoselevelstoxicokineticsfollowingasingleoraldose,wholebloodparametersindicatethekineticsof14c-ethoprophoswasindependentofsexcmax=1.5gequiv/g(4mg/kgbwdoselevel)tmax=0.7h(4mg/kgbwdoselevel)thereafter,concentrationsofradioactivitydeclinedinabiphasicmannert=110-124h(inmalesandfemales)(4mg/kgbwdoselevel)auc(0-=59-63gequiv.h/g(4mg/kgbwdoselevel)auc(0-=108gequiv.h/g(12.5mg/kgbwdoselevel)auc(0-=149gequiv.h/g(25mg/kgbwdoselevel)aucatthehigherdoselevelswasproportionallylowerthanatthelowdoselevel,indicatingreducedabsorptiondistributionwidelydistributed.residueswerehighestinorgansassociatedwithmetabolismandexcretion(lungs,liverandkidney).comparisonofresiduesinplasmaandwholebloodshowaproportionallygreaterassociationofethoprophosorametabolitewiththecellularcomponent.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionexcretionwasrapidandprimarilyviatheurine(~50-60%).excretioninthefaeces(~10%)andexpiredair(~15%)werealsoimportantroutes.valuesforintravenouslydosedanimalsindicatethatbiliaryexcretionmayoccurtoalimitedextent(~8%).tissueresiduesat168hourswererelativelylow.metabolisminanimalsdataindicatethatmetabolismintheratisindependentofsex,routeofadministration,doselevelandfrequencyofadministration.ethoprophoswascompletelymetabolised;nounchangedparentcompoundwasdetectedinurineorfaecalsamples.metabolismofethoprophoswasbydealkylationofoneorboths-propylgroupsfollowedbyhydroxylationandconjugation.ethoprophosmayalsobemetabolisedbyhydrolysisoftheethylesterlinkagetoethanolandco2.invitrometabolismbiologicalmonitoringstudyinagriculturaloperatorindicatethatthemetaboliteo-ethyls-propylphosphorothioate(m1moreppa)ismorepredominantinhumansthaninrats(andisconsideredasareasonablebiomarkerofethoprophosexposureinhumans),howeversincenofurtherinformationonhumanmetaboliteswasretrievedfromthestudiesinhumans,aninvitrointerspeciescomparativemetabolismstudyisneeded(datagap)'9efsajournal2018;16(5):5290toxicologicallyrelevantcompounds(animalsandplants)ethoprophosthetoxicityofmetabolitesidentifiedinplants(m5,m31andm18)isconsideredcoveredbytoxicityandconcernsontheparent(genotoxicityoftheparentisnotclarified)toxicologicallyrelevantcompounds(environment)ethoprophosacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralrat:40-80mg/kgbwmouse:31mg/kgbwh301ratld50dermalrat:226mg/kgbwrabbit:8.5mg/kgbwh310ratlc50inhalation0.123mg/lair(4hr,noseonly)h330skinirritationnotdeterminedduetotoxicity(dermalexposureof0.5mlkilledall6rabbits)eyeirritationnostudysubmittedusepareportsthatallanimalsdiedafterocularinstillationof0.1mleuh070skinsensitisationsensitising(magnusson-kligmanmaximisationtest)h317phototoxicitynophototoxicpotentialshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat(oral,dermalandinhalationexposure)&mouse(oraladministration):erythrocyteandbraincholinesteraseinhibitiondog:brainanderythrocytecholinesteraseinhibitionandlivervacuolisationrabbit(dermalexposure):erythrocyteandbraincholinesteraseinhibitionrelevantoralnoael90-day,rat:0.1mg/kgbwperday6-week,mouse:loael20mg/kgbwperday90-day&1-year,dog:0.025mg/kgbwperdayrelevantdermalnoael21-day,rabbit:0.05mg/kgbwperday21-day,rat:0.3mg/kgbwperdayrelevantinhalationnoael28-day,rat:0.498g/lcorrespondingto0.1mg/kgbwperdaygenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesbacterialreversemutationtest(nota102/e.coliwp2:negative(howeverstrainssensitivetocross-linkingandoxidizingmutagens(ta102ore.coliwp2strain)havenotbeen'", "efs25307-sup-0001-appendix_a.pdf": "oftheactivesubstancefosetylwww.efsa.europa.eu/efsajournal11efsajournal2018;16(6):5307impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidandextensive(80100%)within24hoverthedoseraterangeof100to3000mg/kgbwbasedonsingle/repeatedlow/highdosestudies.toxicokinetics14c-fosetyl-alsingledose3000mg/kgbw(+)cmax:315.4/460.4g/ml(/)tmax:24h(/)auc0-168h:33786/40053gxh/ml(/)t1/2:124/81h(/)distributionwidelydistributed(kidneys,liver,lungs,spleen,fat,skinadrenalglandsandgonads)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(56%doseinairexpiredand30%doseinurine)within24hinsingledosestudies.inrepeateddosestudies,faecesarethemainrouteofexcretionmetabolisminanimalsrapid,metabolisedinco2(excretedviaexhaledair)andphosphonates(eliminatedinurinewithunchangedparentandethanol).invitrometabolismnometabolisminhumanandratlivermicrosomeswasobservedtoxicologicallyrelevantcompounds(animalsandplants)fosetyl-altoxicologicallyrelevantcompounds(environment)fosetyl-alacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.11mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationirritanth319skinsensitisationnon-sensitizer(m&ktests)phototoxicitynotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat,mouse:lowtoxicity,nospecifictargetorgandetecteddog:decreasedabsoluteweightgonadsand'", "efs25308-sup-0001-appendix_a.pdf": "mpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityoral3:1-mcpwasrapidlyabsorbedwithoralabsorptioninexcessof86%(25%urine,3.5%cagewash,66%expiredair)oftheadministereddose.inhalation:1-mcp(gas)appearedrapidlyinthebloodstreamwheninhaled.datanotreliableenoughtoquantifythelimitedabsorptionbyinhalation(datagap).toxicokineticsoral:thebloodandplasmaconcentrationsoftotalradioactivityexhibitedabiphasicdecline:-tmaxrangedfrom1-to3-hr-initialphase:t=11-19hr-terminalphase:t=40-73hrs.inhalation:thepeaklevelsofradioactivitymeasuredinplasmaandwholebloodafter4hoursmayhaverisenfurtherhadtheexposureperiodbeenlonger(noplateauindicatingthatanabsorption/excretionequilibriumhadnotbeenreached).ingeneral,14clevelsinplasmaorwholebloodfellto50%ofthe4hourpeakwithin24hours.distributiontherewasevidenceforwidedistributionthroughoutthebodyfollowingbothoralandinhalationaladministration.(withhigherlevelsinliver,kidneys,spleen,blood,plasma,adrenals,andthyroid).potentialforbioaccumulationlowpotentialforaccumulationviaboththeoralandinhalationalroutesofexposure.rateandextentofexcretionoral:1-mcpwasrapidlyandcompletelyexcreted(virtuallyalladministeredradioactivitywasrecoveredwithin48-hrofdosing).expiredairwasthemajorrouteofexcretion(44-66%)aswellasurine(23-40%).nomajordifferenceswereseeninexcretionbehaviorbetweensingleexposureandrepeatedexposureinhalation:urineandexpiredairwerethemajorroutesofexcretion(limitedreliabilityofavailablequantitativedata).metabolisminanimalsoral:1-mcpwasextensivelymetabolised.unchanged1-mcpwasnotdetectedintheexcreta.nometabolitesinurineorfaeceswere>10%oftheadministereddose.inhalation:metabolismwasnotinvestigated(datagap)invitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)impurities1-chloro-2-methylpropene(1-cmp)and3-chloro-2-methylpropene(3-cmp)toxicologicallyrelevantcompounds(environment)none3-haip,4.5%1-mcpformulatedinan-cyclodextrincomplex)whichisamanufacturingintermediatefortheproductionofsmartfresh(therepresentativeagrofreshformulationcontaining3.3%of1-mcp).'/2013,annexparta,point5.2)ratld50oralld50>5000mg/kgbw(mup-haip)noneratld50dermalld50>5000mg/kgbw(mup-haip)noneratlc50inhalationlc50>5.12mg/litre(4hexposure,noseonly,aerosolgeneratedfrommup-haip,4.5%1-mcp)noneskinirritationnon-irritant(mup-haip)noneeyeirritationnon-irritant(mup-haip)noneskinsensitisationllnanegative(mup-haip)nonephototoxicitynotrequirednonegenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesnegativeresultsintwobacterialreversemutationassays,twomammaliangenemutationassaysandtwochromosomeaberrationassays.noneinvivostudiesmicronucleusassayinmice:negativenonephotomutagenicitynodatanotrequirednonepotentialforgenotoxicity1-mcpisconcludedunlikelytobegenotoxicnonelong-termtoxicityandcarcinogenicity(regulation(eu)n283/2013,annexparta,point5.5)long-termeffects(targetorgan/criticaleffect)nodata,notrequiredonthebasisofthephysicalnatureoftheactivesubstance(gas)togetherwiththeresultsoftheavailable(geno)toxicitystudies.nonerelevantlong-termnoaelcarcinogenicity(targetorgan,tumourtype)short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectinhalation(rats):increasedincidenceofhyalinedropletsintherenalcorticaltubularepithelium,andsplenichaemosiderosis.oral(rats):regenerativeanaemiaoral(dogs):effectsonsomehaematologicalandclinical-chemistryparametersindicativeofanaemia;brownpigmentinliver;spermeffectsintestesandepydidymides-relevantoralnoaelrat:22.4mg/kgbwperday(90-day,mup-haip)dog:4.1mg/kgbwperday(90-day,mup-haip)nonerelevantdermalnoaelnostudyconductednonerelevantinhalationnoaelrat:23.5ppm1-mcpgas(provisionallyconvertedas6.5mga.s./kgbwperday)(90-day,1-mcpgas)noneefsajournal2018;16(53087):'", "efs25378-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityabsorptionwasrapidwithoutapparentlagtimewithanaveragetmaxof2hr.florpyrauxifenbenzylwasmoderatelywellabsorbedwithhigherabsorptionatlowerdoses(36-42%atsingleormultipledosesof10mg/kgbw)comparedtohigherdoses(8-9%atasingledoseof300mg/kgbw)inrats.25%oralabsorptionisrelevanttotheaoelsetting(determinedfromthe2-yearstudyinratsat50mg/kgbwperday)basedonthe%doserecoveredinurineasparentandmetabolitex11438848(florpyrauxifen)toxicokineticsdosegroup10mg/kgbwperdayplasmapkparametersrbcpkparametersmfmftmax(h)2.11.82.21.6cmax(g/g)10.910.80.40.42.21.72.51.850.647.2auc0-t(ghg-1)54491.61.3plasmaeliminationofflorpyrauxifenbenzylisbiphasicwitharapiddecliningplasmaalphaphasephaseplasmahalf--51hours)inbothmaleandfemalerats.nospecificaffinitytorbcwasobserveddistributionconcentrationwashighest,byfar,inthegitract,followedbyurinarybladder,plasma,kidneyandliver,consistentwiththepresenceofthetestmaterialprimarilyintheportalofentryandprimaryexcretiontissuespotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionexcretionisprimarilyviafaeces(51-56%)andurine(36-42%)withthemajorityeliminatedwithin24hr.thefractioneliminatedintheurinewashigherinthelowerdosegroups,consistentwithhigherabsorptionatlowerdosesmetabolisminanimalsflorpyrauxifenbenzyliswellmetabolizedprimarilyintoasinglemetaboliteflorpyrauxifen(x11438848,majorratmetabolite),andreadilyeliminatedinurineandfaecesfromtherat.atotalof13peakswereidentifiedinurineandfaeces.therewasnoparentflorpyrauxifenbenzylidentifiedinurine'acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.23mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationweakdermalsensitizer(llna)h317phototoxicitystudyprovidedbutnotrequired(ultraviolet/visiblemolarextinction/absorptioncoefficientoftheactivesubstanceislessthan10lmol1cm1intherange290-700nm;noabsorptionisobservedinthisrange)short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:kidneytoxicity(renalmedullarytubularmineralization,increaseinurinaryph)dog:noadverseeffectsmouse:reducedbodyweightgainandovaryweights3relevantoralnoael28-day&90-day,rat:300mg/kgbwperday90-day,dog:1008mg/kgbwperday(highestdosetested)90-day,mouse:100mg/kgbwperday4relevantdermalnoael28-dayrat:1000mg/kgbwperday(highestdosetested)3refertoevaluationtablesection2,efsaresponsetodatarequirement2.1samplesfromtheadmestudies.florpyrauxifenmetabolite(x11438848)wasthemostabundantmetaboliteidentifiedintheurinesampleswithremainingmetabolitesaccountingfor<5%.parentflorpyrauxifenbenzylwasthemostabundantinthefaecesaccountingfor~35-92%.invitrometabolismnouniquemetaboliteswereformedinhumanmicrosomalincubationscomparedtorat,mouse,rabbitordogmicrosomalincubations,indicatingthatthemetabolicprofileofflorpyrauxifenbenzylwasconsistentacrossthesespecies.toxicologicallyrelevantcompounds(animalsandplants)florpyrauxifenbenzyltoxicologicallyrelevantcompounds(environment)florpyrauxifenbenzyl'", "efs25379-sup-0001-appendix-a.pdf": "rreviewofthepesticideriskassessmentoftheactivesubstancebas750f(mefentrifluconazole)www.efsa.europa.eu/efsajournal9efsajournal2018;16(7):5379impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityapproximately80%followingsinglelow-doseadministration(urine+biliaryexcretion+cagewash+carcass)..toxicokineticsc-label(rats):cmax=1.67-2.04geq/g(low-dose1);49.9-62.5geq/g(high-dose2)tmax=0.5-1.2h(low-dose1);0.7-5.5h(high-dose2)initialplasmat1/2=2.6-7.7h(low-dose1);4.0-12.9h(high-dose2)terminalplasmat1/2=62.1-85.7h(lowdose1);78.3-87.7h(highdose2)auc=15.7-34.9geq*h/g(lowdose1);845-1650geq*h/g(highdose2)t-label(rats):cmax=2.07-3.04(lowdose1);20.332-57.108(highdose3)tmax=1h(lowdose1);1h(highdose3)plasmat1/2=34.11-43.83h(lowdose1);30.105-38.72h(highdose3)auc=17-38geqxh/g(lowdose1);1148-2629geqxh/g(highdose3)mice:cmax=4.0-5.7geq/g(lowdose4);21.5-26.9geq/g(highdose5)tmax=1-8h(lowdose4);0.5-8h(highdose5)plasmat1/2=54.2-80.4(lowdose4);34.6-31.8(highdose5)auc=126-147geq*h/g(lowdose4);1008-955geq*h/g(highdose5)distributionwideandrapiddistribution.highestlevelsinplasma,liver,adrenalglands,kidney.potentialforbioaccumulationnoevidenceofaccumulation.rateandextentofexcretionfast,extensiveandtoamajorextentviathebiliarypathway(71-74%afterorallowdose);alsoviaurinaryroute(10-11%afterorallowdose).excretionpatternssimilarformalesandfemales.metabolisminanimalsextensiveandrapidmetabolism,resultinginrapidandextensiveexcretion;preferentialmetabolismandeliminationofthes-enantiomerinrats.invitrometabolismnouniquehumanmetabolitedetectedtoxicologicallyrelevantcompounds(animalsandplants)mefentrifluconazoletoxicologicallyrelevantcompounds(environment)mefentrifluconazole'rreviewofthepesticideriskassessmentoftheactivesubstancebas750f(mefentrifluconazole)www.efsa.europa.eu/efsajournal10efsajournal2018;16(7):53791lowdose:5mg/kgbwperday2highdose:180mg/kgbwperday3highdose:360mg/kgbwperday4lowdose:10mg/kgbwperday5highdose:75mg/kgbwperdayacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.3mg/lair(noseonly)skinirritationnotcorrosiveorirritanteyeirritationnotcorrosiveorirritantskinsensitisationskinsensitiser(guinea-pigmaximisationtest)h317phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat=body-weighteffects,increasedliverweight,impairmentofliverfunctionmouse=increaseinliverweight,liverhistopathology,decreasedbody-weightgaindog=increaseinliverweight,decreasedfoodintake,impairmentofliverfunctionrelevantoralnoael90-dayrat=76mg/kgbwperday90-daymouse=2mg/kgbwperday1-yeardog=10mg/kgbwperdayrelevantdermalnoael28-dayrat:1000mg/kgbwperdayrelevantinhalationnoaelnostudydatanotneededgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiestwobacterialreversemutationassays=bothnegativetwoinvitroforwardmutationassaysinmammaliancells=bothnegativetwoinvitrocytogenicityassaysinmammaliancells(micronucleustest)=bothnegativeinvivostudiesinvivomicronucleustest=negativephotomutagenicityunlikelytobephotogenotoxicpotentialforgenotoxicitybas750fisunlikelytobegenotoxic'", "efs25389-sup-0001-appendix_a.pdf": "018;16(7):5389section2mammaliantoxicologyimpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability>80%(basedonurinaryexcretionafterlowdose,repeateddoseandintravenousadministrations(5mg/kgbw)toxicokineticsmicetreatedwith10mg/kgbw:cmax=0.3%oftrrtmax=0.5ht1/2=11.2hdistributionthreedaysafteradministrationtissuelevelswerenegligible(<0.01%oftheadministereddose)potentialforbioaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandextensive(atminimumapp.77%within48h),mainlyviaurine(71%within24h,app.1-4%viafaeces)metabolisminanimalsnotmetabolisedinratsinvitrometabolismnouniquehumanmetabolitesformed;noobservedmetabolismtoxicologicallyrelevantcompounds(animalsandplants)clopyralidtoxicologicallyrelevantcompounds(environment)clopyralidacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.0mg/lair/4h(noseonly,highestattainableconcentration)skinirritationnon-irritant,howeverskinirritationwasobservedafter21-daydermalapplicationsh315eyeirritationsevereirritanth318skinsensitisationnoacceptablestudyavailable;skinsensitisationpotentialcouldnotbeexcluded(datagap)phototoxicitynodata-datagap(howeverthereisnovalidatedtestmethodtoaddressthephototoxicityofuvbabsorbers)short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)'", "efs25390-sup-0001-appendix_a.pdf": "tancecarvonewww.efsa.europa.eu/efsajournal10efsajournal2018;16(7):5390impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability83-90%(lipinskyruleoffiveandoecdtoolbox)toxicokineticsnodataavailabledistributionnoquantitativedataavailable.potentialforbioaccumulationnoquantitativedataavailable.rateandextentofexcretionrapideliminationmostlyviaurine,withahalf-lifeof2.4hours.metabolisminanimalsavailabledatasuggestthatmetabolismofcarvoneislikelytobedifferentbetweenratsandhumans,withcarvonicacid,dihydrocarvonicacidanduroterpenolonebeingthemainhumanmetabolitesandcarveolbeingthemainmetaboliteinrats.invitrometabolismhumanandratmicrosomes:resultsindicatedifferentmetabolismbyhumansandrats.toxicologicallyrelevantcompounds(animalsandplants)nonetoxicologicallyrelevantcompounds(environment)noneacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>4000mg/kgbwratlc50inhalation>5.66mg/lair/4h(stateway,e.g.noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(maximisation)h317phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:decreasedbodyweightgainandfoodconsumption,increasedkidneyandliverweight,increasedpartialthromboplastintime(ptt),decreasedalbuminmouse:increasedliverweight,decreasedthymusweightrelevantoralnoael90-day,rat:5mg/kgbwperday90-daymouse:n.a.(rangefindingstudy)'", "efs25400-sup-0001-appendix_a.pdf": "(componentsoflysateofsaccharomycescerevisiaestrainddsf623)www.efsa.europa.eu/efsajournal11efsajournal2018;16(8):5400impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitynodata,considerednotnecessarytoxicokineticsnodata,considerednotnecessarydistributionnodata,considerednotnecessarypotentialforbioaccumulationnodata,considerednotnecessaryrateandextentofexcretionnodata,considerednotnecessarymetabolisminanimalsnodata,considerednotnecessaryinvitrometabolismnodata,considerednotnecessarytoxicologicallyrelevantcompounds(animalsandplants)nonetoxicologicallyrelevantcompounds(environment)noneacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwbasedonresultsobtainedwiththerepresentativeproductjde01containing325.6g/lofabeit56ratld50dermal>2000mg/kgbwbasedonresultsobtainedwiththerepresentativeproductjde01containing325.6g/lofabeit56ratlc50inhalation>3.8mg/lair/4h(maximumattainableconcentration)basedonresultsobtainedwiththerepresentativeproductjde01containing325.6g/lofabeit56skinirritationnoexpectedskinirritantpotentialeyeirritationnoconclusioncouldbedrawn(datagap).skinsensitisationnoconclusioncouldbedrawn(datagap).inhalationsensitisationpositivecasesofrespiratorysensitisationreportedinhumansexposedtosaccharomycescerevisiae.resp.sens.1.h334phototoxicitynoexpectedphototoxicitypotentialshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectnodata.nohumansafetyconcernsareknownorexpected.-relevantoralnoaelnodata,considerednotnecessary'", "efs25402-sup-0001-appendix-a.pdf": "2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability~50%(basedonbyurinaryexcretionandcagewashesatsinglelowdoselevel)thisvalueof~50isconsideredappropriatefortheaoelandaaoelsetting.toxicokineticscmax=1.8mg/kg,foradoseof2mg/kgtmaxrapidexcretion(t1/2:5.9hforblood),exceptforfat(t1/2>24h)distributionkidney,ovaries,muscleandskin(mainlyfromtheback).highestamountsofresiduesarefoundinfatpotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionatthelowerdose,theexcretionthroughurineandfaecesissimilar,whileatthehigherdose,thefaecalexcretionispredominantsuggestingsaturation.excretioninexpiredairisminimal(0.09%).biliaryexcretionislow(1-1.6%ofanoraldose).afterasingleoraldose,theexcretionisvirtuallycompleteafter72hmetabolisminanimalsfirststepofcypermethrinmetabolismisthehydrolyticcleavageoftheesterbond,betweencyclopropanecarboxylicacidand3-phenoxybenzylmoietieseliminationofthecis/transcyclopropanecarboxylicacidmoiety(cis/trans3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylicacidordcca)inthefreeandconjugatedformisrapidinratsandinman.minimalhydroxylationoccursatthemethylgroupsattachedtothecyclopropanering,givingacomplexmixtureofmetabolites.thereis,asyet,noevidenceforthemetabolismatthe2,2-dichlorovinylgroupofcypermethrin.the3-phenoxybenzylmoietyismainlyconvertedinto3-phenoxybenzoicacid(3pba);3pbaisexcretedfreebutaromatichydroxylationatthe4-position(4oh3pba)mayoccurbeforeexcretionfollowedbysulphation.invitrometabolismacomparativeinvitrometabolismassayrevealsthatmetabolismofcypermethrinissimilarbetweenratandhumanwithnohumanspecificmetabolitesbeingobserved.themajormetabolitesidentifiedareisomersofdccaand3pba.nomassesorproposedstructurehasbeenelucidatedforsomemetabolites.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitestoxicologicallyrelevantcompoundsparentcompoundandmetabolites'2(environment)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral287-500mg/kgbwacutetoxic3(h302)ratld50dermal>2000mg/kgbwratlc50inhalationacutetoxic4(h332)stotse3(h335)skinirritationnon-irritanteyeirritationslightlyirritantbutnotclassifiedskinsensitisationnotsensitizerphototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:liver(hypertrophy),kidney(hypertrophy),nervoussystemdog:nervoussystemcriticaleffect:neurotoxicclinicalsignsinallspeciesstotre2(h373)relevantoralnoael35-daydog:3.75mg/kgbwperday2-year,dog:7.5mg/kgbwperday.90-day,dog:12.5mg/kgbwperday90-dayrat:24mg/kgbwperdayrelevantdermalnoael15-day,rabbit:20mg/kgbwperdayrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesnegativeinvivostudiesnegativephotomutagenicitynotrequiredpotentialforgenotoxicitycypermethrinisunlikelytobegenotoxiclong-termtoxicityandcarcinogenicity(regulation(eu)n283/2013,annexparta,point5.5)long-termeffects(targetorgan/criticaleffect)bodyweightrelevantlong-termnoael2-year,rat:0.5mg/kgbwperday18-month,mouse:62mg/kgbwperday'", "efs25403-sup-0001-appendix_a.pdf": "ww.efsa.europa.eu/efsajournal10efsajournal2018;16(8):5403impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitybasedonurinaryexcretion,-afterlowdose(ld)(1-2mg/kgbw):40%-afterhighdose(hd)(20mg/kgbw):27%toxicokineticsblood:(ld/hd:2/20mg/kgbw)cmax:ld:1.3-1.5mg/kgbwhd:6.7-7.5mg/kgbwtmax:ld:6-7mg/kgbwhd:6-9mg/kgbwt1/2:ld:2.8-4.4hfat:t1/2(ld):2.5-2.7h(initialphased1-8)17-26h(finalphased14-42)distributioninwellperfusedorgansandfattytissuepotentialforbioaccumulationhigheramountsretainedinskinandfat(upto0.6%after7days)butnosignificantpotentialforbioaccumulation.rateandextentofexcretionld(2mg/kgbw):43-46%inurine*;30-35%infaeces(*within24h)hd(20mg/kgbw):27%inurine*;24-28%infaeces(*within96h)metabolisminanimalsmoderatelymetabolised(~25%identified);mainmetabolitesinurine(~16-17%):4-oh-pbasulfateanddcvaglucuronide-cypermethrinexcretedunchangedinfaeces:39-57%hydrolyticcleavageoftheesterboundandexcretionoftheciscyclopropanecarboxylicacidmoietyinfreeandconjugatedforminurine.minimalhydroxylationatthemethylgroupsattachedtothecyclopropane-ring.hydroxylationofthephenoxy-ringandcleavageoftheetherbridgewithlossofthephenylring.invitrometabolismhepaticmicrosomemetabolism:oxidationpredominantinrat,andhydrolysispredominantinhuman.toxicologicallyrelevantcompounds(animalsandplants)alpha-cypermethrintoxicologicallyrelevantcompounds(environment)alpha-cypermethrinacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral40-80mg/kgbwh301ratld50dermal>2000mg/kgbw'", "efs25405-sup-0001-appendix_a.pdf": "mpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitycyfluthrin:>80%(basedoni.v.studieswithexcretionviaurine,faecesandbodywithoutgit;supportedbyoralandduodenalstudies)-50%ofthefaecallyexcretedradioactivityisduetoanabsorbedandbiliaryeliminatedamount.cmax1.0-1.5g/mlat0.5mg/kgbwand18-27g/mlat10mg/kgbw.tmax1.5-2.0hat0.5mg/kgbwand1.5-2.4hat10mg/kgbwbeta-cyfluthrin:77%(males)or85%(females)(basedonlowdoseexperimentsusing0.5mg/kgbwbeta-cyfluthrin;radioactivitydetectedinexpiredair,urine,cagewash,residuesincarcassandtissuescmax0.1-0.3g/mlat0.5mg/kgbwand1.4-1.5g/mlat10mg/kgbw.tmax0.5hat0.5mg/kgbwand6-8hat10mg/kgbwdistributionwidelydistributed(highestvaluesinfattytissue,adrenals,kidneyandliver)cyfluthrin:t1/2plasmadatadependonphaseofeliminationcurvebeta-cyfluthrin:t1/2plasma(terminal)10-14hat0.5mg/kgbwand42-50hat10mg/kgbwpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(>90%within48h),mainlyviaurine(55%,12%viafaeces,33%viabile)metabolisminanimalsextensivelymetabolised(>95%);mainmetabolitesatradiolabelledcyclopropyl-moiety:cis/transdcva,dcvaacylglucuronide;radiolabelledfluorophenyl-moiety:sulfateconjugateof4-oh-fpb,fpbacid.parentcompoundonlydetectedinfaeces(upto20%).cleavageoftheesterbond,oxidation,hydroxylationandconjugation.invitrometabolismratlivermicrosomes:beta-cyfluthrinisextensivelymetabolised(11metabolitefractions)humanlivermicrosomes:limitedmetabolismrate(2metabolitefractions)allmetabolitefractionsobservedinhumanmicrosomeswerealsofoundinratsinsimilarportions.toxicologicallyrelevantcompounds(animalsandplants)beta-cyfluthrintoxicologicallyrelevantcompounds(environment)beta-cyfluthrin'acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral14.3mg/kgbw(cyfluthrin,cremophor/water)-1189mg/kgbw(cyfluthrin,peg400)cat2h300mouseld50oral91mg/kgbw(beta-cyfluthrin,peg400)-609mg/kgbw(cyfluthrin,peg400)rat/rabbitld50dermalrat:>2000mg/kgbw(beta-cyfluthrin,peg400)ratlc50inhalationaerosol(ethanol/peg400)0.081mg/lair(beta-cyfluthrin,4h-exposure,head-noseonly>1.089mg/l(cyfluthrin,1h-exposure,noseonlydust0.532mg/lair(beta-cyfluthrin,4h-exposure,head-noseonly0.967mg/l(beta-cyfluthrin,4h-exposure,head/nosecat2h330skinirritationnon-irritant(beta-cyfluthrin)eyeirritationnon-irritant(beta-cyfluthrin)skinsensitisationnon-sensitizer(cyfluthrin,m&k)phototoxicitynotphototoxic(3t3nru-pt(a)withlimitations)(a)itmightnotbeappropriatetouvbabsorberslikebeta-cyfluthrin(datagap).short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)target/criticaleffectmortality(rats)at16and40mg/kgbwperdbehavioural/motordisturbances,reducedbodyweightdevelopment,choreoathetoticsigns(ratsanddogs)relevantoralnoaelsbeta-cyfluthrin:1mg/kgbwperd(28-dayrat)2.4mg/kgbwperd(90-ddog)cyfluthrin:2.43mg/kgbwperd(1-yeardog)relevantdermalnoaelcyfluthrin:22/23-d,rat:-localeffects:113mg/kgbwperd-systemiceffects:376mg/kgbwperdrelevantinhalationnoaelcyfluthrin:0.09mg/kgbwperd)rat,6h/day,head-noseexposure,13-week,aerosol,5daysperweekbeta-cyfluthrin:0.2mg/lair(~0.07mg/kgbwperday)'", "efs25407-sup-0001-appendix_a.pdf": "actonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidlyabsorbed,approximately100%toxicokineticsnotrelevantdistributionwidelydistributedpotentialforbioaccumulationnotrelevantrateandextentofexcretionnotrelevantmetabolisminanimalsnormalhomeostasismaintainedthroughwellknownmechanismsinvitrometabolismnotrelevanttoxicologicallyrelevantcompounds(animalsandplants)na+iontoxicologicallyrelevantcompounds(environment)-acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.74mg/lair/4h(notclearifnoseonlyorwholebody)skinirritationslightlyirritatingeyeirritationslightlyirritatingskinsensitisationnot-sensitising(buehlertestwithpotassiumhydrogencarbonate,3inductions)phototoxicitynotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectpotassiumhydrogencarbonate:alteredurinaryph/hypertrophyofadrenalzonaglomerulosa/increasedpotassiumexretion.urinarybladderhyperplasia(rats)relevantoralnoaelpotassiumhydrogencarbonate:4-and13-weekratloael:2%relevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesames:negative'", "efs25418-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityreadilyabsorbed(~80%),basedonurinaryexcretionwithin24h.(100%wasconsideredfortheaoel)toxicokineticsnodataavailableontoxicokineticsparametersincludingcmax,tmax,plasmat1/2;forparentandmetabolites(datagap)distributionwidelydistributed,highestlevelinliverpotentialforbioaccumulationnopotentialforaccumulationrateandextentofexcretionrapidandextensive(90%within168h),mainlyviaurine(78-87%within24h,10%viafaeces)metabolisminanimalsextensivelymetabolised(90%).intheproposedmetabolicpathway,theprimarymetabolitesare3,4-dichloroaniline(3,4-dca)andn-hydroxy-3,4-dichloroaniline.themajorityofmetabolitesareeliminatedinurineaspolarconjugates.invitrometabolismhumanandrathepatocyteshaveasimilarmetabolismofpropanilsharingsimilarmetabolitespatternanddistribution,andrateofparentalcompoundmetabolism.dogandmousehepatocytesshowedadifferentbehaviourinmetabolitepatternanddistribution,andrateofmetabolism,respectively.toxicologicallyrelevantcompounds(animalsandplants)propanil;3,4-dichloroaniline(3,4-dca)andn-hydroxy-3,4-dichloroanilinetoxicologicallyrelevantcompounds(environment)propanilacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral960mg/kgbwcat.4,h302ratld50dermal>2000mg/kgbwratlc50inhalation>2.13mg/lair/4h(wholebodyexposure)cat.4,h332skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k,modifiedbuehler)phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat,dog,mouse(oral):increaseofmethaemoglobinandhaematologicalchanges,andhistopathologicalchangesinliver,kidneyandspleen(a.o.ironpigment)stotse1,h370'", "efs25429-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidabsorption,cmaxinplasmaat0.5h.extensivelyabsorbedafteroraldose,84-90%toxicokineticsinmale/femalerats(1mg/kgbw)cmaxmethiocarb~0.77g/mltmax0.5ht1/2absorption0.12ht1/2elimination8.17-17.8h(m/f)distributionextensivelydistributedintoorgansandtissues.highestconcentrationofradioactivityintheorgansbeingresponsibleforthedegradationandexcretion,i.e.stomach,largeandsmallintestine,kidney,urinarybladder,andliverpotentialforbioaccumulationnopotentialforaccumulation.t1/2foreliminationis8h21h.rateandextentofexcretionrapideliminationmainlyinurine(84-90%)within48h.faeceswas5-10%metabolisminanimalsextensivelymetabolisedinmammals.fourtypesofmetabolicreactionswereinferredfollowingoralanddermalapplication:-esterhydrolysisofthecarbamategroup(majormetabolicstep)-hydroxylationofthemethylgroupofcarbamategroup(minorreaction)-oxidationofthethioethergrouptoformthesulfoxideandthesulfone-conjugationofthephenolichydroxygroupwithsulfuricacidorglucuronicacidinvitrometabolismnouniquehumanmetaboliteisexpectedtoxicologicallyrelevantcompounds(animalsandplants)methiocarbandm03,m04andm05.toxicologicallyrelevantcompounds(environment)methiocarbandm03,m04andm05.acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral19mg/kgbwbasedonweightofevidenceofpublisheddatawithrangeof13135mg/kgbw.inthesubmittedstudywas33mg/kgbw.h300ratld50dermal>5000mg/kgbwratlc50inhalation0.433mg/lh330skinirritationnotirritating'", "efs25454-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)-dimethoaterateandextentoforalabsorption/systemicbioavailabilityrapidlyandextensivelyabsorbed,approx.90%basedonurineexcretion(80-90%)within24hoursnodifferencesamongconcentrationsandgendertoxicokineticsnomajordifferencesamongtestedconcentrationsandgender.doselevel(mg/kgbw):0.510100cmax(mgequiv./l)1850-93tmax(h)0.7-10.5-10.25-0.5t1/2(h)22-2742-5913-1536-46auc(mgeq.h.l)4-5417-687distributionwidelyandevenlydistributed,highestconcentrationinthecontentsofthegastrointestinaltract,liverandkidneys.higherlevelsofradioactivitywereobservedintheharderianandintra-andexorbitallachrymalglandsandalsopossiblythepreputialgland.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidlyexcreted(80-90%inurinewithin24h)metabolisminanimalsextensive:unchangeddimethoateinurineaccountedfor0.4-2%oftheadministereddosebyoralorintravenousdosingcleavagetodimethoatecarboxylicacid(metaboliteiii)asmajormetabolitewithdimethyldithiophosphate(metabolitexv);oxidationtoomethoate(~5%),atleastother4metaboliteswereidentified,noneofthemconjugates.therewerenoqualitativedifferencesinthemetabolicprofilesbetweenroutesofadministration,doselevels,orbetweengenders.invitrometabolismdimethoateunderwentinvitromoderatemetabolisminmicrosomes(10-30%,indifferentspecies).theranking:dog(33%)>mouse(30%)>rat(24%)>human(11%)couldbestronglyaffectedbydifferentp450content.noattempttoidentifythemetaboliteswascarriedout,butthesamephaseimetaboliteswereidentifiedinallthespecies.astudyofhumanin-vivourinarymetabolitescanbesupportiveofasimilarmetaboliteprofilebetweenhumanandexperimentalanimalspecies.toxicologicallyrelevantcompounds(animalsandplants)dimethoate,omethoatetoxicologicallyrelevantcompounds(environment)dimethoate,omethoate'acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral245mg/kgbw(rat)160mg/kgbw(mouse)h301cat3ratld50dermal>2000mg/kgbwratlc50inhalation1.68mg/lair(4hours,wholebody);studywithamanufacturingconcentrateh332cat4skinirritationnotirritatingeyeirritationirritanth319cat2skinsensitisationnonsensitizing(buehlertest3-inductionsandmaximizationtestm&k)phototoxicitynodatadatanotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectinhibitionoferythrocyteandbraincholinesteraseactivityinratsanddogsafteroralanddermalexposurerelevantoralnoael1-year,dog:0.18mg/kgbwperday28-day,rat,supportedbyotherstudies:0.5mg/kgbwperday2-year,rat(90-dayinterimsacrifice):0.06mg/kgbwperdayrelevantdermalnoael21-day,rabbit:1000mg/kgbwperday28-dayrat:31.5mg/kgbwperday(dataavailableonaformulation-containing40%a.i.)relevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesthesubmittedstudiesprovidesomeevidencefordimethoatebeingweaklygenotoxicinbacterialandmammaliancellsinvitroassays.amestest:2strainspositivemammaliancellmutation(cho/hgprt):positiveathighdoselevelsudsinrathepatocytes:positivecometassayinhumanlymphocyte:positiveatthe2highdoselevelsinductionofmicronucleiinhepg2cellline:positiveatthe2highdoselevelsinvivostudiesnoadequateinvivofollowupwassubmittedtocontravenethepositivegenotoxicityresultsinvitro.negativeresultswereobtainedin'", "efs25464-sup-0001-appendix_a.pdf": "(ez)-1,3-dichloropropenewww.efsa.europa.eu/efsajournal10impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityoraladministrationinrodents(mouse,rat):>80%absorption(76-97%)basedonurinaryexcretion,exhaledairelimination,carcassandcagewashradioactivityfoundat48hours.inhalationadministrationinrat(nose-only):~50%absorption(mostlythroughthelowerrespiratorytract(73-79%)againstupperrespiratorytract(11-16%)).higherconcentrationoftrans-dichloropropeneisomeragainstcis-dichloropropeneisomerwasabsorbed.toxicokineticsoraladministrationinrodents(mouse,rat):datagapinhalationadministrationinrat:-plateauvaluesinbloodat1h(ppm)-firsteliminationphaserapid(bloodhalf-life3-40min)followedbyaslowerphase(bloodhalf-life30-40min).distributionoraladministrationinrodents(mouse,rat):widelyanduniformlydistributedwithhighestvaluesinnon-glandularstomach,glandularstomach,bladder,liverandkidneys.effectsonnon-proteinsulfhydrylscontentandmolecularbindingconfirmedthedistributioninstomach(nonglandular>glandular),liver,kidneyandbladder.inhalationadministrationinrat:noinformationaboutthedistributionintissues.effectsonnon-proteinsulfhydrylscontentconfirmedthedistributioninliverandkidney,butnotinlung.potentialforbioaccumulationnoevidenceofaccumulationrateandextentofexcretionoraladministrationinrodents:rapidelimination(99%within48h),mainlythroughurine(~60%),faeces(17-5%)andexpirationofcarbondioxide(15-28%).urinaryhalf-lives:5.435.91hintherat,and6.609.62hinthemouse(singledose).inhalationadministrationinrat:initialrapidandpronouncedeliminationphase(bloodhalf-life3-40min)followedbyaslowersecondphase(bloodhalf-life30-40min).metabolisminanimalsextensivelymetabolised.threemetabolicpathwaysidentified:-main:glutathioneconjugationfollowedbyoxidation-secondary:hydrolysisof1,3-d-trace:oxidationof1,3-dmajormetabolite:1,3-dmercapturicacidinvitrometabolismnodataavailabledatagaptoxicologicallyrelevantcompounds(animalsandplants)(e,z)-1,3-dichloropropene,(ez)-3-chloroallylalcohol,3-chloroacrylicacidtoxicologicallyrelevantcompounds(environment)(e,z)-1,3-dichloropropene,(ez)-3-chloroallylalcohol,3-chloroacrylicacid,1,2-dichloropropane,1,1,2-trichloroethane(ez)-1,3-dichloropropenewww.efsa.europa.eu/efsajournal11acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral150mg/kgbw(m/fcombined)h301ratld50dermal333mg/kgbw(m/fcombined)h311ratlc50inhalation2.7-4.7mg/l(whole-body).h331skinirritationirritanth315eyeirritationirritanth319skinsensitisationbuehlertestwith3applications.h317cat1aphototoxicitynodataavailablenotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectoral:rats:hyperkeratosisofthestomachandbasalcellshyperplasiaofnonglandularmucosamice:decreasedbodyweightgaindog:decreasedbodyweight,hypochromicandmicrocyticanemia,increasedhematopoiesisinbonemarrowandspleeninhalation:rat:hyperplasiaofrespiratoryepitheliummice:aggregatesofmononuclearcellsinsubmucosaofurinarybladder(f),andhyperplasiaorrespiratoryepitheliumrelevantoralnoael5mg/kgbwperday(rat,90days)2.5mg/kgbwperday(dog,1year)<15mg/kgbwperday(mice,13-week)relevantdermalnoaelnodata;nonerequiredrelevantinhalationnoael10ppm(rat,90days)10ppm(mice,90days)genotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiespositivemutageniceffectswereobserved.inbacterialsystems(s9mix)positiveeffectsforchromosomeaberrationsinmammalian(chl)cellsinvivostudiessomestudiesshowclearindicationsfordnafragmentationinvivo*;negativeresultsaredemonstratedinmicronucleus*,uds*anddominantlethaltests.*additionalinformationacceptablewithreservationsphotomutagenicitynodata.norequired.potentialforgenotoxicitytheweightofevidenceindicatedthat1,3-disaninvivogenotoxicagentforsomaticcells,actingdirectlyorafteractivationbycytochromep450,andglutathioneprotectsagainstthegenotoxicitydatagap:newcompletepackageofgenotoxicitystudiesperformedwithwellmutagencategory2", "efs25465-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealththetoxicologicaldossierofnapropamide-misbasedonstudiesperformedonbothnapropamideasracemicmixture(50:50r/sisomers)andonther-isomeralone.comparisonoftoxicokinetic,acute,shorttermtoxicityinratsandgenotoxicitystudiesperformedonbothsubstanceshasdeterminedthattheypresentasimilartoxicologicalprofileatequivalentdoselevelsanditwasconsideredacceptabletobridgebetweentheracemateandthepurer-isomer.accordingly,whenthereisnospecificstudyconductedonther-isomeralone,theavailablestudiesperformedwiththeracemicmixturecouldbeconsideredinthehazardidentificationandcharacterisationofnapropamide-m.absorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability70%(roundedfrom67%)basedontheurinaryexcretion,includingcagewashandamountintissues,observedinthenewstudyperformedwiththerisomer(napropamide-m).valueof70%suitableforaoelsetting.basedonnapropamide-mstudytoxicokinetics30mg/kgbw300mg/kgbwplasmacmax(gequiv/ml)4.1237.2tmax(h)66t1/2(h)14.818.6auc(0-t)(gequiv.h/ml)100773auc(0-(gequiv.h/ml)103803basedonnapropamide-mstudydistributionuniformlydistributed;highestlevelsinblood,liver,spleenandkidney.potentialforbioaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandextensive(approx.90%)within72h.majorityexcretedwithin24hoursviaurine(37-60%)andfaeces(29-55%);78%ofadministereddoseexcretedviabilewithin24h,indicatingextensiveenterohepaticcirculationmetabolisminanimalsextensivelymetabolised(>92%);>15metabolitesinurineandfaeces;metabolicpathway:n-dealkylation,oxidation,followedbyconjugationinvitrometabolismnodata-datagaptoxicologicallyrelevantcompounds(animalsandplants)napropamide-mtoxicologicallyrelevantcompounds(environment)napropamide-macutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbw(napropamide-m)'>5000mg/kgbw(napropamide)ratld50dermal>2000mg/kgbw(napropamide+napropamide-m)ratlc50inhalation>4.8mg/lair/4h(nose-only)(napropamide)skinirritationnon-irritant(napropamide+napropamide-m)eyeirritationnon-irritant(napropamide+napropamide-m)skinsensitisationnon-sensitiser(buehler,napropamide;llnanapropamide-m)phototoxicitydatagapnovalidatedtestguidelineisavailabletotestuvbabsorberssuchasnapropamide-mshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat=bloodsystem(regenerativehaemolyticanaemia),spleen(increasedweight,extramedullaryhaematopoiesis),body-weightdecreasedog=gastrointestinalsigns,bloodandurineclinicalchemistry,body-weightdecreaserelevantoralnoael90-day,rat:46mg/kgbwperday(napropamide-m)1-year,dog:50mg/kgbwperday(napropamide)relevantdermalnoael30-day,rat:1000mg/kgbwperday(napropamide)relevantinhalationnoaelnostudy-studynotrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesbacterial(ames)genemutation:negative(+/-s9)(napropamide+napropamide-m)mammalian(l5178ytk+/-)genemutation:negative(-s9),positive(+s9)(napropamide+napropamide-m)mammalian(humanperipheralbloodlymphocytes)chromosomeaberration:negative(+/-s9)(napropamide+napropamide-m)invivostudiesmousebonemarrowmicronucleus:negative(napropamide+napropamide-m)ratlivercomet:negative(napropamide-m)photomutagenicitydatagapnovalidatedtestguidelineis'", "efs25467-sup-0001-appendix_a.pdf": "actonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability70%basedonradioactivityrecoveredinurine,tissuesandresidualcarcasswithin168hinmales,followingsingleoraladministrationof0.5mg/kgbw.higheroralabsorptionisobservedinfemales.thevalueisconsideredappropriateforthederivationoftheaoelandaaoelvalues.toxicokineticsmalesfemalesdoselevel:0.5mg/kgbw0.5mg/kgbwcmax(geq./g):1.471.29tmax(h):88tmax/2(h):4617-1):71.919.1distributionwidelydistributed;highestresiduesinfat,muscle,liver,bloodandkidneys.fatresidueshigherinmalesthanfemales.potentialforbioaccumulationpotentialaccumulationinfat.eliminationwasslowfromovaries,pancreas,thymusandthyroid.rateandextentofexcretionurinary(24h):16-27%(m),77-87%(f)faecal(24h)7-9%(m),2-5%(f)totalexcretion(7d):66-85%(m),92-96%(f)metabolisminanimalsextensivelymetabolised,<0.3%remainingasparent.mainmetaboliteinurine&faeces:clodinafopinvitrometabolismclodinafop-propargylwasfoundtobecompletelymetabolisedbyratandhumanlivermicrosomes.nouniquespeciesmetaboliteswereobserved.toxicologicallyrelevantcompounds(animalsandplants)clodinafop-propargylanditssisomertoxicologicallyrelevantcompounds(environment)clodinafop-propargyl,clodinafopanditss-isomeracutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral1392mg/kgbw(m)2271mg/kgbw(f)acutetox.4;h302ratld50dermal>2000mg/kgbwratlc50inhalation>2.3mg/lair/4h(noseonly;maximumattainableconcentration)skinirritationnon-irritant'", "efs25557-sup-0001-appendix_a.pdf": "actonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidlyabsorbed,almostcompletewithin24h(>92%).>96%after48hrsbasedontheradioactivityrecoveredinurinefollowingsingleoraladministrationof0.3mg/kgbw.toxicokineticsmalesfemales(0.3mg/kgbw)(0.3mg/kgbw)cmax(ng/g)72.1117tmax(h)1.000.25auct(ng.h/g)229342auc(ng.h/g)249360k(1/h)0.30650.0968t(h)2.37.2distributionwidelydistributed,butnotincompactbonestructures,thespinalmarrowandthebrain,indicatingminimalabilitytocrosstheblood-brainbarrierpotentialforbioaccumulationnopotentialforaccumulationrateandextentofexcretion40-80%wasexcretedrenallywithin4hoftreatment,after48h>96%wasexcreted.faecalexcretionwas1.5%(i.v.)-3.7%(oral).metabolisminanimalsextensivelymetabolised.identifiedmetabolitescovermorethan93%ofthetotalradioactivity.fenamiphoswasmetabolisedtofenamiphos-phenols(methylthiometacresol-derivatives)indifferentstagesofoxidationatthesulphuratomandtheirrespectivesulphuricacidconjugates.invitrometabolismnodataavailable(datagap)toxicologicallyrelevantcompounds(animalsandplants)parentcompoundanditsmetabolitesfenamiphos-sulfoxide(m01),fenamiphos-sulfone(m02),des-isopropylfenamiphos(m06),des-isopropylfenamiphos-sulfoxide(m07)andtherotationalcropmetabolitem09toxicologicallyrelevantcompounds(environment)parentcompoundanditsmetabolitesfenamiphos-sulfoxide(m01),fenamiphos-sulfone(m02)fenamiphossulfone-phenol,4-methylthiometacresol-sulfone(m13)andfenamiphos-sulfone-anisole(m14(fanon))acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral6.0-6.1mg/kgbwperdayacutetox.2;h300ratld50dermal72-92mg/kgbwperdayacutetox.2;h310ratlc50inhalation65-79g/l/4h(aerosol)acutetox.2;h330skinirritationnon-irritating-'", "efs25575-sup-0001-appendix_a.pdf": "mpactonhumanandanimalhealth(regulation(eu)n283/2013,annexparta,point5andregulation(eu)n284/2013,annexparta,point7)medicaldata(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)nohealtheffectshavebeenreportedinmanufacturingplantpersonnelorgreenhouseworkers.sensitisation(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)consideringthatallmicrobialsshouldberegardedaspotentialacuteoralinfectivity,toxicityandpathogenicity(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iim7.1.1)nodataavailable;notrequired.acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)nodataavailable;notrequired.acuteintravenous/intraperitonialinfectivity(ma5.2.2.3;oecd5.3.4)ratnoael=1.7x107cfu/animalnotreatment-relatedfindings.genotoxicity(ma5.2.3;oecdiim5.3.5)nodataavailable;notrequired.cellculturestudy(ma5.2.4;oecdiim5.3.6)notapplicableinformationonshort-termtoxicityandpathogenicity(ma5.2.5;oecdiim5.3.7)nodataavailable;notrequired.dermaltoxicity(mp7.1.3;oecdiim7.1.2)nodataavailable;notrequired.specifictoxicity,pathogenicityandinfectivity(ma5.3;oecdiim5.5)notapplicablegenotoxicityinvivostudiesingermcells(ma5.5;oecdiim5.5.3)nodataavailable;notrequired.referencevaluesaoelnotapplicable.basedontheintendeduse,onlyanegligiblehumanexposureisexpected.adinotapplicable.basedontheintendedusenoconsumerexposureisexpected.arfdnotapplicable.basedontheintendedusenoconsumerexposureisexpected.exposureexposure(operator,workers,bystander,consumer)(ma6.1&mp7.3,8.0;oecdiim5.6&iiim7.2,7.3)operator/worker:theclosedinjectiontoolpreventsspillsoftheformulatedproductintotheenvironmentaswellasontohandsandclothesoftheusers.anegligibleexposureofoperatorsisexpectedwhenopeningandconnectingthevialtotheinjectiontool.there-entryworkersarenotexposedtoverticilliumwcs850.furthermore,onlytrainedpersonnelapplytheproduct,whichisnotsoldtothegeneralpublic.bystander:noexposureforthisrepresentativeuse.consumer:noexposureforthisrepresentativeuse.'", "efs25595-sup-0001-appendix_a.pdf": "www.efsa.europa.eu/efsajournal8efsajournal2019;17(3):5595impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability>80%basedonthecomparisonofexcretionpatternsafteri.vandoraladministration.(excretionofradioactivityfromi.v.administrationshowedsimilarlevelsofexcretionafter48hrs(m/f:68/61%inurineand29/28%infaeces)comparedtooraladministrationafter48hrs(m/f:65/60%inurineand28/21%infaeces))thisvalueisestablishedforthederivationofthesystemicaoel.thereisnoneedforabsorptionadjustment.toxicokinetics1mg/kgbw,intravenous,14c-methylene-labelledthiaclopridmalefemalet1/2aplasma(h)81.47.4auc(0-48h)(g/ml/h)9.312.9aterminalhalf-lives,mostlybasedontwoexponentialterms.1mg/kgbw,gavage,14c-methylene-labelledthiaclopridmalefemalet1/2aplasma(h)82.025.2auc(0-48h)(g/ml/h)5.55.81mg/kgbw,gavagerepeat,14c-methylene-labelledthiaclopridmalefemalet1/2aplasma(h)38.1405bauc(0-48h)(g/ml/h)5.49.1bthereportconsideredthisresulttobeartificialbecausetheunsatisfactorymathematicaldescriptionoftheplasmacurverequiredthreeeliminationterms.100mg/kgbw,gavage,14c-methylene-labelledthiaclopridmalefemalet1/2aplasma(h)9.212.3auc(0-48h)(g/ml/h)9.016.81mg/kgbw,gavage,14c-thiazolidine-labelledthiaclopridmalefemalecmax(g/ml)0.70.7'www.efsa.europa.eu/efsajournal9efsajournal2019;17(3):5595tmax(h)2.03.0t1/2a&bplasma(h)2.23.3auc(0-48h)(g/ml/h)9.210.4a&bbasedonthefirsteliminationphase.theterminaleliminationhalf-livesrangedfromapprox.1044hours.100mg/kgbw,gavage,14c-thiazolidine-labelledthiaclopridmalecmax(g/ml)50.3tmax(h)4.0t1/2a&bplasma(h)4.0auc(0-48h)(g/ml/h)1560distributionrapidandrelativelyevendistributionofthiaclopridand/oritsmetabolitesintissues.levelsintissuesandplasmawerehighestat14hoursfollowingoraladministration.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidlyexcreted.radioactivitywasexcretedprimarilyinurine(53.082.9%)andlargelyduringthefirst24hours;faecalexcretion(13.339.1%)wasalsosignificantandexcretionofradiolabelledcarbondioxideinexpiredairwasfoundtobeminimal.significantbiliaryexcretion.someexcretioninsweatandmucus.metabolisminanimalsextensivelymetabolised.upto17metaboliteswereidentifiedinurineand/orfaeces,accountingfor55.378.7%oftheadministeredradioactivity.anumberofmetabolictransformationreactionswereproposed,includingopeningofthethiazolidinering.invitrometabolismthenewcomparativeinvitrometabolismstudyprovidesnomeaningfulinformationonanypotentialdifferencesinthemetabolismofthiaclopridbetweenratsandhumans.differencesintheresultsoftheinvitrometabolismstudywhencomparedtotheinvivostudies(wherethiaclopridwasextensivelymetabolised)raiseconcernsregardingwhethersuitablesystemswereused(lackofphaseiienzymeactivity,femaleratmicrosomesandrelevantspeciese.g.rabbitnotinvestigated).adatagaphasthereforebeenidentified.toxicologicallyrelevantcompounds(animalsandplants)thiaclopridtoxicologicallyrelevantcompounds(environment)thiacloprid,m30,m34,m46acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral177mg/kgbwa)h301'", "efs25633-sup-0001-appendix_a.pdf": null, "efs25732-sup-0001-appendix_a.pdf": "thepesticideriskassessmentoftheactivesubstancepyriproxyfenwww.efsa.europa.eu/efsajournal9efsajournal2019;17(6):5732impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityoralabsorption40%basedonbileandurineexcretion(bile-cannulatedanimals)andconsideringallavailabledatafromnon-cannulatedanimals.toxicokinetics2mg/kgbw:bloodcmaxof90-400ng/g,tmaxof4-8h,t1/2of10h;auc(0-72h):7910ngequiv.h/ginmalesand1420ngequiv.h/ginfemales1000mg/kgbw:bloodcmaxof11-70g/g,tmaxof2-8h,t1/2of12h;auc(0-72h):1050000ngequiv.h/ginmalesand331000ngequiv.h/ginfemalesdistributionwidelydistributedbutatlowlevels(0.1-0.3%intissues);highestresiduesinfat,liver,kidneyandblood.potentialforbioaccumulationpotentialforaccumulationinfat(t1/2is35hours,sameorderofmagnitudeasliverandkidney)rateandextentofexcretionrapidandextensive,mainlyviafaeces(46-76%in24h)andurine(3-9%in24h).biliaryeliminationaccountsfor34-37%.metabolisminanimalsextensivelymetabolised(mainmetabolicrouteishydroxylationatthe4-positionfollowedbyafurtherhydroxylationstepandconjugation).invitrometabolismdatagaptoxicologicallyrelevantcompounds(animalsandplants)pyriproxyfentoxicologicallyrelevantcompounds(environment)pyriproxyfenacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw(ratandmouse)ratld50dermal>2000mg/kgbw(ratandmouse)ratlc50inhalation>1.3mg/lair/4h(wholebody,max.attainableconcentration)(ratandmouse)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(maximisation)phototoxicitydatagap(foruvbabsorber)short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:liver(weight,hypertrophy),clinicalchemistry,andhaematologicalparametersdog:liver(weight,hypertrophy),clinical'", "efs25755-sup-0001-appendix_a.pdf": "eerreviewofthepesticideriskassessmentoftheactivesubstancemancozebwww.efsa.europa.eu/efsajournal11efsajournal2020;18(12):5755impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability50%(basedonurinary(42%)andbiliary(7%)excretionwithin24handtissue(2.5%)within96h)basedonsingleadministrationat1.5and100mg/kgbwinratstoxicokineticstmax=3-6hr;absorptiont1/2=0.7-1.7hrdistributionwidelydistributedwiththyroidhavingthehighestlevelsofradioactivitypotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(app.74-94%within24h),viaurine(42%within24h),42%%viafaeces(within24h)and7%viabile(within96h)metabolisminanimalsextensivelymetabolised(>95%);mainmetaboliteetu(ethylenethiourea)(18%ofdoseinurineinrats);othersignificantmetabolites:ebis,edaandeu.onepathwayinvolveshydrolysisofthedithiocarbamatelinkagestoproduceeda;edaisthenoxidisedtoglycine.theotherinvolvesoxidationtoebisandthentoetu,variousderivativesofetuandeu.etu,eu,edaandn-acetyl-eda).invitrometabolismnottechnicallyfeasible;however,informationontheinvivometabolismofmancozebindifferentspecies,includinghumans(epidemiologyandhealthsurveys)showaqualitativelysimilarmetabolism.toxicologicallyrelevantcompounds(animalsandplants)etutoxicologicallyrelevantcompounds(environment)etuacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5mg/lair/4h(5studies,wholebodyorhead/nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(buhelerandm+k)h317phototoxicityonepositivestudyandonenegativestudyphototoxicitypotentialcannotbeconcluded(datagapandissuenotfinalised)'", "efs25817-sup-0001-appendix_a.pdf": "9efsajournal2019;17(9):5817impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)(animalsandplants)terbuthylazine,desethyl-metabolite(mt1),mt13andmt14toxicologicallyrelevantcompounds(environment)terbuthylazine,desethyl-metabolite(mt1),mt13,mt14,lm1,lm2,lm4andlm5atstep5(refinedriskassessmentforconsumers)datagapregardinglm3,andlm6othertoxicologicalstudies(annexiia,point5.8)menonesubmittedstudiesperfmt14acuteoralld50(rats):>2000mg/kgbw.90-daydietaryrats:noaelandloaelof10.3and45.7mg/kgbw/day,basedonincreasedmortalityandwaterconsumption,changesinhaematology,clinicalchemistryandurinalysisparametersandincreasedkidneyweight,renal(histo)pathologysecondarytochronicrenalfailure.mutagenicityinbacterialcells:negative.clastogenicityincho(chinesehamsterovary)cells:negative.mouselymphomaassay:negativemt13acuteoralld50(rats):>2000mg/kgbw.90-daydietaryrats:noaelandloaelof3.4and10.3mg/kgbw/daybasedonchangesinhaematologyandclinicalchemistryparameters.mutagenicityinbacterialcells:negativemouselymphomaassayinl5178ycells:negativeclastogenicityinculturedhumanlymphocytes:negativemt20acuteoralld50(rats):>5500mg/kgbw90-daydietaryrats:m:noaelandloaelof16.7and34.1mg/kgbw/day,basedondecreasedbodyweight,changesinclinicalchemistryandurinalysisparametersandorganweighteffectsf:noaelandloaelof0.7and7.6mg/kgbw/day,basedonalteredoestruscyclelengthandprolongedoestrusand/ordioestrusmutagenicityinbacterialcells:negativemousemicronucleusassay:10efsajournal2019;17(9):5817mt1acuteoralld50(rats):236mg/kgbwacuteoralld50(rats):300-500mg/kgbwmutagenicityinbacterialcells:negativesecondmutagenicityinbacterialcells:negativeinvitrocytogeneticassayinhumanlymphocytes:negativegenemutationassay:weaklypositivemousemicronucleusassay:negativeinvivounscheduleddnasynthesis:negative90-dayratstudyreducedbodyweightgaintotalwbc(whitebloodcells)reducednonoaellm1mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm2mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm3mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativettcclassiii:1.5g/kgbwperday(forallsourcesoflm3andlm6)(efsapprpanel,2019)lm4mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm5mutagenicityinbacterialcells:negativemammaliancellgenemutationassay:negativeinvitrochromosomeaberration:negativelm6mutagenicityinbacterialcells:negativegenemutationassay:weaklypositiveinvitrochromosomeaberration:negativemousemicronucleusassay:negativettcclassiii:1.5g/kgbwperday(forallsourcesoflm3andlm6)(efsapprpanel", "efs25820-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1)limiteddata:noadverseeffectswereobservedamongresearches,productionworkersandfieldtechnicianswhenappropriateprotectiveequipmentwasused.noadverseeffectshavebeenobservedinpersonsinvolvedinresearchanddevelopment,productionanduseofp.giganteaproductsduring50years.sensitisation:(ma5.2.1&mp7.2.3)negativeresultinbuehlertest(p.giganteavra1835).(buehlertestisnotacceptable.)acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)ratld50>4.26x107cfuofp.giganteavra1835/kgbw)noninfectivenonpathogenicacuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)ratlc50>1.12x106cfuofp.giganteavra1835/kgbwnoninfectivenonpathogenicoccurrenceoftreatment-relatedwhitenodulesobserveduponi.p.administrationofphlebiopsisgiganteaonorgans(liver,spleen,kidneysandintestines)isapotentialconcernjustifyingfurtherthedatagapsetonsecondarymetabolites/toxinsacuteintravenous/intraperitonealinfectivity:(ma5.2.2.3)ratld50=9.31x1041.27x105cfuofp.giganteavra1835/animalnoninfectivenonpathogenicgenotoxicity:(ma5.2.3)open,pendingontheidentificationandquantificationofsecondarymetabolites/toxinscellculturestudy:(ma5.2.4)nodatarequiredinformationonshort-termtoxicityandpathogenicity:(ma5.2.5)nodatarequireddermaltoxicity:(mp7.1.3)ratld50>2000mg/kgbwspecifictoxicity,pathogenicityandinfectivity:(ma5.3)noinvitrocytotoxicitywasobservedinliquidculturebrothofp.giganteastrainsvra1835,vra1984andfocpg410.3.thereweresomeindicationsofcytotoxicityinextractsofsolidculturemediumofp.giganteavra1835andvra1984,butduetointerferenceofthetestsubstance(solidgrowthmedium)withthetestmethod,itcannotunequivocallybeconcludedthatp.giganteahasthepotentialtoproducecytotoxicsubstancesinsolidculture.genotoxicityinvivostudiesingermcells:(ma5.5)nostudiesprovided.invivogenotoxicitystudiesarenotrequiredbasedontheabsenceofconcernsarisingfromtheabovetests.referencevalues'", "efs25821-sup-0001-appendix_a.pdf": "europa.eu/efsajournal13efsajournal2019;17(10):5821impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability85-90%oforaldosesystemicallyavailableinmaleandfemalesrats(basedonurinary(6-13%)andbiliary(67-81%)excretionwithin72h,singleoralgavagedoseat5mg/kgbw)oralabsorptionwasreducedto50-55%at100mg/kgbwand19-24%at300mg/kgbwbasedon>85%oralavailabilityatthelowdosetested,nocorrectionfortheaoeloraaoelisrequiredtoxicokineticst1/2<2hfollowingivadministrationof1mg/kgbw.systemicexposure(auc(0-t))wasnon-linearfrom300mg/kgbwinmaleratand100mg/kginfemalerat.followingasingleoraladministration,cmax:0.5-2hours(5mg/kgbw)and8hours(0-t)increasedsubproportionallybetween5mg/kgbwandhigherdoses.5mg/kgbw1000mg/kgbwmalefemalemalefemalecmax(ngequiv/g)5627151120010100tmax(hours)112424t1/2(hours)46432220auc(0-t)(ngequiv.h/g)852012800449000353000auc(0-inf)(ngequiv.h/g)1190018100562000401000distributionwidelydistributed,withhighestconcentrationsofradioactivityobservedintheliverandkidneypotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionfollowingasingleoralgavagedose,ca.91%wasexcretedwithin48hwithexcretioncompleteby168h;predominantlyinfaecesviabiliaryexcretion.theremainderofthedosewasrecoveredfromurine,with<0.1%ofdoserecoveredinexpiredairorinthecarcass.metabolisminanimalsextensivelymetabolised(>95%);inrat,unchangedparentinurineaccountedforlessthan3.9%ofthe5mg/kgbworaldose.theprimarymetabolicroutesincludeddemethoxylation,n-dealkylation,singleanddihydroxylation,o-demethylationandoxidativeandreductivedechlorination.themajorityofthesemetaboliteswerealsomonoanddi-hydroxylatedandinmanycasesconjugatedwithglucuronideorglutathione.metabolicprofileverysimilarinmouse,goatandhen.invitrometabolismnonotabledifferenceofpydiflumetofenmetabolisminacomparativeinvitrostudywithratandhumanliver'europa.eu/efsajournal14efsajournal2019;17(10):5821microsomes.toxicologicallyrelevantcompounds(animalsandplants)pydiflumetofenand2,4,6-trichlorophenoltoxicologicallyrelevantcompounds(environment)pydiflumetofenacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.11mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(llna)phototoxicitynot-phototoxic(invitro3t3nruassay)short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectbodyweightreduction(dog)liver:increasedliverweight,bloodclinicalchemistryparameterschanges,hepatocellularhypertrophy(rat,mouse,dog)thyroid:hypertrophyofthyroidfollicularepithelium(rat)relevantoralnoael90-day,rat:18.6mg/kgbwperday90-day,mouse:17.5mg/kgbwperday90-day,dog:30mg/kgbwperdayrelevantdermalnoael28-day,rat:1000mg/kgbwperdayrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesnotgenotoxic(negativeamesandmlaassays),negativeresponseforclastogenicity(ca)invivostudiesnotgenotoxic(negativemousebonemarrowmicronucleusandratchromosomeaberrationassays)photomutagenicitynotrequiredpotentialforgenotoxicitypydiflumetofenisunlikelytobegenotoxic'", "efs25842-sup-0001-appendix_a.pdf": "7efsajournal2019;17(10):5842section2impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapid(<48h)andincomplete20%basedonradioactivityretrievedinurine168hafteradministrationof100mg/kgbwtoxicokinetics100mg/kgbw500mg/kgbwtmax(h)5-1024cmax(9-1334-36t1/2(h)300-4511739-2286auc(g-eq/mlh)56-6354-62distributionwidelydistributed;higherlevelsinfat,liver,kidney,bloodpotentialforbioaccumulationaffinityforfat,butnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(77-91%)within48hmainlyfaecal(73%),18%viaurine,10%viabilemetabolisminanimalsbenfluralinwassubjecttodi-dealkylationandreduction,andfurthermetabolisedintonumerouspolarcompounds,eachpresentat<1%ofthedose.parentcompoundpresentatabout35%infaeces.datagap:theapplicanttoproposearesiduedefinitionforbodyfluidsandtissues.invitrometabolismallmetabolitesformedinhumanlivermicrosomes>5%oftheinitialsubstrateconcentrationwerealsoformedinmouse,rat,dog,andrabbitlivermicrosomes.qualitativeandquantitativedifferencesinmetabolitesformationwereobservedbetweenmouse,rat,dog,andrabbit.datagap:twopeaks(peak3andpeak7)shouldbecharacterizedandtheirtoxicologicalrelevanceshouldbeassessedbecausetheyaresignificantlyhigherinhumanmaterialthanintheotherfourspeciestested.toxicologicallyrelevantcompounds(animalsandplants)benfluralintoxicologicallyrelevantcompounds(environment)benfluralinacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>2.16mg/lair/4h(dust,noseonly)h371skinirritationirritanth315eyeirritationirritanth319skinsensitisationsensitising(m&kandbuehlertest)h317phototoxicitynotphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectstudiesoflimitedreliabilitysincenovalidatedanalyticalmethodswerereported:rat:kidneytubulepigmentation(females),kidneyweightincrease;liverweightincrease;rbceffectsdog:liverweightincrease,liver/spleenpigmentation(indicationofhaemosiderosis),", "efs25905-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(regulation(eu)n544/2011,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitynoinvivotoxicokineticstudy-expectedtobeabsorbedtoxicokineticsnoinvivotoxicokineticstudydistributionnoinvivotoxicokineticstudy-expectedtobedistributedpotentialforbioaccumulationnoinvivotoxicokineticstudy-notexpectedrateandextentofexcretionnoinvivotoxicokineticstudyexcretionmainlyviaurinemetabolisminanimalsinvitrorathepatocyte:rapidmetabolismwithformationofmethanethiolanddimethylsulphide(dms).toxicologicallyrelevantcompounds(animalsandplants)dmds,methanesulfonicacid(msa)toxicologicallyrelevantcompounds(environment)dmds,formaldehyde,sulfurdioxide,methanesulfonicacid(msa)andmethanethiolacutetoxicity(regulation(eu)n544/2011,annexparta,point5.2)ratld50oral>125mg/kgbwh301h336ratld50dermal>2000mg/kgbwh336ratlc50inhalation>3.26mg/lair/4hh331respiratoryirritationirritant,noaecof34.7mg/m324hwholebodyexposureh370skinirritationnon-irritanteyeirritationirritanth319skinsensitisationsensitising(llna)h317short-termtoxicity(regulation(eu)n544/2011,annexparta,point5.3)targetorgan/criticaleffectrat:reducedbodyweightgain,clinicalchemistrychangesandnasalirritation(inhalation);mortalityanddermalcorrosion(dermal)relevantoralnoaelnodataavailablerelevantdermalnoael28-day,rabbit:systemic:106mg/kgbwperday;localloael=10.63mg/kgbwperdayh336relevantinhalationnoaec90-day,rat:loaecsystemicandlocal=10ppm(39.5mg/m3)'", "efs25985-sup-0001-appendix_a.pdf": "riskassessmentoftheactivesubstancebenalaxylwww.efsa.europa.eu/efsajournal10efsajournal2020;18(1):5985section2mammaliantoxicologyimpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidandextensiveabsorption,morethan90%within24hbasedonurinary(10%)andbiliary(90%)excretiontoxicokinetictmax0.5hfollowingsingle(10or100mg/kgbwperday)orrepeatedoraldoses(10mg/kgbwperday)ofbenalaxylterminalhalf-lifeca.30h.distributionwidelydistributed30%(singledose)40%(repeateddose)incarcassattmax(mainlystomach,liverandkidneysand,toalesserextent,intestinewall),butonlytracesat72h.levelsstillquantifiableinliveronlyat168hfollowingrepeateddoseadministration.potentialforbioaccumulationnoevidenceforbioaccumulation.rateandextentofexcretionmorethan90%excretedwithin24hours,independentlyfromgender,ordoselevelorregimeofadministration(singleormultipledoses).excretionmainlyviafaecesthroughbile(>95%within72hrs,60-86%occurringwithinthefirst8hrs),limitedviaurine(approx.14%).metabolisminanimalsmetabolismextensiveandmainlybyoxidationofthemethyl(xylene)groupoftheanilineringtoahydroxymethylgroup,andthenfinallytocarboxylicacid;minormetabolicpathwayswerethehydroxylationofphenylringandhydrolysisofcarboxymethylgroup.invitrometabolismextensivelymetabolisedwhenincubatedwithratandhumanhepatocytes,completelymetabolisedbydoghepatocytes.metaboliteprofilesqualitativelysimilarinallspeciestested.nouniquemetabolitesinhumanhepatocytes.toxicologicallyrelevantcompounds(animalsandplants)benalaxyltoxicologicallyrelevantcompounds(environment)benalaxyl'riskassessmentoftheactivesubstancebenalaxylwww.efsa.europa.eu/efsajournal11efsajournal2020;18(1):5985acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectliver:increasedweight,clinicalchemistryand/orhistopathologicalfindings(eghepatocellularhypertrophy)(rat,mouse,dog)testes:atrophyofseminiferoustubules(1-yrdog)relevantoralnoaelrat:58.9mg/kgbwperday(13-week)62mg/kgbwperday(90-dcombinedneurotoxicity)dog:25mg/kgbwperday(90-day)6.5mg/kgbwperday(1-year)mouse:range-findingstudynotsuitabletoderiveanoaelrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesamestests(3studies):negativednadamageandrepairtestinsaccharomycescerevisiae:negativegenemutationtestinschizosaccharomycespombe:negativechromosomeaberrationtestinhumanlymphocytes(supplemental):negativechromosomeaberrationtestinchocells:negativeunscheduleddnasynthesisassayinprimaryrathepatocytes:negativegenemutationtestinmouselymphomacells:indicationsofclastogeniceffect,notconfirmedinchromosomeaberrationtestsgenemutationinchinesehamsterv79cells(supplemental):negativeinvivostudiesmicronucleustests(2):negativephotomutagenicitynodata,notrequiredpotentialforgenotoxicityunlikelytobegenotoxiclong-termtoxicityandcarcinogenicity(regulation(eu)n283/2013,annexparta,point5.5)long-termeffects(targetorgan/criticaleffect)heart:changesinweight,ldhandk(rat)amyloidosis(liverandmultipletissues)(mouse)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbw(alsorabbit)ratlc50inhalation>4.2mg/l(highestattainableconcentration;nose-only,rat)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(llnaandmagnussonandkligman)phototoxicitynotrequired-benalaxyldoesnotabsorbelectromagneticradiationintherange290-700nm'", "efs25986-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitylowbioavailability.valueof50%fororalbioavailabilityofironfromferricpyrophosphatetoxicokineticslowsolubilityofinorganicsubstanceinwaterandlipidsresultsinverylowsystemicallyabsorptiondistributionwidelydistributed,highestresiduesinliver,absorptiontospecifictransportproteins.potentialforbioaccumulationnopotentialforaccumulationundernormalphysiologicalconditions.excessiveironisstoredinliver,endocrineorgans(pancreas)andspleen.rateandextentofexcretionalowlevelofironexcretionundernormalphysiologicalconditions.metabolisminanimalsferricpyrophosphatedissociatesintotrivalentiron-cationsandphosphate-anions,ironisseparatelyabsorbedasferrousions.invitrometabolismnodata-notrequired.toxicologicallyrelevantcompounds(animalsandplants)irontoxicologicallyrelevantcompounds(environment)ironacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermalnotrequiredratlc50inhalation>2.69mg/lair/4h(maximumattainableconcentration)skinirritationnon-irritanteyeirritationmildirritant,classificationandlabellingisrequired.eyeirrit.2,h319skinsensitisationnoindicationofsensitisingpotential,dietarysupplementandfoodadditive.phototoxicitynodata-notrequired.short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectironsalts:gastrointestinaltract,liver,centralnervoussystem,thecardiovascularsystemrelevantoralnoael28-day,rat:1000mg/kgbwperday90-day,rat:1000mg/kgbwperday'", "efs26006-sup-0001-appendix_a.pdf": "ww.efsa.europa.eu/efsajournal10efsajournal2020;18(2):6006impactonhumanandanimalhealthbloodmealhasanon-toxicmodeofactionandisnon-toxicbyitself.inordertoensurethattheactivesubstanceisoflowrisktohumans,thefollowingqualitycriteriaareapplied:foodgradequalitybloodcollectedinauthorizedslaughterhousesdestructionofpathogensandproteindenaturationoccurringduringbloodprocessingbloodofporcineoriginbloodmealisproducedinaccordancewithcurrentfeedandfoodeulegislations.baseduponthesestatements,takingintoaccountthatthesubstancedoesnotinitselfpresentatoxicologicalconcern,andthatbloodisamajorconstituentofthehumanbodyandingeneralofallvertebrates,thewaiverfortoxicologicalstudieswasdeemedacceptable.absorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitynodata-notrequiredtoxicokineticsnodata-notrequireddistributionnodata-notrequiredpotentialforbioaccumulationnodata-notrequiredrateandextentofexcretionnodata-notrequiredmetabolisminanimalsnodata-notrequiredinvitrometabolismnodata-notrequiredtoxicologicallyrelevantcompounds(animalsandplants)nodata-notrequiredtoxicologicallyrelevantcompounds(environment)nodata-notrequiredacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralnodata-notrequiredratld50dermalnodata-notrequiredratlc50inhalationnodata-notrequiredskinirritationnodata-notrequiredeyeirritationnodata-notrequiredskinsensitisationnodata-notrequiredphototoxicitynodata-notrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectnodata-notrequiredrelevantoralnoaelnodata-notrequiredrelevantdermalnoaelnodata-notrequired'", "efs26028-sup-0001-appendix_a.pdf": "tonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityabove85%(basedpredominantlyonexcretioninexpiredair,aswellasurineandfaeceswithin168h)toxicokineticsbloodcmax0.417ppm;tmax6hinmalesbloodcmax0.443ppm;tmax24hinfemalesdistributionsmallamountsoftotalradioactivitywerefoundintissues,mainlyinthestomachandliver.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive:mainlyviaexpiredair(60%);urine(20%)andfaeces(15%)metabolisminanimalsextensivelymetabolized.mainpathway:dechlorinationtodichloronitromethane(dcnm)chcl2no2withconversionofgshtogssg,andconversiontoraphanusamicacidviathiophosgene.minorpathway:adductformationwiththiolproteins(hb-adduct)invitrometabolismnoreliabledatasubmitted,nonearerequiredunderdatarequirementsofeuregulation(ec)544/2011toxicologicallyrelevantcompounds(animalsandplants)chloropicrin,dcnmtoxicologicallyrelevantcompounds(environment)chloropicrin,dcnm,phosgeneacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral250mg/kgbwcat3h301ratld50dermal926mg/kgbwcat3h311ratlc50inhalation0.044mg/l(4h;noseonly)cat1h330skinirritationcausessevereskinburnsskincorrcat1ch314eyeirritationcausessevereeyedamageskincorrcat1ch314skinsensitisationnodata,nonerequiredbecauseofcorrosivityphototoxicitynodata,nonerequiredbecauseofcorrosivity'", "efs26054-sup-0001-appendix_a.pdf": null, "efs26056-sup-0001-appendix-a.pdf": null, "efs26058-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitycyfluthrin:>80%(basedoni.v.studieswithexcretionviaurine,faecesandbodywithoutgit;supportedbyoralandduodenalstudies)-50%ofthefaecallyexcretedradioactivityisduetoanabsorbedandbiliaryeliminatedamount.cmax1.0-1.5g/mlat0.5mg/kgbwand18-27g/mlat10mg/kgbw.tmax1.5-2.0hat0.5mg/kgbwand1.5-2.4hat10mg/kgbwbeta-cyfluthrin:77%(males)or85%(females)(basedonlowdoseexperimentsusing0.5mg/kgbwbeta-cyfluthrin;radioactivitydetectedinexpiredair,urine,cagewash,residuesincarcassandtissuescmax0.1-0.3g/mlat0.5mg/kgbwand1.4-1.5g/mlat10mg/kgbw.tmax0.5hat0.5mg/kgbwand6-8hat10mg/kgbwdistributionwidelydistributed(highestvaluesinfattytissue,adrenals,kidneyandliver)cyfluthrin:t1/2plasmadatadependonphaseofeliminationcurvebeta-cyfluthrin:t1/2plasma(terminal)10-14hat0.5mg/kgbwand42-50hat10mg/kgbwpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(>90%within48h),mainlyviaurine(55%,12%viafaeces,33%viabile)metabolisminanimalsextensivelymetabolised(>95%);mainmetabolitesatradiolabelledcyclopropyl-moiety:cis/transdcva,dcvaacylglucuronide;radiolabelledfluorophenyl-moiety:sulfateconjugateof4-oh-fpb,fpbacid.parentcompoundonlydetectedinfaeces(upto20%).cleavageoftheesterbond,oxidation,hydroxylationandconjugation.invitrometabolismratlivermicrosomes:beta-cyfluthrinisextensivelymetabolised(11metabolitefractions)humanlivermicrosomes:limitedmetabolismrate(2metabolitefractions)allmetabolitefractionsobservedinhumanmicrosomeswerealsofoundinratsinsimilarportions.toxicologicallyrelevantcompounds(animalsandplants)beta-cyfluthrintoxicologicallyrelevantcompounds(environment)beta-cyfluthrin'acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral14.3mg/kgbw(cyfluthrin,cremophor/water)-1189mg/kgbw(cyfluthrin,peg400)cat2h300mouseld50oral91mg/kgbw(beta-cyfluthrin,peg400)-609mg/kgbw(cyfluthrin,peg400)rat/rabbitld50dermalrat:>2000mg/kgbw(beta-cyfluthrin,peg400)ratlc50inhalationaerosol(ethanol/peg400)0.081mg/lair(beta-cyfluthrin,4h-exposure,head-noseonly>1.089mg/l(cyfluthrin,1h-exposure,noseonlydust0.532mg/lair(beta-cyfluthrin,4h-exposure,head-noseonly0.967mg/l(beta-cyfluthrin,4h-exposure,head/nosecat2h330skinirritationnon-irritant(beta-cyfluthrin)eyeirritationnon-irritant(beta-cyfluthrin)skinsensitisationnon-sensitizer(cyfluthrin,m&k)phototoxicitynotphototoxic(3t3nru-pt(a)withlimitations)(a)itmightnotbeappropriatetouvbabsorberslikebeta-cyfluthrin(datagap).short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)target/criticaleffectmortality(rats)at16and40mg/kgbwperdbehavioural/motordisturbances,reducedbodyweightdevelopment,choreoathetoticsigns(ratsanddogs)relevantoralnoaelsbeta-cyfluthrin:1mg/kgbwperd(28-dayrat)2.4mg/kgbwperd(90-ddog)cyfluthrin:2.43mg/kgbwperd(1-yeardog)relevantdermalnoaelcyfluthrin:22/23-d,rat:-localeffects:113mg/kgbwperd-systemiceffects:376mg/kgbwperdrelevantinhalationnoaelcyfluthrin:0.09mg/kgbwperd)rat,6h/day,head-noseexposure,13-week,aerosol,5daysperweekbeta-cyfluthrin:0.2mg/lair(~0.07mg/kgbwperday)'", "efs26121-sup-0001-appendix_a.pdf": "ww.efsa.europa.eu/efsajournal7efsajournal2020;18(5):6121impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))basedonthetotaltoxicologicalpackageoftheactivesubstanceakanthomycesmuscarius,itisconcludedthattheactivesubstanceanditsproductsdonotexhibitinfectivitynorpathogenicity.akanthomycesmuscariusstrainve6maygiverisetoantibodyformationwhileisnotindicatedtobesignificantlyallergenic,eventoamorehighlyallergenicpopulationthanaverage.thestrainsdonotappeartobetoxic.sensitisation:(ma5.2.1&mp7.2.3)noevidencewasfoundthatexposureunderpilotplantconditionshadresultedinsensitisationofanysortinthesesubjectswhowereallhealthyandwithoutsymptoms.theuseofakanthomycesmuscariuswasnotrelatedtoanysymptomsofsensitizationandinflammatorylungdiseasesamonggreenhouseworkers.exposuretomicrobialbiopesticidescontainingakanthomycesmuscariusmayconferariskofige-mediatedsensitization.infutureresearchthereisaneedtoidentifyallergeniccomponentsinthepreparations,performstudiesonnon-exposedcontrolsandanalysetherelationbetweensensitizationandhealthparameters.akanthomycesmuscariusspp(strainnotindicated)wasnegativeinamaximisationtestitishoweveracknowledgedthatsensitisationstudieswithmicroorganismsareoflimitedvalue,sincereactionstoforeignproteinscanbeanticipatedandallmicroorganismsshouldberegardedaspotentialsensitisers.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)noadversetoxicologicaleffects.ratoralld50>3.0x108spores/animal.noindicationofinfectivityorpathogenicityacuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)noadversetoxicologicaleffects.ratinhalationld50>maximalpracticaldose(1.08109cfu/m3).noindicationofinfectivityorpathogenicity,howeverinadequatedescriptionofmethod.acuteintravenous/intraperitonialinfectivity:(ma5.2.2.3)mortality,clinicalsigns,changesinclinicalpathology(rat,highdose(ca108cfu/animal),bwloss,lesionintheabdominalcavity(ratandmouse,lowandhighdose:ca106-107orca108cfu/animal),consideredtobeunspecificeffectsduetoi.pinjectionofproteinaceousmaterial.rati.p.ld50>1.2x108spores/animal.noindicationofinfectivityorpathogenicitygenotoxicity:(ma5.2.3)nogenemutationpotential(chromosomeaberrationnotinvestigatedinvitro)cellculturestudy:(ma5.2.4)notrequiredinformationonshort-termtoxicityandpathogenicity:(ma5.2.5)localeffectswerenotedinthelungs,possiblyimmune(irritation)related,sincetheformulationwastested,whichcontains-inadditiontoakanthomycesmuscariusve6-a'", "efs26132-sup-0001-appendix_a.pdf": "www.efsa.europa.eu/efsajournal14efsajournal2020;18(6):6132impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityoralabsorptionisaround10%(publicliterature)toxicokineticsrapiddistributionandexcretion(publicliterature)distributionwidespread(publicliterature)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionmainlyviaurineandfaecesmetabolisminanimalsmetabolisedbyenzymaticdegradationtobileacids(publicliterature)invitrometabolismnodata-notrequiredtoxicologicallyrelevantcompounds(animalsandplants)24-epibrassinolidetoxicologicallyrelevantcompounds(environment)-acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.08mg/lair/4h(maximalattainableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitisingphototoxicitynotrequired'", "efs26151-sup-0001-appendix_a.pdf": "pactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability70%basedonradioactivityrecoveredinurine,tissuesandresidualcarcasswithin168hinmales,followingsingleoraladministrationof0.5mg/kgbw.higheroralabsorptionisobservedinfemales.thevalueisconsideredappropriateforthederivationoftheaoelandaaoelvalues.toxicokineticsmalesfemalesdoselevel:0.5mg/kgbw0.5mg/kgbwcmax(geq./g):1.471.29tmax(h):88tmax/2(h):4617-1):71.919.1distributionwidelydistributed;highestresiduesinfat,muscle,liver,bloodandkidneys.fatresidueshigherinmalesthanfemales.potentialforbioaccumulationpotentialaccumulationinfat.eliminationwasslowfromovaries,pancreas,thymusandthyroid.rateandextentofexcretionurinary(24h):16-27%(m),77-87%(f)faecal(24h)7-9%(m),2-5%(f)totalexcretion(7d):66-85%(m),92-96%(f)metabolisminanimalsextensivelymetabolised,<0.3%remainingasparent.mainmetaboliteinurine&faeces:clodinafopinvitrometabolismclodinafop-propargylwasfoundtobecompletelymetabolisedbyratandhumanlivermicrosomes.nouniquespeciesmetaboliteswereobserved.toxicologicallyrelevantcompounds(animalsandplants)clodinafop-propargylanditssisomertoxicologicallyrelevantcompounds(environment)clodinafop-propargyl,clodinafopanditss-isomeracutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral1392mg/kgbw(m)2271mg/kgbw(f)acutetox.4;h302ratld50dermal>2000mg/kgbwratlc50inhalation>2.3mg/lair/4h(noseonly;maximumattainableconcentration)skinirritationnon-irritant'", "efs26156-sup-0001-appendix_a.pdf": "substancebacillusamyloliquefaciensah2www.efsa.europa.eu/efsajournal6efsajournal2020;18():6156impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)noindicationsofanytoxicologicaleffectstothelaboratoryorproductionteaminvolvedintheproductionorpackagingofpb001(bacillusamyloliquefaciensah2)since2008havebeenobserved(withuseofprotectiveclothing,glovesandeyeprotectionwhennecessary).sensitisation/allergenicityobservations,ifappropriate:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)warningphrase:bacillusamyloliquefaciensah2.micro-organismsmayhavethepotentialtoprovokesensitizingnosensitisationorallergenicresponseshaveoccurredorhavebeenreportedforthestaffinvolvedinthelaboratory,productionorpackagingofresearchorproductionofpb001(bacillusamyloliquefaciensah2)since2008.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)nomortality,notoxicseffectsandnotpathogenicitywereobservedinratsfollowingadministrationofb.amyloliquefaciensah2atadoselevelof5.6107cfuperanimal.noabnormalitiesandnosignsofinfectivitywereobservedduringgrossnecropsyconductedattermination.completeclearanceofkidneys,spleenandmesentericlymphnodesbyday21,estimatedlungclearancearound22days,lowremainingcaecumconcentrationsnotconsideredinfectious.acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)nomortality,notoxiceffectsandnopathogenicitywereobservedinratsfollowingintratrachealinstillationofb.amyloliquefaciensah2at9.1107cfuperanimal.nosignificantconcentrationsinblood,brain,liver,kidneys,spleenandmesentericlymphnodesatanytimepointduringthestudy.lungclearanceby14daysandestimatedcaecumclearanceof39days.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)nomortality,notoxiceffectsandnopathogenicitywereobservedinratsfollowingintravenousapplicationofb.amyloliquefaciensah2at7.2106cfuperanimal.completeclearancefromblood,brain,lungs,kidneys,mesentericlymphnodesandcecumcontentsbyday21.clearancestartingfromday3andestimatedaround41daysforliverand50daysforspleen.genotoxicity:(ma5.2.3;oecdiim5.3.5)b.amyloliquefaciensah2isnotknowntoproducegenotoxinsorothermetabolitesofgenotoxicologicalconcernanditisnotrelatedtospeciesknowntoproducegenotoxins.cellculturestudy:(ma5.2.4;oecdiim5.3.6)b.amyloliquefaciensah2isnotanintracellularreplicatingmicroorganism.informationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)notrequired.dermaltoxicity:(mp7.1.3;oecdiiim7.1.2)notrequiredbecausebacteriadonotpenetrateintactskin.sincetheformulationdoesnotcontainanyco-formulantclassifiedregardingacutedermaltoxicity,itisconsideredthatpb001doesnotrequireclassificationregardingacutedermaltoxicity.specifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)inacutetoxicitystudieswithb.amyloliquefaciensah2,noadverseeffectsandnosignsofinfectivityoraccumulationwereobserved.clearanceoccurredrapidly.(pleaserefertopointsiim5.3.2-5.3.4.).'", "efs26181-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthothertoxicologicalstudies(annexiia,point5.8)studiesperformedonmetabolitesorimpurities-cga159902(ca1118a):acuteoralld50>2000mg/kgbwacutedermalld50>2000mg/kgbwnotaskinoreyeirritantsensitiser(m&ktest)h317invitrogenotoxicitytests-amestest:negative;mouselymphomaassay:positive(smallcolonies);cytogeneticassayinhumanlymphocytes:positiveinvivogenotoxicitytestsudsassay:negative;mousebonemarrowmicronucleustest:negativeunlikelytobegenotoxicinvivo.-cga150829(triazineamine):acuteoralld50>2000mg/kgbw(m);=1000mg/kgbw(f)r22acutedermalld50>2000mg/kgbwacuteinhalationlc50>5.2mg/lnotaskinoreyeirritantnotasensitiser(m&ktest)genotoxicpotentialcannotbeconcluded.-cga325025:invitrogenotoxicitytests-amestest,mouselymphomaassay:negative;cytogeneticassayinhumanlymphocytes:equivocal.genotoxicpotentialcannotbeexcluded.-cga349707:invitrogenotoxicitytests-amestest,mouselymphomaassayandcytogeneticassayinhumanlymphocytes:negative.adiof0.001mg/kgperday.-syn547308:invitrogenotoxicitytests-amestest,mouselymphomaassay:negative;cytogeneticassayinhumanlymphocytes:positive.invivogenotoxicitytestsmousebonemarrowmicronucleustest:negativegenotoxicinvitro,notinvivo.'", "efs26182-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))limiteddata:noadverseeffectsobservedamongresearches,productionworkersandfieldtechniciansexcepttwoinstancesofallergicreactions.sensitisation:(ma5.2.1&mp7.2.3)twoinstancesofrespiratoryallergicreactions(norespiratoryprotectiveequipment)magnusson-kligmanmaximisationtestgavepositiveresult:moderatesensitiser.thefollowingstandardwarningphraseformicrobialproductsisproposedinsstreptomycesk61.microorganismsmayhavethepotentialtoprovokesensitisingreactiacuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)ratld50>5000mgmycostop/kgbodyweight(>108cfu/kgbw).acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)ratlc50=3.46x107cfu/animal(male)=25mgmycostop/animal(bodyweightrange96127g)=197-260mgmycostop/kgbw=2.7-3.6x108cfu/kgbwratlc50=3.02x107cfu/animal(female)=20mgmycostop/animal(bodyweightrange96127g)=157-208mgmycostop/kgbw=2.4-3.1x108cfu/kgbw.acutesubcutaneous/intraperitonealinfectivity:(ma5.2.2.3)mouseld50=1000mgmycostop/kgbodyweight/day=5.47x106-7.41x106cfu/kgbw.genotoxicity:(ma5.2.3)noevidenceofmutagenicactivityinanamestesttoxicological/genotoxicitydatamaybeneededonsecondarymetabolites/toxinspotentiallypresentafterapplicationofthemicroorganism.cellculturestudy:(ma5.2.4)nodatarequired.informationonshort-termtoxicityandpathogenicity:(ma5.2.5)28-dayoral,rat:noel=1000mg/kgbwperday;microorganismclearance,infectivityandpathogenicitynotinvestigated.dermaltoxicity:(mp7.1.3)tieriiassessmentisnotrequired.specifictoxicity,pathogenicityandinfectivity:(ma5.3)streptomycesk61didnotshowcellcytotoxicityinvitroonmousecelllinel929.bothtestsamples(streptomycesk61culturebroth)andadditionalcontrols(uninoculatedculturebroth)gavesimilarcytotoxiceffectsonthestudiedcellcultures.basedontheavailabledataandthedeficienciesofthestudies,theassessmentofinfectivityandpathogenicityofstreptomycesk61cannotbefinalized.genotoxicityinvivostudiesingermcells:(ma5.5)tieriiassessmentisnotrequired.referencevaluesaoel:basedonsubmitteddataitisnotpossibletoestablishaoelvalue.adi:basedonsubmitteddataitisnotpossibletoestablishadi'", "efs26190-sup-0001-appendix_a.pdf": "reviewofthepesticideriskassessmentoftheactivesubstanceaqueousextractfromthegerminatedseedsofsweetlupinusalbuswww.efsa.europa.eu/efsajournal9efsajournal2020;18(7):6190impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitynospecificstudieshavebeenconducted.asprobladpluscontainsthenaturallyoccurringpolypeptidecomponent,blad,theproteinwillbebrokendown,entertheaminoacidpoolandbeconsumedintonormalcatabolicprocesses.fortheriskassessment,anoralabsorptionof100%isassumed.toxicokineticsdistributionpotentialforbioaccumulationrateandextentofexcretionmetabolisminanimalsinvitrometabolismtoxicologicallyrelevantcompounds(animalsandplants)notrelevanttoxicologicallyrelevantcompounds(environment)notrelevantacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.34mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(buehler)phototoxicitynotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffect90-doralrat:vacuolationinbrainandspinalcordinonefemale22-ddermalrat:increasedadrenalweightrelevantoralnoael90-dayrat:500mg/kgbwperdayrelevantdermalnoael22-day,rat:300mg/kgbwperdayrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesames:negativemouselymphomagenemutation:positive+s9,negatives9humanlymphocytemicronucleus:negative'", "efs26227-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityapproximately86%(basedonurinaryexcretionafteroralorintravenousadministration).toxicokineticsmaximumbloodconcentrationwithin4-8h.distributiondistributedthroughoutallmajororgansandtissues.potentialforbioaccumulationnopotentialforaccumulationuponrepeatedoraladministration.rateandextentofexcretionrapidlyeliminated,almostexclusivelyinthefaeces(morethan92%).metabolisminanimalsmajorpathwaysinratsandhumanincludedemethylation,hydroxylation,cleavageoftheoleandrosylringandoxidationreactions.invitrometabolismratandhumanmetabolismaresimilarandnouniquehumanmetabolitewasidentified.toxicologicallyrelevantcompounds(animalsandplants)parentand[8,9-z]-isomerofavermectinb1a(photodegradationproduct)toxicologicallyrelevantcompounds(environment)parentand[8,9-z]-isomerofavermectinb1a(photodegradationproduct)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralld50=8.712.8mg/kgbwcat2h300ratld50dermalld50=1914mg/kgbwcat4h312ratlc50inhalation(4h,noseonly)lc50=<0.21mg/lcat1h330skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitizing(magnussonkligmanmaximiationassay)phototoxicitynotrequiredshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrats:clinicalsigns,bwlossstomach(inflammatorychanges.dogs:centralnervoussystemtoxicitytremors,ataxiaandmydriasis,absentordecreasedpupilreflex,liver.'", "efs26230-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)invitroacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)h331h318h317'", "efs26232-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability15%basedonoralbioavailabilitystudy(rat,singledose,30mg/kgbw).toxicokineticslowdose(0.5mg/kgbwperday):tmax=0.5hrs.highdose(1000mg/kgbwperday):tmax=0.25hrs.nosignificantsex-relateddifferences.distributionatlowdose(0.5mg/kgbwperday),radioactivityinalmostallofthetissueswasbelowlodafter168hrs.highestconcentrationsweredeterminedinblood,kidneys,liver,muscleandfatattmax.nosignificantsex-relateddifferences.potentialforbioaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandextensive(app.90%within24h),equivalentlyviaurinefaecesandbileatlowdose(0.5mg/kgbwperday),andmainlyviafaecesathighdose(1000mg/kgbwperday).nosignificantsex-relateddifferences.metabolisminanimalshydrolysisofthedimethylsulfonamidegroup(ccim)followedbyoxidationofthebenzylmethylgroup(ccba).glutathioneandcysteineconjugationthroughthebenzylmethylgroup.mainmetaboliteinraturinewasccba.invitrometabolismcomparativeinvitrometabolismstudynotprovided(datagap)toxicologicallyrelevantcompounds(animalsandplants)cyazofamid,ccim.toxicologicallyrelevantcompounds(environment)cyazofamid.acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbw(mouse,rat)ratld50dermal>2000mg/kgbw(rat)ratlc50inhalation>5.5mg/lair/4h(rat,whole-bodyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(m&k)phototoxicityprobablyphototoxic'", "efs26237-sup-0001-appendix-a.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidandalmostcomplete(84%within24h)aftersingledoseapplication.toxicokineticscmax(g-eq/g):524.6and9699.3,singleadministrationof1or25mg/kgbw,respectively.tmax(hours):0.5hhalf-lives(t1/2)distributionphase:0.2to6.0hhalf-lives(t1/2)eliminationphase:41to1543hdistributionwidelydistributed.highestlevelsinwholeblood(rat).potentialforbioaccumulationnoevidenceofaccumulation(rat)rateandextentofexcretionmainlyviaurine(70-80%at24h)butalsoviafaeces(5-10%at24h).biliaryexcretionnotmeasured(duetoalmostcompleteoralabsorptionandpredominantlyurinaryexcretion).metabolisminanimalsinvolvedthiophosphorylhydrolysis,s-methylation,oxidationofthesulfurtothesulfoxide(u3)andtothesulfone(u6),hydrolysisofthephthalimideringtotherespectivephthalimideacid.twomajormetaboliteswereidentifiedinurine:n-(methylsulfinylmethyl)-phthalamicacid(paams(o)m)andthecorrespondingsulfoxiden-(methylsulfonylmethyl)-phthalamicacid(paams(o2)m).invitrometabolismafterincubationtoratlivermicrosomes[14c]phosmetwasrapidlymetabolised.themajormetabolitefractionwasidentifiedasphosmet-oxon.allmetabolitesfoundinhuman(includingphosmet-oxon)werealsodetectedinrat,dogandmousehepatocytes.uniquehumanmetaboliteswerenotidentifiedwerenotidentified.toxicologicallyrelevantcompounds(animalsandplants)phosmetandphosmet-oxontoxicologicallyrelevantcompounds(environment)phosmetacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral230mg/kgbw113mg/kgbwacutetox.3h301ratld50dermal>1000mg/kgbwrabbitld50dermal>5000mg/kgbw'", "efs26238-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)thereisnodirectobservationsuggestingthatexposuretopurpureocilliumlilacinumstrain251couldberelatedtoharmfuleffectsinhumans.thereisnoinformationsuggestingtheoccurrenceofpoisoningincidentswhichcouldberelatedtoanexposuretopurpureocilliumlilacinumstrain251.purpureocilliumlilacinumstrain251ispartofthenaturalenvironmentandwasneverreportedtobeahumanpathogenand,therefore,apossibleimpactonhumanhealthwasnotsubjectedtomoredetailedinvestigations.moreover,sincenovember1999personneloftheandofthedevelopmentallaboratoriesingermanyhasbeenexposedtothisfunguswithouthavingshownanyhealthproblems(includingallergicreactions),fungalinfectionsorsymptomsofpathogenicity.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)thestudyonskinsensitizationpotentialofbioact,didnotrevealanysensitisationreactions.however,therearenovalidatedtestsfortheidentificationofskinsensitizationpotentialofmicroorganisms.therefore,theuseofthestaacuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)thereisnoevidenceoftoxicityorinfectivity/pathogenicitytoratsfollowingasingleoraladministrationof1.8x109spores/gpurpureocilliumlilacinumstrain251.acuteoralld50>2000mg/kg(>3.6x108sporesofpurpureocilliumlilacinumstrain251/rat.)acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)thereisnoevidenceoftoxicity,infectivity/pathogenicitytoratsfollowingasingleintratrachealinjectionof2.5x108sporescfu/ratpurpureocilliumlilacinumstrain251formulatedaswgacuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)thereisnoevidenceofinfectivitytoratsfollowingasingleintraperitonealadministrationof1x1010spores/ratpurpureocilliumlilacinumstrain251formulatedaswg.clearanceoccurredwithin3weeksafterintraperitonealtreatmentgenotoxicity:(ma5.2.3;oecdiim5.3.5)thereisnoindicationoftoxinproductionbypurpureocilliumlilacinumstrain251.cellculturestudy:(ma5.2.4;oecdiim5.3.6)nodata;notrequiredinformationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)nodata;notrequireddermaltoxicity:(mp7.1.3;oecdiiim7.1.2)rat:ld50>2000mg/kgbw;nomortality,nosignsofpathogenicityandinfectivity.specifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)nodata,notrequiredgenotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)nodata,notrequiredreferencevalues'", "efs26246-sup-0001-appendix_a.pdf": "esticideriskassessmentoftheactivesubstanceflumioxazinwww.efsa.europa.eu/efsajournal6efsajournal2020;18(9):6246classificationandproposedlabellingwithregardtophysicalandchemicaldata(annexiia,point9andannexiiia,point11.3)activesubstance:noneformulation500g/kg:nonechapter3(impactonhumanandanimalhealth)absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption83%basedonurinaryandbiliaryexcretionsintheratdistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapidlyexcreted,30-40%viaurineand60%viafaeceswithin7daysmetabolisminanimalsextensivelymetabolised;hydroxylationofcyclohexeneringandcleavageoftheimidelinkagetoxicologicallyrelevantcompounds(animalsandplants)parenttoxicologicallyrelevantcompounds(environment)parentacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>3.93mg/l(4-hours,wholebody)skinirritationnon-irritanteyeirritationminimallyirritating.notclassified.skinsensitisationnon-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectanaemia(rats)hepatotoxicity(rats,miceanddogs)relevantoralnoael2.2mg/kgbwperd;90-drat10mg/kgbwperd,90-dand1y,dogrelevantdermalnoael300mg/kgbwperd(21-drat)relevantinhalationnoaelnodata,nostudyrequired'", "efs26261-sup-0001-appendix_a.pdf": "ithregardtoecotoxicologicaldata:notrequiredmethodsofanalysis(regulation(eu)n283/2013,annexpartb,point4andregulation(eu)n284/2013,annexpartb,point5)analyticalmethodsforthemicroorganism(ma4.1&mp5.1)manufacturedmicroorganism(principleofmethod):biopotency(bioassaywitht.ni),cfu(validatedmethod)impuritiesandcontaminatingmicroorganismsinmanufacturedmaterial(principleofmethod):standardmicrobiologicalmethodsfordetectionofmicrobialcontaminantsmicrobialpestcontrolproduct(principleofmethod):seeaboveanalyticalmethodsforresidues(viableandnon-viable)inexposedcompartmentsandorganisms(ma4.2&mp5.2)oftheactivemicroorganism(principleofmethod):specificmarkersareavailabletomonitorthestraininagriculturalfields.ofrelevantmetabolites(principleofmethod):cry1absoil:extractionwithphosphatebufferedsalinetween,quantificationwithcommercialelisakit.loq0.25ng/ml.water:processingvialyophilizationandfiltercentrifugation,quantificationwithelisa.methoddetectionlimit2.1ng/l.impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))therearenoconfirmedcasereportslinkingagriculturaluseofplantprotectionproductsbasedonbtkstrainswithhumandiseasealthoughbtkproductshavebeenusedworldwideformorethansixtyyears.noincidentsrelatedtoadversehealtheffectssuchastoxicologicaleffects,allergicresponse,orirritation,toemployees,resultingfromexposuretob.thuringiensissubsp.kurstakisa-11duringdevelopment,manufacture,preparationorfieldapplicationoftheproducthavebeenreportedsensitisation:(ma5.2.1&mp7.2.3)ina3-yearfollowupstudyonsensitizationandhealtheffectsofexposuretomicrobiologicalcontrolagentsusedindanishgreenhousesincludingbacillusthuringiensissubsp.kurstaki,increasedigelevelswasobservedin53%ofthebloodsamples(measurementwasonlyqualitativeapositiveigewasdefinedasexceedingthedetectionlimitof0.025odunits).bacillusthuringiensissubsp.kurstakistrainsa-11shouldberegardedaspotentialsensitizersandthefollowingwarningphraseisbacillusthuringiensissubsp.kurstakistrainsa-11.micro-organismsmayhavetheacuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)nosignsoftoxicity,pathogenicityorinfectivityhavebeendetecteduponsingleoralexposuretobtksa-11(delfinwgformulation).ld50>5000mg/kgbwcorrespondingto1.121011cfubtksa-11/kgbw'cuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)nopathogenicityuponpulmonaryexposureobservedlc50>1.00mg/l(3.4107cfubtksa-11/l)acuteintravenous/intraperitonialinfectivity:(ma5.2.2.3)thereisnoevidencethatbtksa-11actstoxicorpathogenicfollowingintravenousadministration.genotoxicity:(ma5.2.3)novalidatedmethodsavailableformicroorganisms.mousemicronucleusstudy(intraperitonealadministration)withthespore-crystalcomplexcontainingcry1aaandcry1ac,cry1abandcry2aa:equivocalresults.datagap:unclearwhethertoxinshadbeensolubilised/activatedpriortoadministrationornot.possibleconcernfornon-dietaryroutesbutnotfordietaryroute.dataislackingforcry2aaandcyt.cellculturestudy:(ma5.2.4)notrequired.informationonshort-termtoxicityandpathogenicity:(ma5.2.5)3-weekstudyinratsdidnotrevealanyindicationsofdirecttoxicity,infectivityorpathogenicitynoael108cfuperanimalperday.noadverseeffectsobserved.inhalation14-daymousestudyconductedwithformulatedbtk(dipel):loael4.2x104cfu/mousebasedonpatchesofinterstitiallunginflammationin18%ofanimalsat70days.noael:notestablished(datagap).fullclearanceobservedat70days.dermaltoxicity:(mp7.1.3)delfinwg(containingbacillusthuringiensissubsp.kurstakistrainsa-11/bylaboratory:9.1x1010cfu/g.):rabbit:ld50>20mg/kgbw(3.5x109cfu/site)specifictoxicity,pathogenicityandinfectivity:(ma5.3)dermaltoxicitystudywith4mljavelinwgsan415wg354(correspondingto40mgtestitem):negative.eyeirritation:delfinwg/javelinwgrevealedconjunctivalirritationthatwascompletelyreversiblewithin14days.thehazardstatementh319:causesseriouseyeirritationisrequiredgenotoxicityinvivostudiesingermcells:(ma5.5)nostudiesconductedwithbtk.referencevaluesaoel:asnoexposuremodelsexistformicrobials,settinganaoelwouldbeoflowrelevancetotheriskassessment.therecommendeduseofrpeforbothoperatorsandworkersisconsideredtocoverthepotentialriskafterrepeatedexposurebyinhalation.adi:thethresholdof105cfu/gfoodisapplicabletocovertheriskoffood-bornepoisoningscausedbytheb.cereusgroupofmicro-organisms.arfd:thethresholdof105cfu/gfoodisapplicabletocovertheriskoffood-bornepoisoningscausedbytheb.cereusgroupofmicro-organisms.exposure(operator,workers,bystander,consumer)(ma6.1&mp7.3,8.0)operators:noriskisanticipated.ppe(coverallsandgloves)andrpe(disposablefilteringfacepiecerespiratortoatleasten149ffp3orequivalent)arerecommended.workers:transplantationorhandlingofpots:ppe(coverallsandgloves)andrpeisrecommended.bystanders:notapplicable'", "efs26262-sup-0001-appendix_a.pdf": "impuritiesandcontaminatingmicroorganismsinmanufacturedmaterial(principleofmethod):standardmicrobiologicalmethodsfordetectionofmicrobialcontaminantsmicrobialpestcontrolproduct(principleofmethod):seeaboveanalyticalmethodsforresidues(viableandnon-viable)inexposedcompartmentsandorganisms(ma4.2&mp5.2)oftheactivemicroorganism(principleofmethod):avalidatedenumerationmethodinhighwatercommodities(lettuce)wasprovidedwithaloqof1.3x103cfu/gandforunambiguousidentificationofbtksa-12anaflpmethodwithtwohighlyspecificprimerpairsisavailable.thestrainspecificmolecularmarkerscanbeusedtomonitorthestraininagriculturalfields.ofrelevantmetabolites(principleofmethod):cry1absoil:extractionwithphosphatebufferedsalinetween,quantificationwithcommercialelisakit.loq0.25ng/ml.water:processingvialyophilizationandfiltercentrifugation,quantificationwithelisa.methoddetectionlimit2.1ng/l.impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))therearenoconfirmedcasereportslinkingagriculturaluseofplantprotectionproductsbasedonbtkstrainswithhumandiseasealthoughbtkproductshavebeenusedworldwideformorethansixtyyears.noincidentsrelatedtoadversehealtheffectssuchastoxicologicaleffects,allergicresponse,orirritation,toemployees,resultingfromexposuretob.thuringiensissubsp.kurstakisa-12duringdevelopment,manufacture,preparationorfieldapplicationoftheproducthavebeenreported.sensitisation:(ma5.2.1&mp7.2.3)ina3-yearfollowupstudyonsensitizationandhealtheffectsofexposuretomicrobiologicalcontrolagentsusedindanishgreenhousesincludingbacillusthuringiensissubsp.kurstaki,increasedigelevelswasobservedin53%ofthebloodsamples(measurementwasonlyqualitativeapositiveigewasdefinedasexceedingthedetectionlimitof0.025odunits).-organismsmayhavethepotentialtoprovokesensitisingacuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)nosignsoftoxicity,pathogenicityorinfectivityhavebeendetectedinratsuponsingleoralexposuretobtksa-12oraliquidformulationofbtksa-12(thuricidesc).ld50rat>5.4108cfu/animalcorrespondingto2.7109cfu/kgbw(clearance7days)acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)notoxicity,infectivityandpathogenicityuponpulmonaryexposureobservedinratsuponsingleacuteinhalation'(intranasal)exposuretoaliquidformulationofbtksa-12(thuricidesc).lc50>1.35108cfu/animal(clearance7days)acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3)nosignsoftoxicity,pathogenicity,orinfectivityweredetectedinratsuponsingleacuteintravenousadministrationofaliquidformulationofbtksa-12(thuricidesc).ld50rat>9107cfu/animal(clearance14days)genotoxicity:(ma5.2.3)novalidatedmethodsavailableformicroorganisms.mousemicronucleusstudy(intraperitonealadministration)withthespore-crystalcomplexcontainingcry1aaandcry1ac,cry1abandcry2aa:equivocalresults.datagap:unclearwhethertoxinshadbeensolubilised/activatedpriortoadministrationornot.possibleconcernfornon-dietaryroutesbutnotfordietaryroute.cellculturestudy:(ma5.2.4)btkisnotanintracellularreplicatingmicro-organisms,cellculturestudiesarenotrequired.informationonshort-termtoxicityandpathogenicity:(ma5.2.5)inhalation14daymousestudyconductedwithformulatedbtk(dipel):loael4.2x104cfu/mousebasedonpatchesofinterstitiallunginflammationin18%ofanimalsat70days.noael:notestablished(datagap).fullclearanceobservedat70days.dermaltoxicity:(mp7.1.3)nostudiesconductedwithbtk.adermaltoxicitystudyconductedwiththereferenceformulationforbtksa-11(delfinwg/javelinwgsan415wg354,correspondingto40mgbtksa-11andconsideredsimilartocostarwg)resultednegative.specifictoxicity,pathogenicityandinfectivity:(ma5.3)costarwgdoesnotrequireclassificationwithregardtoeyeirritation.eyeirritationstudyconductedinrabbitswithsan420i(sa-12)technicalrevealedtransientslightconjunctivalirritationonly.genotoxicityinvivostudiesingermcells:(ma5.5)nostudiesconductedwithbtk.referencevaluesaoel:asnoexposuremodelsexistformicrobials,settinganaoelwouldbeoflowrelevancetotheriskassessment.therecommendeduseofrpeforbothoperatorsandworkersisconsideredtocoverthepotentialriskafterrepeatedexposurebyinhalation.adi:thethresholdof105cfu/gfoodisapplicabletocovertheriskoffood-bornepoisoningscausedbytheb.cereusgroupofmicro-organisms.arfd:thethresholdof105cfu/gfoodisapplicabletocovertheriskoffood-bornepoisoningscausedbytheb.cereusgroupofmicro-organisms.'", "efs26274-sup-0001-appendix_a.pdf": "cytochalasinsfromdustandsolidandliquidculturefiltratesusingamultianalyticalmethodwithliquidchromatography/tandemmassspectrometryandhplc-uvwithinternalstandardcontaminatingmicroorganisms:-bipesco5/f52:standardmicrobiologicalmethodsfrominternationalofficialstandardisationbody(suchasisomethods)microbialpestcontrolproduct(principleofmethod):thesamemethodsasdescribedfortheactivemicroorganismapply.analyticalmethodsforresidues(viableandnon-viable)inexposedcompartmentsandorganisms(ma4.2&mp5.2)oftheactivemicroorganism(principleofmethod):selectivemediaossrmicrosatellitemarkeranalysis)ofrelevantmetabolites(principleofmethod):destruxins:hplc-uvmethodforcrops,soil,water,insectcadaversquechersmethodwithuhplc-qtof-msoruhplcms/msforcropscytochalasins:multi-targetmethodusinguhplc-ms/msorlc-ms/msimpactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))afewcasesofkeratitis,rhinitisandskininfectioninimmunocompromisedorinjuredpeople.nomedicalincidencesinmanufacturingplantpersonnelotherthanhypersensitivity.sensitisation:(ma5.2.1&mp7.2.3)nostudyonsensitisationisrequiredduetotheabsenceofpropertestmethodstomicro-organisms.warningsentenceformicrobialsisapplicable:containsmetarhiziumbrunneumbipesco5/f52.micro-organismsmayhavethepotentialtoprovokesensitisingreactionssomereportsofhypersensitivityinmanufacturingpersonnelrelatingtoincorrectuseofppe.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)noadverseeffects,notpathogenic,notinfectiveld50>1x108cfu/animalacuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)increasedlungweightlikelyrelatedtoimmuneresponsetothetestsubstance.brown,mottledpigmentationofthelungsatday21.ld50>1.17x108cfu/animalacuteintravenous/intraperitonialinfectivity:(ma5.2.2.3)notpathogenic,notinfective.toxicity:increaseofrelativespleenweightsatday3inmalesandday7infemales.ld50>1x107cfu/animalgenotoxicity:(ma5.2.3)supportiveinformation:negativeresultsinacombinedcytotoxicityandgenotoxicitytest(vitotoxtests)withcrudeextractsand'", "efs26293-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))noadversehealtheffectssuchastoxicologicaleffects,allergicresponse,orirritation,toemployees,resultingfromexposuretobacillusthuringiensisaizawaigc-91duringproduction,formulation,andpackagingoftheproducthavebeenreported.sensitisation:(ma5.2.1&mp7.2.3)specificigehasbeendetectedinworkersexposedtobacillusthuringiensis,intheabsenceofanysymptomsofsensitisation.btastraingc-91shouldberegardedaspotentialsensitizersandthefollowingwarningphrascontainsbacillusthuringiensisssp.aizawaistraincg-91.micro-organismsmayhavethepotentialtoprovokesensitisingreactionsacuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)noacuteoraltoxicity,pathogenicityorinfectivityinmammals.ratld50>9.4108cfu/kgbw,ld50>5050mg/kgbwacuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)ratlc50byinhalation:>3.16mg/l(correspondingto3.77107cfu/l)ratld50intratracheal>3.76x108cfu/kgbwincompletelungclearanceafterintratrachealadministration.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3)intravenous(rat):noael7.6x107cfuperanimalintraperitoneal(mouse):noael1.16x106cfuperanimal,ld50>107cfuperanimalnotoxicity,pathogenicityorinfectivitybtagc-91wasfoundtobeextremelyirritatinguponsubcutaneousapplicationwiththehighesttesteddose3.8106cfu/animalinmice.genotoxicity:(ma5.2.3)mousemicronucleusstudy(intraperitonealadministration)withthespore-crystalcomplexcontainingcry1aaandcry1ac,cry1abandcry2aa:equivocalresults(datagap)cellculturestudy:(ma5.2.4)btaisnotanintracellularreplicatingmicro-organism,cellculturestudiesarenotrequired.informationonshort-termtoxicityandpathogenicity:(ma5.2.5)oral13-weekrat:noael108cfu/animal;noadverseeffectrepeatedexposurebyinhalationwithmice(2x5days):loael4.2x104cfu/mousebasedonpatchesofinterstitiallunginflammationin18%ofanimalsat70days.noael:notestablished(datagap).fullclearanceobservedat70days.dermaltoxicity:(mp7.1.3)dermalrabbit:ld50>2020mg/kgbw,notirritatingeyeirritationrabbit:notirritatingspecifictoxicity,pathogenicityandinfectivity:(ma5.3)nodata,notrequiredgenotoxicityinvivostudiesingermcells:(ma5.5)noindicationsofgenotoxicityareknownforbta.referencevaluesaoel:asnoexposuremodelsexistformicrobials,settinganaoelwouldbeoflowrelevancetotheriskassessment.forthepotentialriskafterrepeatedexposureby'", "efs26294-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))thereisnoreportingofadverseeffectsorsensitisationreactionsinindividualsasaresultofcontactwithbacillusthuringiensisssp.aizawaistrainabts-1857duringitsdevelopment,manufacturing,preparationorfieldapplicationsensitisation:(ma5.2.1&mp7.2.3)buehlerassay(unclearapplicabilitytomicrobials):negative.specificigehasbeendetectedinworkersexposedtobacillusthuringiensis,intheabsenceofanysymptomsofsensitisation.btastrainabts-1857shouldberegardedaspotentialsensitizersandthefollowingwarningphraseisproposed:containsbacillusthuringiensisssp.aizawaistrainabts-1857.micro-organismsmayhavethepotentialto.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)ratoralld50>5050mg/kgbw(6x109cfu/kgbw).noevidenceofpathogenicityorinfectivityfollowingoraldosing.acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)intratrachealrat:lc50>5.33mg/l(3.9x108cfu/l)mildclinicalsignsoftoxicitybutnosignsofpathogenicityorinfectivity.completelungclearanceatday35.acuteintravenous/intraperitonialinfectivity:(ma5.2.2.3)intraperitoneal(mice):noael25mg/kgbw(5x109cfu/kgbw),nosignsoftoxicity,pathogenicityorinfectivity.subcutaneous(mice):noael3mg/kgbw(5x108cfu/kgbw),nosignsoftoxicity,pathogenicityorinfectivity.intravenous(rats):mildtoxicityat2.94x107cfu/ml,nosignsofpathogenicity,incompleteclearancefromthespleenandlungsafter66days.genotoxicity:(ma5.2.3)novalidatedmethodsavailableformicro-organisms.noevidenceofgenotoxicityinvitro.publisheddatadonotindicateanyconcernswithregardtogenotoxicityinvivo.mousemicronucleusstudy(intraperitonealadministration)withthespore-crystalcomplexcontainingcry1aaandcry1ac,cry1abandcry2aa:equivocalresults(datagap).cellculturestudy:(ma5.2.4)notrequired.informationonshort-termtoxicityandpathogenicity:(ma5.2.5)repeatedexposurebyinhalationwithmice(2x5days):loael4.2x104cfu/mousebasedonpatchesofinterstitiallunginflammationin18%ofanimalsat70days.noael:notestablished(datagap).fullclearanceobservedat70days.dermaltoxicity:(mp7.1.3)xentariwg(abg-6314):-slightskinirritantinrabbits-seriouseyeirritantinrabbits(possiblytriggeringclassification)specifictoxicity,pathogenicityandinfectivity:(ma5.3)nodata:notrequiredgenotoxicityinvivostudiesingermcells:(ma5.5)nostudiesconductedwithbta'", "efs26295-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)noadversereactionsinindividualsasaresultofcontactwithbeauveriabassianastrain203duringitsdevelopment,manufacture,preparationorfieldapplicationhavebeenreportedb.bassianawasisolatedinafewcasesfrompeoplesufferingfromeyeinfection.disseminatedinfectionshavebeenobservedonlyinpeopleunderimmunosuppression.nodataonadverseeffectsinemployeesareavailable.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)thereisenoughevidencetoconsiderbeauveriabasssiana,irrespectiveofthestrain,apotentialhumanallergenbybothskinandinhalatoryexposurebasedoninformationfromtheopenliterature.aswithallmicroorganisms,beauveriabassianastrain203mayhavethepotentialtoprovokesensitisingreactions.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)ld50>1.98108cfu/ratwithnoevidenceoftoxicity,pathogenicityorinfectivity.completeclearancebyday4postdosing.acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)lc50>1.8108cfu/ratwithnoevidenceoftoxicity,pathogenicityorinfectivity.completeclearancebyday8postdosing.enlargedparathymiclymphnodeswerefoundforthemajorityofdosedanimalssacrificedfromday4(males)andday8(females)onwards.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)ld50>9.5x107cfu/ratwithnoevidenceoftoxicity,pathogenicityorinfectivity.completeclearancebyday8postdosing.genotoxicity:(ma5.2.3;oecdiim5.3.5)notmutagenic(theextractofbeauveriabassianastrain203negativeintheamestest).cellculturestudy:(ma5.2.4;oecdiim5.3.6)notrequiredinformationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)notrequireddermaltoxicity:(mp7.1.3;oecdiiim7.1.2)notrequired:notorallytoxic,pathogenicorinfective.specifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)notrequired:noevidenceofintrinsictoxicityorpathogenicitywasobservedinacuteexposurestudies,andnofurthertestingoftoxicityisrequired.genotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)nodata:notrequired.metabolitesitcannotberuledoutthatbeauvericinisgenotoxicbasedoninvitro(positivechromosomalaberrationsandmicronucleustest)andinvivodata.genotoxicityshouldbefurtherinvestigated(datagap).referencevalues'", "efs26296-sup-0001-appendix_a.pdf": "assessmentoftheactivesubstancepythiumoligandrumstrainm1www.efsa.europa.eu/efsajournal5efsajournal2020;18(1):6296classificationandproposedlabelling(symbol,indicationofdanger,riskphrases,safetyphrases)withregardtophysical/chemicaldata:notapplicablewithregardtotoxicologicaldata:containspythiumoligandrumm1.microorganismsmayhavethepotentialtoprovokesensitisingreactions.withregardtofateandbehaviour:notapplicablewithregardtoecotoxicologicaldata:notapplicablemethodsofanalysis(regulation(eu)n283/2013,annexpartb,point4andregulation(eu)n284/2013,annexpartb,point5)analyticalmethodsforthemicroorganism(ma4.1&mp5.1;oecdiim4.3&iiim5.1)manufacturedmicroorganism(principleofmethod):lightmicroscopy.molecularmethodsareavailabletoseparatep.oligandrumm1fromotherstrainsofthesamespecies.impuritiesandcontaminatingmicroorganismsinmanufacturedmaterial(principleofmethod):norelevantimpurities.cultivationonagarplatestotestthepresenceofcontaminatingmicroorganisms.microbialpestcontrolproduct(principleofmethod):lightmicroscopyanalyticalmethodsforresidues(viableandnon-viable)inexposedcompartmentsandorganisms(ma4.2&mp5.2;oecdiim4.5&iiim5.2)oftheactivemicroorganism(principleofmethod):cultivationonselectivemediapcr-onthespecieslevelofrelevantmetabolites(principleofmethod):pendingonthedatagapforproductionandidentityofthesecondarymetabolitesimpactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)pythiumoligandrumm1hasbeensoldsince1998astheactiveingredientinhumancosmeticproductssuchasfootcreams,vaginalcreamsandmouthrinsesagainstsuperficialfungalinfections,aswellasinveterinaryproductsforthesamepurpose.noadverseeffectshavebeenreported.noregulatoryevaluationformedical/cosmeticsuseshasbeenprovided.theliteraturesearchandreportingofdatafrommedicalsurveillanceareincomplete(datagaps).consequently,thesemedicaldatacannotbeusedtowaiveanimaldata.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)invitroare-nrf2luciferasetestmethod:negative.**pythiumoligandrumm1shouldbelabelledwiththepythiumoligandrumm1.microorganismsmayhavethepotentialtoprovokeacuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)ratld50>5000mg/kgbw,correspondingto2.9x107oospores/kgbw*acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)lc50>5mg/lcorrespondingto1.3x104oospores/l*studyconsideredtobesupportiveduetounspecificeffects(inlungs)anduncertaindoselevelsacuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)i.p.rat:ld50>3.6x104oospores/animal*studyconsideredtobesupportiveduetouncertaindoselevels'assessmentoftheactivesubstancepythiumoligandrumstrainm1www.efsa.europa.eu/efsajournal6efsajournal2020;18(1):6296genotoxicity:(ma5.2.3;oecdiim5.3.5)bacterialreversemutationtest:negative.**testnotappropriateformicroorganisms,onlyaddressingpossiblemetabolitesinthempca.cellculturestudy:(ma5.2.4;oecdiim5.3.6)notrelevantinformationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)nodatanotrequired.dermaltoxicity:(mp7.1.3;oecdiiim7.1.2)ld50>5000mg/kgbw,correspondingtoapproximately1x107oospores/kgbw*studyconsideredtobesupportiveduetouncertaindoselevelsspecifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)75-dayneurotoxicityrat:noael2.4mg/kgbwperday,correspondingto4x106oospores/kgbwperday*effect:increasedrunningtimethroughthelabyrinthinmales.studyconsideredtobeunreliableforthemicroorganismbutrelevantforpotentialmetabolites.infectivity/clearancehasnotbeensufficientlyinvestigatedintheavailablestudies(datagap).antimycoticassay:nosignsofinfection,irritationorinflammationafterdermalapplicationtoguineapigs.thepurposeofthestudywastoinvestigatetheefficacyofp.oligandrumagainstadermatophytewithwhichtheanimalshadbeenartificiallyinfected.studyconsideredtobesupportive.genotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)nodatanotrequired.*note!viabilityoftheoosporeshasnotbeenverified(claimeddatagap).**testmaterialnotrepresentativeofcurrentspecification,studyconsideredsupplemental.referencevaluesaoel:openadi:openarfd:openexposure(operator,workers,bystander,consumer):(ma6.1&mp7.3,8.0;oecdiim5.6&iiim7.2,7.3)assessmentnotfinalised.intheabsenceofaquantitativeriskassessment,theuseofpersonalandrespiratoryprotectiveequipment(ppe/rpe)fortheoperatorsandworkersmightbeconsideredtoreducetheexposure(viadermalandinhalationroutes).residues(regulation(eu)n283/2013,annexpartb,point6andregulation(eu)n284/2013,annexpartb,point8;oecdiimpoint6&iiimpoint8)viableresidues:informationonthemagnitudeofresiduesonedibleplantpartsisrequired(datagap)non-viableresidues:informationonthemagnitudeoftoxicologicallyrelevantnon-viableresiduesonedibleplantpartsisrequired(datagap).'", "efs26317-sup-0001-appendix_a.pdf": null, "efs26381-sup-0001-appendix_a.pdf": "impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1;oecdiim5.1)noadversehealtheffectshavebeenobservedinanyoftheemployeesinvolvedintheresearchlaboratoryorproductionplant.casereportsoninfectionorotherincidentsinhumansrelatedtobacillusamyloliquefaciensorbacillussubtilisareveryscarceandmainlyrelatedtoimmunecompromisedconditions.sensitisation:(ma5.2.1&mp7.2.3;oecdiim5.2&iiim7.1.6)microorganismsmayhavethepotentialtoprovokesensitisingreactions.noreportsofsensitizationorallergenicresponseamonglaboratoryorproductionteam.inthepublishedliteratureacaseoffamilialhypersensitivitypneumonitisinducedbybacillussubtilishasbeendescribedafterexposuretowooddust.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1;oecdiim5.3.2&iiim7.1.1)noevidenceofadverseeffectsratld50oral>5x108cfu/kgbwcompleteclearancewithin14dacuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2;oecdiim5.3.3&iiim7.1.3)minorandtransienteffectsratld50intratracheal>5x108cfu/kgbwextendedclearancetimewithnoevidenceofpathogenicity,furthersporegerminationorvegetativegrowth.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3;oecdiim5.3.4)noevidenceofadverseeffectsratld50intravenous>4107cfu/kgbwextendedclearancetimewithnoevidenceofpathogenicity,furthersporegerminationorvegetativegrowth.genotoxicity:(ma5.2.3;oecdiim5.3.5)nodata(novalidatedmethodsformicroorganisms)cellculturestudy:(ma5.2.4;oecdiim5.3.6)nodatanotrequiredinformationonshort-termtoxicityandpathogenicity:(ma5.2.5;oecdiim5.3.7)rat28dinhalation(nose-only):noclinicaleffects,minororganweightchanges,noael5x108cfu/animalperday;completeclearanceinlungsanddrainedlymphnodes8weeksafterfinalexposuredermaltoxicity:(mp7.1.3;oecdiiim7.1.2)rabbitld50dermal>2.3-2.7x1011cfu/animalspecifictoxicity,pathogenicityandinfectivity:(ma5.3;oecdiim5.5)rabbit:veryslightirritatingeffects(skin,eye)genotoxicityinvivostudiesingermcells:(ma5.5;oecdiim5.5.3)nodatanotrequiredsecondarymetabolites/toxinscycliclipopeptidesiturinsandsurfactinsarestrongsurfactantsshowingmembranedamagingproperties(lyticactivity)invitro.surfactinc:28-dayratnoael500mg/kgbwperdaybasedondecreasedbodyweightandlivertoxicityinvitroamesandchromosomeaberrationassays:negativeinvivomicronucleustest(supplementary):'", "efs26385-sup-0001-appendix_a.pdf": "hepesticideriskassessmentoftheactivesubstancespiroxamineintidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleswww.efsa.europa.eu/efsajournal6efsajournal2020;19(2):6385appendixiii.3:chapter3(impactonhumanandanimalhealth)absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid,about60%within48h,basedonurinaryexcretiondistributionwide,highestresiduesinliver,thymus,adrenals(highdose:fat)potentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion>80%within48h(urine:>60%,faeces:>20%)metabolisminanimalsextensivelymetabolised(oxidation,sulphateconjugation,dealkylation)toxicologicallyrelevantcompounds(animalsandplants)spiroxaminetoxicologicallyrelevantcompounds(environment)spiroxamineandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral~500mg/kgbwh302ratld50dermal1068mg/kgbwh312ratlc50inhalation2mg/lair;slightpulmonaryirritation(4-hexposure,nose-only)h332skinirritationsevereirritanth315eyeirritationnon-irritantskinsensitisationsensitiser(m&k;buehler)h317shorttermtoxicity(annexiia,point5.3)target/criticaleffectchemistry),clinicalsigns,effectsonmucosalepitheliumofoesophagusandfore-stomach;additionallyindogs:eye(cataracts),stotre2(eye)dermal:skinirritationbyinhalation:irritationoftherespiratorytractrelevantoralnoael28-day,rat:3.4mg/kgbw/day90-day,rat:1.9mg/kgbw/day90-day,dog:15.1mg/kgbw/day1-year,dog:2.5mg/kgbw/day90-day,mouse:25mg/kgbw/dayrelevantdermalnoael21-day,rabbit:localeffects:0.2mg/kgbw/daysystemiceffects:5mg/kgbw/dayhighestdosetested)relevantinhalationnoael28-day,rat:14.3mg/mair(6-hexposure,noseonly,3.9mg/kgbw/day)'", "efs26388-sup-0001-appendix_a.pdf": null, "efs26495-sup-0001-appendix_a.pdf": "ftheactivemicroorganism(principleofmethod):notrequiredasbtkeg2348isproposedforinclusionintoannexivofregulation(ec)no396/2005.however,specificmarkersareavailabletomonitorthestraininagriculturalfields.ofrelevantmetabolites(principleofmethod):cry1absoil:extractionwithphosphatebufferedsalinetween,quantificationwithcommercialelisakit.loq0.25ng/ml.water:processingvialyophilizationandfiltercentrifugation,quantificationwithelisa.methoddetectionlimit2.1ng/l.impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))therearenoconfirmedcasereportslinkingagriculturaluseofplantprotectionproductsbasedonbtkstrainswithhumandiseasealthoughbtkproductshavebeenusedworldwideformorethansixtyyears.noincidentsrelatedtoadversehealtheffectssuchastoxicologicaleffects,allergicresponse,orirritation,toemployees,resultingfromexposuretob.thuringiensissubsp.kurstakieg2348duringproductionandpackagingoftheproducthavebeenreported.fewdatafromtheliteraturehavereportedclinicalinfections(e.g.ocular)anddermalirritationcausedbyb.thuringiensisspecies.availableresultsindicatethatproductionofspecificigecanoccuringreenhouseworkersexposedtoproductscontainingbt,butdonotshowanyeffectsontheincidenceorprevalenceofrespiratorysymptoms,lungfunctionorbronchialresponsiveness.sensitisation:(ma5.2.1&mp7.2.3)basedontheircharacteristics,microorganismssuchasbacillusthuringiensissubsp.kurstakistraineg2348mayhavethepotentialtoprovokesensitisingreactions.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)ratld50(btksa-12incostar)>4.61011cfu/kgbwnomortalityorsignificanttoxiceffects,clearancenotinvestigated.acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)rat(intratracheal):lc50(btkeg2348incondorof)>2.4107cfu/animalnomortalityorsignificanttoxiceffects,lungclearanceincompleteatday21.acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3)ratld50>1107cfu/animalnomortalityorsignificanttoxiceffects,clearanceincompleteatday21(spleen,liver,lungs).genotoxicity:(ma5.2.3)novalidatedmethodsavailableformicroorganisms.crytoxins:mousemicronucleusstudy(intraperitonealadministration)withthespore-crystalcomplexcontainingcry1aaandcry1ac,cry1abandcry2aa:equivocalresults(datagap).'", "efs26496-sup-0001-appendix_a.pdf": "oil:extractionwithphosphatebufferedsalinetween,quantificationwithcommercialelisakit.loq0.25ng/ml.water:processingvialyophilizationandfiltercentrifugation,quantificationwithelisa.methoddetectionlimit2.1ng/l.impactonhumanandanimalhealth(regulation(eu)n283/2013,annexpartb,point5andregulation(eu)n284/2013,annexpartb,point7)medicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(ma5.1.1))therearenoconfirmedcasereportslinkingagriculturaluseofplantprotectionproductsbasedonbtkstrainswithhumandiseasealthoughbtkproductshavebeenusedworldwideformorethansixtyyears.noincidentsrelatedtoadversehealtheffectssuchastoxicologicaleffects,allergicresponse,orirritation,toemployees,resultingfromexposuretob.thuringiensissubsp.kurstakipb54duringproductionandpackagingoftheproducthavebeenreported.availableresultsindicatethatproductionofspecificigecanoccuringreenhouseworkersexposedtoproductscontainingbtk.thesedatadonotshowanyeffectsontheincidenceorprevalenceofrespiratorysymptoms,lungfunctionorbronchialresponsiveness.sensitisation:(ma5.2.1&mp7.2.3)basedontheircharacteristics,microorganismssuchasbacillusthuringiensissubsp.kurstakistrainpb54mayhavethepotentialtoprovokesensitisingreactions.acuteoralinfectivity,toxicityandpathogenicity:(ma5.2.2.1&mp7.1.1)intwoacuteoraltoxicitystudieswithrats,bacillusthuringiensissubsp.kurstakistrainpb54assuchorasaformulatedproductshowednosignsoftoxicityorpathogenicity.clearance/infectivitywerenotinvestigatedinthesestudies.1)ld50rat>1108cfubtkpb54/animal,equivalentto>5.0108cfu/kgbw/day2)ld50rat>2000mgbelthirul/kgbw(correspondingto1.01010cfubtkpb54/kgbw/day)acuteintratracheal/inhalationinfectivity,toxicityandpathogenicity:(ma5.2.2.2&mp7.1.2)noadverseeffectsobserved,clearance7daysnotoxicityorpathogenicityafter4h-noseonlyadministration,clearancenotinvestigated.lc50rat>2.746mgbelthirul/lair(correspondingto2.6109cfubtkpb54/kgbw)acuteintravenous/intraperitonealinfectivity:(ma5.2.2.3)notoxicityorpathogenicityafterintraperitonealadministration,clearancenotinvestigated.ld50rat>1107cfubtkpb54/animalgenotoxicity:(ma5.2.3)novalidatedmethodsavailableformicroorganisms.crytoxins:mousemicronucleusstudy(intraperitonealadministration)withthespore-crystalcomplexcontainingcry1aaandcry1ac,cry1abandcry2aa:equivocalresults(datagap).cellculturestudy:(ma5.2.4)notrequired.informationonshort-termtoxicityandpathogenicity:acutetoxicitystudiesdidnotrevealanysignsoftoxicityorpathogenicity.'ma5.2.5)nostudiesarepresentedonthestrainpb-54ortheformulatedproductbelthirul.apublishedstudywiththeproductdipel(strainhd-1)isreportedinthesheep(administrationinthedietfor5months),wherenopathogenicitywasobserved.repeatedexposurebyinhalationwithmice(2x5days):loael:4.2x104cfu/mousebasedonpatchesofinterstitiallunginflammationin18%ofanimalsat70days.noael:notestablished(datagap)dermaltoxicity:(mp7.1.3)noadverseeffectsobserved.ld50rat>2000mgbelthirul/kgbwspecifictoxicity,pathogenicityandinfectivity:(ma5.3)rabbit:noacutedermaltoxicity/infectivity;mildskinirritation.genotoxicityinvivostudiesingermcells:(ma5.5)novalidatedmethodsavailableformicroorganisms.referencevaluesaoel:asnoexposuremodelsexistformicrobials,settinganaoelwouldbeoflowrelevancefortheriskassessment.theuseofrespiratoryprotectiveequipmentfortheoperatorsandworkersmightbeconsideredtoreducetheexposureviainhalation.adi:thethresholdof105cfu/gfoodisapplicabletocovertheriskoffood-bornepoisoningscausedbytheb.cereusgroupofmicro-organisms.arfd:thethresholdof105cfu/gfoodisapplicabletocovertheriskoffood-bornepoisoningscausedbytheb.cereusgroupofmicro-organisms.exposure(operator,workers,bystander,consumer):(ma6.1&mp7.3,8.0)intheabsenceofaquantitativeriskassessment,theuseofrespiratoryprotectiveequipmentfortheoperatorsandworkersmightbeconsideredtoreducetheexposureviainhalation.theriskassessmentbyinhalationforresidentsandbystanderscouldnotbeconcludedconsideringthelackofdataonthegenotoxicpotentialofthecryproteinsandlackofdataonrepeatedexposurebyinhalation.residues(regulation(eu)n283/2013,annexpartb,point6andregulation(eu)n284/2013,annexpartb,point8)viableresidues:b.thuringiensissubsp.kurstakisporesarenotpersistingormultiplyingoncrops,neverthelessastoragestabilityofbacillusthuringiensissubsp.kurstakistrainpb54inhigh-water(tomato)andhigh-acid(stonefruits)contentcommoditiesat-18cisstillrequired(datagap).basedonuncertaintiesinthetoxicologysectionrelatedtopotentialproductionofenterotoxininthehumangut,athresholdlevelof1x105cfu/gwasproposedatharvest.toensurethatconsumersarenotexposedtolevelshigherthanthis,aquantificationofviablecountsaccordingtotherepresentativeusesontomatoesandstonefruitslinkedtospecificphisisrequested(datagap).non-viableresidues:notrelevantfordietaryexposure(seesection2)'", "efs26500-sup-0001-appendix-b.pdf": "mpactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitymoderateoralabsorption(range20-40%)toxicokineticsfollowingasingleoraldose(250mg/kg)inrat,bloodkineticsparameters,basedoncalciumcontentwereasfollows.forfoodbulkcaco3cmax:13.39g/mltmax:2ht1/2:2.50hforfoodnanocaco3cmax:21.55g/mltmax:1ht1/2:2.86hforreagentgradecaco3cmax:31.56g/mltmax:1ht1/2:1.59hdistributioncalciumionsaredistributedintheserumandthenthroughoutthebody.themajorityofcalciumisstoredintheskeleton.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionexcesscalciumisexcretedwithwaterviakidneys(andalsofaecesandskin)andexcesscarbonateisexcretedascarbondioxideviarespiration.metabolisminanimalsuponoralingestion,calciumcarbonatedissociatesintoitsconstituentionsinthestomach.someoftheseionsareabsorbed.afterintestinalabsorption,calciumandcarbonate/bicarbonateionsenternormalmetabolicpathwaysandbodypools.invitrometabolismnodataavailable;notrequiredtoxicologicallyrelevantcompounds(animalsandplants)nonetoxicologicallyrelevantcompounds(environment)noneacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oralld50>2000mg/kgbwratld50dermalld50>2000mg/kgbwratlc50inhalationlc50>3mg/l/4h(maximumaerosolconcentrationachievable,noseonly)skinirritationnon-irritanteyeirritationnon-irritant'", "efs26593-sup-0001-appendix_b (1).pdf": "ubstancepotassiumhydrogencarbonatewww.efsa.europa.eu/efsajournal17efsajournal2021;19(5):6593impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidlyabsorbed(>90%)toxicokineticsnodata.distributionwidelydistributedbasedonnaturaloccurrenceofpotassiumandbicarbonateinthebody.potentialforbioaccumulationnoevidenceforaccumulation.homeostasisismaintainedthroughwell-knownmechanisms.rateandextentofexcretionmainlyexcretedviaurinemetabolisminanimalsdissociationtopotassiumandhydrogencarbonate.invitrometabolismnodata,notrequired.toxicologicallyrelevantcompounds(animalsandplants)none.toxicologicallyrelevantcompounds(environment)none.acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral2064mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.88mg/lair/4h(nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitisingbasedonphysiologicalroleofpotassiumandhydrogencarbonateinhumans.phototoxicitynotrequired.short-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:increasedurinaryphandvolume,increasedplasmaandurinarypotassium,hypertrophyoftheadrenalzonaglomerulosa,urinarybladderhyperplasiarelevantoralloael4-weekand13-week,rat:1482mg/kgbwperdayformalesand1662mg/kgbwperdayforfemales26-week,rat:1638mg/kgbwperdayrelevantdermalnoaelnodata-notrequired'"}